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ABSTRACT 
Introduction: Cholangiocarcinoma (CC) is a malignancy of the biliary tract. It has a dismal 
prognosis and complete surgical resection offers the only chance of cure.  The aim of this study 
was to identify prognostic DNA/microRNA signatures, and to identify key targets and pathways in 
CC to improve treatment. 
 
Methods: We performed a retrospective study to assess the role of surgery and adjuvant therapy 
on the survival outcomes of patients with CC based on the experience of two institutions.  
 
We investigated the molecular pathogenesis of CC assessing DNA copy number alterations and 
differential miRNA expression. We used array comparative genomic hybridization (CGH) (1Mb 
BAC array-CGH, and 180K Oligonucleotide array-CGH) on 71 UK and 24 Thai cases CC.  We 
performed microRNA-arrays (Agilent Human miRNA slides V3) on 34 CC and 10 normal 
cholangiocyte samples. 
 
Results: Survival analysis showed a statistically significant difference in survival between those 
resected and those receiving medical management only. 
 
Thai CC cases exhibited a lower proportion of CNA compared to UK cases.  A common UK 
alteration was seen at 17q12, the region encoding ErbB-2. The copy number gain at 17q12 was 
validated using CISH and IHC for ErbB-2 expression, revealing heterogeneous expression. 
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Copy number gain of chromosome 8q24.21-24.3 was significantly related to survival. Median 
survival was 14.4 months vs 28.3 months with and without the gain (p = 0.016).  
 
Thirty-eight miRNAs showed significantly different expression, including several microRNAs 
implicated in other malignancies, with predicted gene targets including the p53 signaling pathway 
and the TGF-beta signaling pathway.  
 
We identified a 4-microRNA signature that correlated with overall survival. With a median 
survival of 15.7 months vs 35.6 months: p = 0.00016. 
 
Conclusion: This study illustrates the genetic variability of CC, highlights several potential 
therapeutic targets, and identified a DNA and miRNA signature that correlated with prognosis.
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1.1 Anatomy and Classification of Cholangiocarcinoma 
Cholangiocarcinoma (CC) is a malignant tumour of epithelial cells (cholangiocytes) lining bile 
ducts.  It was first described by Durand-Fardel in 1840, presenting a case of common bile duct 
malignancy (Renshaw 1922).  The term cholangiocarcinoma was originally derived from ancient 
Greek: Chol- meaning ‘bile’; –angio meaning ‘tube or duct’; and -carcinoma meaning cancer.  
 
Figure 1: Anatomy of the Biliary Tree 
 
1.1.1 Anatomy of the biliary tree 
The biliary tree drains bile from the liver to the duodenum (small bowel).  Intrahepatic bile ducts 
are those within the liver, forming part of the portal triad (encompassing the bile duct, hepatic 
artery, and portal vein), draining the right and left lobes of the liver.  The intrahepatic bile ducts 
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converge within each lobe to form the right and left hepatic ducts, exiting the liver in an 
invagination of Glisson’s capsule (a layer of connective tissue surrounding the liver).  They follow 
a short course within Glisson’s capsule, and then converge at the hilum to form the common 
hepatic duct (see Figure 1).  The common hepatic duct continues as the common bile duct when 
joined by the cystic duct.  The common bile duct is joined by the pancreatic duct, and terminates at 
the ampulla of Vater, where it enters the duodenum.   
 
The bile ducts within the liver are termed ‘intrahepatic bile ducts’, and those outside the liver are 
termed ‘extrahepatic bile ducts’.  As the bile ducts converge at certain points their name changes, 
starting as simply intrahepatic bile ducts, then becoming the left and right hepatic ducts 
respectively, until joined at the hilum (the name for the point where the left and right hepatic ducts 
converge) to become the common hepatic duct, which is termed the common bile duct once it is 
joined by the cystic duct from the gallbladder.  The ampulla of Vater is formed by the joining of 
the pancreatic and common bile duct at the entry to the duodenum draining bile and pancreatic 
juice. 
 
1.1.2 Embryological development of biliary tree 
The biliary system develops from a hepatic diverticulum formed from the caudal part of the 
foregut.  The hepatic diverticulum separates into two buds, the pars cystic, and the pars hepatica 
(Desmet 1998, Roskams and Desmet 2008). 
 
The pars cystic elongates and forms the gallbladder, cystic duct, hepatic duct, common bile duct, 
and ventral pancreas.  Initially resembling a conical tube, the hepatic duct develops folds through 
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rapid cellular proliferation, forming the distal left and right hepatic ducts.  The proximal left and 
right hepatic ducts are formed from the intrahepatic portion of the biliary tree from the ductal 
plates of the pars hepatica. 
 
The development of the intrahepatic biliary tree is less well understood.  The most commonly 
accepted theory is that it develops following a phenotypic change of primitive hepatoblasts into 
cholangiocytes.  Hepatoblasts surrounding larger portal veins become smaller and more cylindrical 
with a slit-like lumen forming a sleeve around the portal vein termed the ductal plate.  The cells 
continue their phenotypic differentiation into cholangiocytes, with strong immunoreactivity for 
cytokeratin 8, 18 and 19 (biliary specific cytokeratins).  Cytokeratins are intermediate-size 
filaments of keratin-like proteins found in the cytoskeleton of epithelial cells that are used to assess 
the origin of the cell type (Moll et al. 1982).   Luminal continuity is maintained between the intra- 
and extrahepatic biliary tree from the beginning of organogenesis.  Maturation of the biliary 
system continues throughout childhood. 
 
The intra- and extrahepatic biliary trees develop separately, from the pars cystic and the pars 
hepatica, and it therefore maybe expected that the molecular changes and clinical courses 
associated with diseases arising in the two biliary trees may be distinct. 
 
1.1.3 Anatomical Classification of Cholangiocarcinoma 
Originally the term cholangiocarcinoma was used to describe only primary liver tumours of the 
intrahepatic biliary tree.  Tumours of the extrahepatic biliary tree, including gallbladder and 
ampullary tumours, were classified as ‘biliary tract tumours’ (de Groen et al. 1999).  Biliary tract 
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tumours were further subdivided into Klatskin (also known as perihilar), mid-duct, and distal-CBD 
tumours.   
 
Klatskin tumours were named after Gerald Klatskin, who described a series of 13 cases of perihilar 
tumours in 1965 ‘arising in the hepatic duct at its bifurcation within the porta hepatis’ (Klatskin 
1965).  In 1975 Bismuth-Corlette further subdivided Klatskin tumours into four subtypes, I to IV 
according to which part of the porta hepatis was involved (Bismuth and Corlette 1975), shown in 
Figure 2. 
Figure 2: Bismuth-Corlette Classification of Perihilar Cholangiocarcinoma (Bismuth and 
Corlette 1975) 
The biliary hilum is demonstrated with normal bile duct in green, and malignant cholangiocarcinoma in brown 
demonstrating the pattern of involvement in the classification 
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Malignant tumours of cholangiocytes, whether intrahepatic, or extrahepatic, are now known as 
cholangiocarcinomas. 
 
Various methods of sub classifying CC exist, but the most commonly used is an anatomically 
classification.  Nakeeb et al from Johns Hopkins presented a retrospective cohort study of 294 
surgically managed patients with CC, and proposed the anatomical classification.  This 
classification has been adopted by the International Union Against Cancer for classification of CC, 
and is incorporated into the TNM classification (Nakeeb et al. 1996, Sobin, Gospodarowicz and 
Wittekind 2009).   Cholangiocarcinoma is classified as either: intrahepatic; perihilar; or 
extrahepatic. Intrahepatic cholangiocarcinomas (ICC) are located within the liver parenchyma 
down to the second order bile ducts, perihilar cholangiocarcinomas (PHCC) from the left and right 
hepatic ducts to the origin of the cystic duct, and extrahepatic cholangiocarcinomas (ECC) distal to 
the insertion of the cystic duct down to, but not including, the ampulla of Vater. 
 
During this study the terms intrahepatic CC (ICC), perihilar CC (PHCC), and extrahepatic CC 
(ECC) will be used to classify CC. 
 
1.1.4 Pathological Classification of Cholangiocarcinoma 
1.1.4.1 Macroscopic  
Weinbren and Mutum assessed 33 CC surgical resection specimens from Blumgart at 
Hammersmith Hospital, London, in 1983.  They described three macroscopic subtypes of CC: 
sclerosing; nodular; and papillary.  These remain the three main macroscopic subtypes of CC, 
however they are now known by the terms proposed by the Liver Cancer Study Group of Japan:  
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mass-forming (sclerosing); periductal-infiltrating (nodular); and intraductal growth (papillary) 
pattern.  This classification is used for ICC, PHCC and ECC (Japan 1997). 
 
Mass-forming (MF) tumours are the commonest, with a solid, firm grey-white mass, often with a 
sclerotic core, and a clear distinction between tumour and non-tumour tissue (Lim and Park 2004, 
Weinbren and Mutum 1983, Leong et al. 2007).  They have a well-defined, rounded and 
undulating margin, which compresses the bile ducts.  They are commonly solitary, but can form 
several small satellite lesions by invading along the portal tracts. Intrahepatic tumours are 
frequently MF type, and more than half are poorly differentiated (Lim and Park 2004, Lim 2003). 
   
Periductal-infiltrating (PI) tumours cause a concentric, firm, grey-white thickening along the bile 
duct wall extending longitudinally along the portal tract, causing obstruction and proximal bile 
duct dilatation.  There is often an irregular intra-luminal surface of the bile duct (Weinbren and 
Mutum 1983).  Perihilar tumours are frequently PI type, and are frequently well differentiated 
(Lim 2003, Lim and Park 2004). 
 
Intraductal growth type tumours (IG) are polypoid lesions within the bile duct, superficially 
spreading along the mucosal surface, and can develop into intraductal obstructing lesions.  They 
characteristically produce copious amounts of mucin.  Lymph node metastasis appear to be less 
common among IG tumours (Suh et al. 2000).  The majority of IG tumours are papillary 
adenocarcinomas (Lim 2003). 
 
Chapter I: Introduction 
 
 
1-35 
Due to the low incidence of CC, studies reporting survival following resection of CC classified by 
macroscopic subtype frequently combine data from R0, R1 and R2 resection, and do not separate 
lymph node positive from lymph node negative cases.  Therefore drawing conclusions from this 
mixed data is difficult, however it is clear that the IG subtype is related to significantly better 
survival than MF and PI subtypes.  For example, Yamamoto et al. presented data of ICC 
undergoing surgery with curative intent, and showed a 5-year survival of 69% for IG (10 cases), 
and 39% (26 cases) for MF (Yamamoto et al. 1998).  Isaji et al. presented 36 resected cases of ICC 
(Isaji et al. 1999).  Five-year survival rates were 6.7% for MF-PI and MF, 33.3% for PI, and all 
three IG cases were alive at follow-up (26-138 months).  However, this is a small study, and all 
three IG cases had complete resections with negative lymph nodes, whereas the other groups 
contained a heterogeneous mix with regard to completion of resection and lymph node status.  Paik 
et al. examined 70 cases of resected ICC with 7.2% positive margins (Paik et al. 2008).  They 
found the macroscopic subtype to be related to overall survival, but not disease free survival, with 
a median overall survival of 26.4, 9.6, and 54.9 months with MF, PI and IG tumours, and a 5-year 
survival of 41.3%, 0% and 50% respectively.  In summary, from these studies the 5-year survival 
according to the macroscopic subtype ranges from: 6.7-41.3% for MF; 0-33% for PI; and 50-69% 
for PI.  
 
1.1.4.2 Microscopic 
Intrahepatic CC, PHCC, and ECC all exhibit the same range of microscopic features, and are 
classified by the World Health Organisation into the following types: 
 
1. Adenocarcinoma 
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2. Adenosquamous carcinoma 
3. Squamous carcinoma 
4. Cholangiocellular carcinoma 
5. Lymphoepithelioma-like carcinoma 
6. Clear-cell variant carcinoma 
7. Mucoepithelial carcinoma 
 
More than 90% of CC are well to moderately differentiated adenocarcinomas (Carriaga and 
Henson 1995).  They are frequently associated with a fibrous stroma, secondary to a desmoplastic 
response, accompanied by an acute or chronic inflammatory reaction (Leong et al. 2007).  There is 
a prominent fibroblast infiltration over expressing matricellular proteins.  The degree of stroma is 
variable, from little to prolific levels.  Kajiyama et al. examined 58 ICC and PHCC, and 
categorised the tumours according to the degree of stroma, and found CC with a high proportion of 
stroma had poorer survival, with a 3-year survival of 22% vs 55.8% (Kajiyama et al. 1999).  In 
fact, stromal fibroblasts have recently been implicated as a ‘driver’ of tumour (Sirica, Campbell 
and Dumur 2011). 
 
 
Perineural, lymphatic and vascular invasion are frequently observed in CC.  Bhuiya et al. 
examined 70 cases of CC, and found perineural invasion in 81.4% of cases, which was associated 
with significantly lower 5-year survival rate of 32% vs 67% (Bhuiya et al. 1992).  Cho et al 
examined 63 resected ICC, 23.8% had perineural invasion, 34.9% had lymphatic invasion, and 
Chapter I: Introduction 
 
 
1-37 
29.5% had lymph node metastasis:  all of which were associated with poor survival, with 
lymphatic invasion being most significant (median survival 9 vs 23 months) (Cho et al. 2010). 
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1.2 Epidemiology 
Cholangiocarcinoma (CC) is a relatively rare, yet deadly, tumour, with the annual incidence almost 
equaling the annual mortality rate. The incidence of ICC has steadily increased worldwide over the 
previous three decades, from 0.11 to 1.33 per 100,000 men in England and Wales from 1971-2001.  
This increase in incidence is paralleled with a concomitant rise in mortality rates, with age-
standardised mortality rates increasing from 0.2 to 0.83 per 100,000 population in England and 
Wales during the same period, a trend mirrored worldwide (Shaib and El-Serag 2004, Patel 2001, 
West et al. 2006, Khan et al. 2002a).  Intrahepatic CC now represents the commonest primary liver 
cancer among women in the UK, and the second commonest worldwide (West et al. 2006).   
 
There is considerable worldwide variation in the incidence of cholangiocarcinoma due to 
differences in geographical risk factors.  The lowest reported incidence for ICC is in Australia, 
with only 0.7 cases per 100,000 men, compared to the highest incidence in northeast Thailand, of 
96 cases per 100,000 men (Khan et al. 2002b).   
 
Epidemiological data for mortality rates and incidence of CC has been confused in the past by the 
following factors: 
• The sub classification of PHCC; 
• The misclassification of ICC as a primary hepatic tumour without further classification; 
• ECC classification including gallbladder carcinomas; 
• 8th and 9th editions of International Classification of Diseases (ICD) coding.   
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In the ICD coding ICC was often coded as a ‘primary liver tumour’ without further classification, 
rather than ‘intrahepatic bile duct tumour’ (IHBT).  Since the 10th edition of ICD in 2001 all ICC 
are classified as IHBT (C22.1) topographically.  Additionally, until recently gallbladder carcinoma 
(GBCC) was included in the coding for ‘extrahepatic bile duct tumour’, as well as ECC. 
 
Clinicians classify PHCC either as its own entity, as in this report, or a subset of ECC.  However, 
ICD-0-2 classified PHCC (Klatskin tumour 8162/3) histologically, then cross-referenced it 
topographically to ICC. This led to over reporting of ICC incidence, due to misclassification of 
perihilar CC.  In recent editions of ICD the coding has changed to classify PHCC as a subset of 
ECC.   
 
From 1992-2001 the Surveillance Epidemiology and End Results (SEER) database in US used 
ICD-0-2 classification, and it has been calculated that 91% of PHCC were incorrectly classified as 
ICC, rather than ECC.  This overestimated the incidence of ICC by 13%, and underestimated ECC 
by 15%.  However, even with adjustment for the differential classification of CC, there has been a 
striking divergence in the incidence of ICC, PHCC and ECC, with an increase in ICC (Welzel et 
al. 2006). 
 
Studies have shown the rate of ICC to be increasing worldwide.  This was first demonstrated in the 
UK in the 1990s.   From 1968 to 2001 age-standardised mortality rates (ASMR per 100,000 
population) in England and Wales for ICC have increased from 0.10 to 1.49 in males, and 0.05 to 
1.24 in females.  With a 30-fold increase in the total number of annual deaths (36 in 1968, to 1,003 
in 2004), and ICC overtook HCC as the commonest primary liver tumour in women in the UK.  
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Increasing rates of ICC have similarly been demonstrated worldwide (Khan, Toledano and Taylor-
Robinson 2008). 
 
Conversely, the rate of ECC has fallen worldwide.  In England and Wales the age-standardised 
incidence rate (per 100,000 population) from 1971 to 2001 for ECC reduced from of 0.86 to 0.42 
in males, and 0.67 to 0.37 in females (West et al. 2006). 
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1.3 Risk Factors for Cholangiocarcinoma 
There are several known risk factors for CC, however, the majority of western cases have no 
identifiable risk factors, with only 10% of western cases being associated with a known risk factor 
(Ben-Menachem 2007). There are several established risk factors for CC, including: primary 
sclerosing cholangitis; liver flukes and nitrosamines; fibropolycystic liver disease; hepatolithiasis; 
chemical carcinogen exposure; and viral hepatitis (detailed below).   
 
Six case-control studies have been performed to identify risk factors for CC, summarised in Table 
1, with 3 North American, 2 European and 1 Chinese studies (Shaib et al. 2005, Welzel et al. 
2007a, Grainge et al. 2009, Cai et al. 2011, Welzel et al. 2007c).  Liver cirrhosis, of any cause, is 
the most significant risk factor in the West, with an odds ratio of up to 75.86 in one study.  Biliary 
tract stones and biliary inflammation are also important risk factors for cholangiocarcinogenesis.  
Chronic pancreatitis was assessed in one study, and revealed a surprisingly high odds ratio (5.9-
9.3).  Diabetes mellitus, obesity, and smoking were linked to CC, but the association was not as 
strong as with other risk factors. A recent systematic review of diabetes mellitus as a risk factor for 
the development of CC calculated that individuals with diabetes mellitus has a 50% increased risk 
compared to non-diabetic individuals (Ren et al. 2011). 
 
1.3.1 Primary Sclerosing Cholangitis (PSC) 
Primary sclerosing cholangitis is a chronic cholestatic liver disease of unknown aetiology, 
associated with inflammation and fibrosis of intra- and extrahepatic bile ducts ultimately leading to 
liver cirrhosis (Lee and Kaplan 1995).  It is the commonest known risk factor for CC in the west.  
Two large European studies have investigated the incidence of CC among patients with PSC:  a 
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Swedish study was performed by Bergquist et al., involving 604 patients with PSC (Bergquist et 
al. 2002); and Boberg et al. performed a multicentre European review of 394 patients with PSC 
(Boberg et al. 2002).  In the two studies 12.2–13.3% PSC patients developed CC, 37–50% of 
which were diagnosed with CC within the 1st year of diagnosis of PSC.   Patients that developed 
CC were found to have significantly higher bilirubin levels, lower albumin levels, and more severe 
coagulopathy than PSC patients without malignancy.  Overall 82% of PSC patients also had 
inflammatory bowel disease (IBD), and those with CC had a significantly longer history if IBD 
before diagnosis of PSC and subsequently CC (median 17.4 vs 9.0 years).  Bergquist calculated 
that, compared to the general population, patients with PSC had 161 times the risk of developing 
CC.  
 
1.3.2 Liver Flukes and Nitrosamines 
Liver flukes are parasitic helminths.  Part of their life cycle is in freshwater snails and fish, from 
which they are transmitted to humans via the consumption of improperly cooked fish.  They 
ascend the bile duct, where they mature into adult worms approximately 7 x 1.5mm in size, 
residing in the small and medium sized bile ducts in the liver (Smout et al. 2011). The adult worms 
lifespan can be up to 30 years (Upatham and Viyanant 2003).   
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Table 1: Summary of Risk Factors for Cholangiocarcinoma from Case-Control Studies  
Shaib: USA   
(Shaib et al. 2005) 
Welzel: Denmark 
(Welzel et al. 2007a) 
Welzel: USA  
(Welzel et al. 2007b) 
Welzel: USA 
(Welzel et al. 2007b)  
Grainge: UK 
(Grainge et al. 2009) 
Cai: China 
(Cai et al. 2011) 
 
625 ICC 
90,834 Controls 
764 ICC 
3,056 Controls 
535 ICC  
102,782 Controls 
549 ECC 
102,782 Controls 
372 CC 
5760 Controls 
313 PHCC 
608 Controls 
 Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI 
Cirrhosis/Alcohol 
Cirrhosis (non-
infective/non-
specified) 
27.2** 19.9-37.1 75.86* 10.17-
565.68 
10.0* 6.1-16.4 5.4* 2.9-10.2 - - - - 
Alcoholic liver 
disease 
7.4 4.3-12.8 19.22 5.55-66.54 3.1 1.3-7.5 4.5 2.2-9.1 - - NS - 
Infectious Aetiology 
HBV 0.8 0.1-5.9 - - - - - - - - NS - 
HCV 5.2 2.1-12.8 - - 4.4 1.4-14.0 1.5 0.2-11.0 - - NS - 
HCV (including 
unspecified 
hepatitis) 
6.1 4.3-8.6 - - - - - - - - - - 
HIV 5.9 1.8-18.8 - - - - - - - - - - 
Biliary Tract Condition 
Choledocholithiasis 4.0 1.9-8.5 23.97 2.89-198.87 22.5 16.9-30.0 34.0 26.6-43.6 - - 2.7 1.05-6.94 
Cholangitis 8.8 4.9-16.0 6.32 2.29-17.48 64.2 47.7-86.5 45.7 32.9-63.6 - - - - 
Cholelithiasis - - 4.02 2.02-7.99 13.5 11.3-16.1 11.0 9.1-13.2 1.78 1.19-2.67 4.49 2.99-6.77 
Liver fluke - - - - - - - - - - 10.08 1.09-93.76 
Other risk factors 
IBD 2.3 1.4-3.8 4.67 1.57-13.89 4.0 2.5-6.4 2.1 1.1-4.0 - - NS - 
Diabetes Mellitus 2.0 1.64-2.4 1.43 0.78-2.63 1.8 1.5-2.1 1.5 1.3-1.8 1.48 1.00-2.17 NS - 
Chronic Pancreatitis     5.9 2.9-12.0 9.3 5.3-16.46     
Obesity - - 2.05 0.75-5.58 1.7 1.1-2.6 1.1 0.7-1.8 1.52 1.03-2.24 - - 
Smoking 1.8 1.2-2.70 - - 1.8 1.0-3.2 1.7 1.0-3.0 1.38 1.01-1.87 NS - 
* = non-specified       ** = non-infective        NS = not significant 
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Opisthorchis viverrini (O. viverrini) and Clonorchis sinensis (C. sinensis) are two 
liver flukes implicated in the carcinogenesis of CC. Opisthorchis viverrini infects 10 
million people in Thailand, Laos, Cambodia, and Vietnam (Sripa et al. 2010, Keiser 
and Utzinger 2009, Smout et al. 2011); in fact O. viverrini infection is endemic in 
northeastern Thailand, the area with the highest incidence of ICC worldwide (Bisseru 
and Chong 1969).  Clonorchis sinensis is endemic in southeast Asia (Viranuvatti and 
Stitnimankarn 1972), and infects 35 million people in China, Korea, Taiwan, 
Vietnam, and Thailand (Smout et al. 2011, Keiser and Utzinger 2009, Traub et al. 
2009). 
  
Syrian golden hamsters infected with O. viverrini developed ICC when fed 
nitrosamine containing compounds, but not with O. viverrini infection alone, or 
nitrosamine containing compounds alone (Thamavit et al. 1978).  In Asia many foods 
contain high levels of nitrosamines, or nitrosating agents.  Nitrosamines are believed 
to act as a cofactor with liver flukes in cholangiocarcinogenesis. 
 
Two case control studies, in Korea and Thailand, were performed to investigate the 
link between CC and liver flukes.  Choi et al enrolled 185 Korean patients, and found 
that the risk of CC was significantly increased with C. sinensis infection (odds ratio 
8.615), and a history of eating freshwater fish (Choi et al. 2006).  Honjo et al. enrolled 
258 Thai patients, and found infection with O. viverrini significantly increased the 
risk of developing CC (odds ratio 27.09) (Honjo et al. 2005).  An increased risk of CC 
was also associated with eating fermented products (including fish) and smoking. 
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Liver flukes are believed to be carcinogenic through three mechanisms causing 
chronic inflammation: physical damage caused by hooking on with oral and ventral 
suckers for feeding; antigen release into the infected biliary epithelial cells, leading to 
a sustained and massive inflammatory cell infiltration; excretory/secretory (ES) 
parasitic soluble proteins which induce an inflammatory reaction in the bile ducts 
(Smout et al. 2011). 
 
Opisthorchis viverrini was classified as a Group I carcinogen by the International 
Agency for Research on Cancer in 1994, and in 2009 C. sinensis was also recognized 
as a Group I carcinogen (Bouvard et al. 2009). 
 
1.3.3 Fibropolycystic Liver Disease 
Congenital abnormalities of the biliary tree are associated with an increased risk of 
CC.  These conditions include: choledochal cysts; Caroli’s syndrome; and congenital 
hepatic fibrosis. 
 
Choledochal cysts are cystic dilatations of the bile ducts. Choledochal cysts are rare, 
more frequent in Japan and Asia than the West, and more common in women (Todani 
et al. 1977, Cho et al. 2011).  They are classified by the Todani classification, a 
modification of the Alonso-Lej classification, according to which part of the bile duct 
is affected (Table 2).   
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Table 2: Todani Classification of Choledochal Cysts (Todani et al. 1977) 
Type Description 
Type I Segmental dilatation; diffuse or cylindrical dilatation 
Type II Diverticulum type in the whole extrahepatic duct 
Type III Choledochocele 
Type IVa Multiple cysts at the intra- and extrahepatic ducts 
Type IVb Multiple cysts at the extrahepatic duct only 
Type V Intrahepatic bile duct cyst (single or multiple) (Caroli’s disease) 
 
A recent Korean study of 204 adults with surgically treated choledochal cysts found 
concurrent CC in 9.8% patients (Cho et al. 2011). The incidence of malignant 
transformation increased with age, with a risk of 14.3% when treated over the age of 
20 years (Voyles et al. 1983), increasing to 37.5% when treated between the ages 61-
67 years (Cho et al. 2011).  Choledochal cysts with anomalous pancreaticobiliary duct 
union (APBDU) are associated with an increased risk of CC (Metcalfe, Wemyss-
Holden and Maddern 2003, Han et al. 1997).  APBDU is where the pancreatic duct 
enters common bile duct (CBD) at an abnormal angle proximal to the muscular layers 
of the ampulla of Vater, leading to damaging reflux of pancreatic juice along the 
CBD, causing chronic inflammation.  
 
Caroli’s disease is an autosomal recessive disease characterised by Todani Type V 
cysts: multiple cystic dilatations of medium sized intrahepatic bile ducts (Desmet 
1992).  Congenital hepatic fibrosis is an autosomal recessive disease characterised by 
periportal fibrosis of the small-sized intrahepatic bile ducts (Shorbagi and Bayraktar 
2010).  Caroli’s syndrome is a combination of Caroli’s disease and congenital hepatic 
fibrosis (Desmet 1992).  Individually Caroli’s disease and congenital hepatic fibrosis 
are risk factors for CC, however, Caroli’s syndrome, the combination of Caroli’s 
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disease and congenital hepatic fibrosis, further increases the risk of development of 
CC.  They cause biliary stasis and recurrent cholangitis, leading to chronic biliary 
inflammation. 
 
Cholangiocarcinogenesis associated with fibropolycystic liver disease is thought to be 
caused by pancreatic juice reflux and recurrent cholangitis, resulting in chronic 
inflammation, and biliary stasis, resulting in de-conjugation of carcinogens in bile 
(Khan et al. 2005a). 
 
1.3.4 Hepatolithiasis 
Hepatolithiasis are intrahepatic bile duct stones proximal to the common hepatic duct, 
a distinct entity from common bile duct stones originating from the gallbladder 
(choledocholithiasis) (Tsui et al. 2011).  Stone formation is related to Escherichia 
Coli (E. Coli) infection transmitted from the portal circulation (Maki 1966).  E. Coli 
causes de-conjugation of bilirubin glucuronide by ß-glucuronidase.  Biliary ß-
glucuronidase is normally inhibited by glucaro-1:4-lactone, however the low protein 
and low fat oriental diet decreases biliary glucaro-1:4-lactone levels, leading to 
bilirubin glucuronide de-conjugation and stone formation (Tsui et al. 2011).   
Hepatolithiasis cause biliary stasis, leading to recurrent cholangitis, chronic 
inflammation, and malignant transformation (Koga et al. 1985).  Hepatolithiasis is 
rare in the West, with a higher frequency in Asia (Wen and Lee 1972).  In Taiwan, 
31-51.6% of patients treated for cholelithiasis (gallbladder stones) also had concurrent 
hepatolithiasis (Chen et al. 1993).  Two cases series, from Japan and Taiwan, of 
patients with hepatolithiasis reported a frequency of CC of 4.9-10% (Koga et al. 1984, 
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Kubo et al. 1995).  In a further case series from Taiwan, 69% of ICC resections were 
found to have hepatolithiasis (Okuda, Nakanuma and Miyazaki 2002). 
 
1.3.5 Chemical Carcinogen Exposure 
Thorotrast is a radiological contrast agent used worldwide from 1928 to 1955 (Sahani 
et al. 2003).  Thorotrast is a 20-25% colloidal solution of thorium dioxide (282ThO2) 
that emits radioactive α-particles.  It was used intravenously and was commonly used 
for angiography (Mori et al. 1999).  Intravenous injection of Thorotrast causes 
chronic exposure of the epithelium to α-radiation, as the thorium dioxide particles 
remain in the reticulo-endothelial system for life, with greater than 60% stored in the 
liver (Mori and Kato 1991).  The first case of CC secondary to Thorotrast was 
described in 1957, 11 years after it was administered (Okinaka et al. 1957).  
Thorotrast has been linked to several different malignancies, including lung cancer, 
leukaemia, and HCC; however, the commonest malignancy resulting from thorotrast 
exposure is CC (Kido et al. 1999).  The Portuguese Thorotrast Study Group reported a 
rate ratio of 70.8 (95% CI 19.9-251.3) for the development of CC with thorotrast 
exposure (dos Santos Silva et al. 1999).   Thorotrast administration is associated with 
latent period to development of CC, with a significant increase in CC after 20 years 
(Mori et al. 1999). 
 
1.3.6 Viral Hepatitis 
Viral hepatitis is an established risk factor for the development of hepatocellular 
carcinoma (HCC).  Viral hepatitis is also a risk factor for the development of CC, 
though at a much lower frequency.  A cohort study of 600 patients with Hepatitis C 
virus (HCV)-related cirrhosis found 11 patients (1.8%) developed CC, compared to 
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206 patients (34.4%) that developed HCC (Kobayashi et al. 2000).   A large US case-
controlled study identified HCV infection  (including cases with unspecified hepatitis) 
as a risk factor for CC, with a prevalence of 5.6% compared to 1% in controls (Shaib 
et al. 2005). Hepatitis B infection was not found to be a risk factor in this US study, 
however three smaller case control studies from Korea, Japan and Italy have 
identified both Hepatitis C and Hepatitis B infection as risk factors for the 
development of CC (Shin et al. 1996, Donato et al. 2001, Kobayashi et al. 2000, Shaib 
et al. 2005).  Liver cirrhosis from any cause is associated with the development of CC 
(Khan et al. 2009).   
 
Table 3: A Summary of Strong and Weak Associations with 
Cholangiocarcinoma 
 
Strong Associations Weak Associations 
Primary Sclerosing Cholangitis Smoking 
Liver Flukes and Nitrosamines Obesity 
Fibropolycystic Liver Disease Diabetes Mellitus 
Hepatolithiasis  
Chemical Carcinogen Exposure  
Viral Hepatitis / Liver Cirrhosis  
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1.4 Clinical Presentation, Diagnosis, and Treatment 
1.4.1 Presentation 
Cholangiocarcinoma often presents late, with overt jaundice caused by biliary 
obstruction, associated pale stools and dark urine.  Due to the advanced stage of 
disease at presentation, it is often accompanied by constitutional symptoms: weight 
loss, malaise, fatigue, and abdominal pain.  It can be also detected through 
investigation of incidentally identified deranged liver function tests (bilirubin, 
alkaline phosphatase, gamma glutamyl transpeptidase). 
 
In the 1970s the average age of presentation of CC was in the 6th decade of life 
(Lazaridis and Gores 2005).  However the age of presentation has been increasing, 
and presently the presentation of CC peaks in the 7th and 8th decades (Lepage et al. 
2011). In a recent epidemiological study from Italy the incidence of CC was highest 
in the 8th decade, with a leap in incidence for ECC from the 7th to 8th decade, 3.7 times 
that of ICC (176.3 per 1,000,000 compared to 47.8 per 1,000,000 population) (Alvaro 
et al. 2010).  It is not known why the age of presentation is increasing.  There is a 
slight male preponderance, with a male to female ratio of approximately 1.5:1 for ICC 
in the United States (Lazaridis and Gores 2005). 
 
1.4.2 Diagnosis 
Cholangiocarcinoma remains a diagnostic challenge, as in the early stages it is often 
asymptomatic, tending to present late, contributing to its high mortality.  
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Three sets of consensus guidelines have been produced for the diagnosis and 
treatment of cholangiocarcinoma:  
• The British Association for the Study of the Liver (BASL) and The British 
Society of Gastroenterology (BSG) in 2002 (Khan et al. 2002a);  
• The European Society of Medical Oncology (ESMO) in 2011 (Eckel, Brunner 
and Jelic 2011);  
• The National Comprehensive Cancer Network (NCCN) updated online in 
2011 (Benson et al. 2009).   
 
Diagnosis is challenging, based on a combination of radiology and pathology.   
 
1.4.2.1 Radiology 
Computerised tomography (CT) and/or magnetic resonance imaging (MRI) are used 
as routine imaging techniques, however imaging cannot detect CC at an early stage 
nor differentiate between benign and malignant lesions. 18F-FDG-Positron emission 
tomography-CT (FDG-PET-CT) is being increasingly used in the assessment of 
malignant tumours.  FDG-PET-CT combines the anatomical information derived 
from the CT component, and functional/metabolic information derived from the FDG-
PET component of the scan.  PET uses a glucose analogue labeled with 18F to give 
18F-fluorodeoxyglucose (18F-FDG, also known as FDG), and identifies area of 
increased FDG/glucose uptake.  Malignant cells demonstrate increased glucose/FDG 
uptake, however this is not specific to malignant cells (Blodgett, Meltzer and 
Townsend 2007).  A study of 99 patients with CC, gallbladder cancer, and benign 
biliary disease compared FDG-PET-CT and multi-detector row CT for diagnosis (Lee 
et al. 2010).  They found that FDG-PET-CT offered no significant advantage over 
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standard CT for diagnosing the primary tumour or regional lymph node spread, with 
sensitivity for diagnosing the primary tumour of 84.2% with CT compared to 90.2% 
with FDG-PET-CT, and detecting regional lymph node metastasis with a sensitivity 
of 79.5% with CT compared to 82.1% with FDG-PET-CT.   Distant metastases were 
identified with improved sensitivity with FDG-PET-CT (sensitivity 94.7% vs 63.2%).  
However, some tumours exhibit poor uptake of FDG, possibly due to low cellularity 
(Fevery et al. 2005).  At present the consensus groups do not advocate its routine use, 
although it is likely to be introduced into the guidelines when they are next updated.    
 
1.4.2.2 Histology/Cytology: ERCP and PTC 
Histology provides the definitive diagnosis, yet this is an inaccessible and difficult 
area to biopsy.  A common presenting sign of CC is overt obstructive jaundice with 
abnormal liver function tests, as the result of the tumour either partially or completely 
blocking the bile ducts.  In order to both diagnose and treat these patients they 
frequently undergo either an endoscopic retrograde cholangio-pancreatogram (ERCP) 
or percutaneous transhepatic cholangiogram (PTC).   ERCP involves passing an 
endoscope via the mouth down to the duodenum, and cannulating the bile duct 
distally.  PTC involves cannulating the proximal bile ducts using a needle and 
subsequently a catheter.  Both these procedures cannulate the bile duct, enabling bile 
duct imaging (cholangiogram), sampling of bile and brushing of the bile duct to 
obtain cells for cytological analysis.   
 
Unfortunately biliary cytology and brushings have poor sensitivity for detecting CC, 
often requiring repeat diagnostic procedures. Hattori et al. performed cytological 
analysis on bile samples from 100 patients with PHCC, and found a sensitivity of 
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55%, specificity of 100%, and accuracy of 56% (Hattori et al. 2011).  This is much 
more sensitive than many other clinical studies.  They aspirated 5ml bile either from 
endoscopic nasobiliary-drainage or percutaneous transhepatic biliary-drainage.  
However, it is not standard practice to perform endoscopic nasobiliary drainage in the 
UK, and often smaller volumes of bile are obtained during ERCP, and repeat 
sampling requires repeat endoscopic procedures.  Siqueira et al. performed biliary 
cytology in 151 patients with primary sclerosing cholangitis, with and without CC 
(Siqueira et al. 2002).  They found that the sensitivity of the technique increased with 
repeat testing, improving the sensitivity from 32.1% to 46.4% as you increase the 
number of procedures from 1 to 3.  However, neither ERCP nor PTC are complication 
free procedures.  In a study including 2,103 patients, complications were reported 
from ERCP in 4.95%, including: pancreatitis; haemorrhage; perforation; and death (in 
0.12%) (Masci et al. 2001).  In a study of PTC and with drainage and stenting 
involving 984 procedures in 704 patients, complications were reported in 10%, 
including: sepsis; haemobilia; bile leak; false passage; early stent blockage; liver 
abscess and death (2%, and 13% 30-day mortality) (Tapping, Byass and Cast 2011). 
This repeated procedural burden to the patient, with a procedural risk of pancreatitis, 
perforation, sepsis and death, to achieve a sensitivity of only 46.4% to 55% is not 
ideal, and improved diagnostic techniques are desperately needed.  Kipp et al. used 
FISH centromeric probes for chromosomes 3, 7, 17, and chromosomal band 9p21 to 
examine bile and biliary brushings, and cytology to examine biliary brushings in 39 
cases CC (Kipp et al. 2004).  They found the sensitivity of biliary brushing cytology 
to be 18%, increasing to 33% when combined with FISH analysis. 
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1.4.2.3 New Techniques 
Technological advances are improving the imaging and biopsy techniques in CC, with 
technologies such as endoscopic ultrasound (EUS) and spyglass endoscopy, however 
the utility of these technologies is still being validated.  Endoscopic ultrasound can be 
used to assess the nature of the biliary stricture, and also to obtain EUS-guided-fine 
needle aspiration (FNA) for cytological analysis.  Variable sensitivity has been 
reported, from 25-91% (Van Beers 2008).  Spyglass is a new technique, where direct 
video endoscopy is possible of the bile duct, enabling direct visualisation of a biliary 
stricture, and biopsies under direct vision.  Spyglass enables a diagnostic triad, of 
direct visualisation, biopsy, and cytology.  In a study from Texas with 20 malignant 
biliary strictures, cytology was diagnostic in 4/20 (20%), spyglass assisted biopsy 
showed malignant features in 6/11 (54.5%) (Fishman et al. 2009).  Diagnosis of 
malignancy was increased to 11/20 (55%) cases when combining direct visualisation, 
cytology and biopsy. 
 
1.4.2.4 Immunohistochemistry Markers 
It can be a challenge, especially with poorly differentiated tumours, to distinuguish 
between: CC; hepatocellular carcinoma (HCC); and metastatic adenocarcinoma.  
Differentiation between these three different tumour types is vital as they have very 
respond to different treatments.  There are no pathognomonic markers for CC, and a 
panel of immunohistochemistry markers is used to aid differentiation between tumour 
types.  The differing expression of each marker aids identification of the tissue of 
origin, i.e. cholangiocyte, hepatocyte, or distant epithelial origin.  Cytokeratins  (CK) 
are the most frequently used markers.  Cytokeratins are intermediate-size filaments of 
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keratin-like proteins found in the cytoskeleton of epithelial cells (Moll et al. 1982).  
Maeda et al examined 90 liver tumours (30 CC; 30 HCC; 30 metastatic colorectal 
adenocarcinomas (mCRC)) using immunohistochemistry for CK 7, CK 19, CK 20, 
AFP (alpha feto-protein), CEA (carcino-embryonic antigen), and Ca 19.9 
(Carbohydrate antigen 19.9), see Table 4 (Maeda et al. 1996).  
  
Table 4: Expression of immunohistochemistry markers in CC, HCC, and mCRC 
(frequently expressed markers shaded in orange) 
Marker CC HCC mCRC 
CK 7 97% 7% 3% 
CK 19 77% 0% 64% 
CK 20 10% 0% 74% 
AFP 7% 10% 0% 
CEA 43% 0% 87% 
Ca 19.9 63% 0% 50% 
 
Cases showing diffuse expression (3+) were recorded as ‘positive’ (see table).  CK 7 
and CK 20 were the most useful markers to distinguish CC from mCRC.  CK 19, 
AFP, CEA and Ca 19.9 showed differing expression between HCC vs CC and mCRC.   
 
A more recent study by Rullier et al examined 48 CC and 31 mCRC, and observed 
similar data to Maeda et al: 96% CC were positive for CK 7, and 19% mCRC; 70% 
CC were positive for CK 20, and 100% mCRC (Rullier et al. 2000).  Many other 
markers have been investigated to diagnose CC, though no significant advantage has 
been identified over CK7, CK 19, CK 20, CEA, and Ca 19.9.  To further complicate 
the use of IHC markers used to diagnose CC, markers appear to be differentially 
expressed along the biliary tract.  Guedji et al examined 111CCc (59 ICC and 52 
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PHCC), and found the expression of several proteins to differ between ICC and 
PHCC, for example MUC5AC (22% vs 66%), Akt 2 (27% vs 54%), CK 8 (81% vs 
98%) and VEGF A (69% vs 25%) (Guedj et al. 2009).  Despite multiple markers 
being used to diagnose CC, the lack of a pathognomonic marker demonstrates the 
need to identify new diagnostic markers for CC. 
 
In summary, the following markers are used to distinguish between each type of 
tumour: 
• CC vs mCRC: CK 7 and CK 20 
• HCC vs CC and mCRC: CK 19, AFP, CEA, and Ca 19.9 
 
1.4.2.5 Serum Tumour Markers 
At present there are no serum tumour markers specific for CC.  Although several 
tumour markers are frequently raised in CC, they are also raised in a variety of benign 
conditions, including primary sclerosing cholangitis, biliary obstruction, cholangitis, 
and other malignancies such as pancreatic and gastric carcinoma, which are key to 
distinguish from CC.   
 
1.4.2.5.1 Ca 19.9 
Carbohydrate Antigen 19.9 (Ca 19.9) was first identified by Herlyn et al from 
hybridoma antibodies with human colon, gastric and pancreatic adenocarcinoma cell 
lines (Herlyn et al. 1982).  Ca 19.9 is a sialylated lacto-N-fucopentase II epitope 
related to the Lewis blood group antigens.  Raised Ca 19.9 levels are found in a 
variety of malignant tumours, including: CC; pancreatic carcinoma; gastric 
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carcinoma; colon carcinoma; and breast cancer (Gupta et al. 1985).  As it is expressed 
in multiple malignancies, its main utility is for distinguishing malignant from non-
malignant disease.   
 
Primary sclerosing cholangitis (PSC) is a disease causing bile duct strictures and is a 
risk factor for developing CC.  It is vital to be able to differentiate between benign 
PSC strictures, and the development of malignant PSC-associated strictures, which is 
not possible with radiology.  Three studies by Ramage, Levy and Siqueira have 
reviewed the utility of serum Ca 19.9 for differentiating PSC with or without CC 
(Ramage et al. 1995, Levy et al. 2005, Siqueira et al. 2002).  The median Ca 19.9 
level for patients with PSC and concurrent CC was 275.4 - 377.1 U/ml (range 6.5 - 
81,362 U/ml), and in PSC alone was significantly lower at 15 - 66.7 U/ml (range 0.2 - 
839 U/ml).  Each group suggested a diagnostic cut-off level, as summarised in Table 
5.  Ca 19.9 levels have also been investigated for other benign biliary diseases.  Li et 
al. measured Ca 19.9 levels in 115 CC patients compared to 85 patients with benign 
biliary disease, and 120 normal blood donors (Li and Zhang 2009).  In the CC cohort 
40 patients had liver cirrhosis, 5 had hepatitis C, and 12 had PSC.  In the benign 
biliary disease cohort 45 had cholangitis (including 12 with PSC), 35 had bile duct 
stones, and 12 had primary biliary cirrhosis.  The mean Ca 19.9 level for CC was 
359.58 – 366.57 U/ml, and a statistical cut off of greater than 37 U/ml was selected 
for malignant disease, with a sensitivity of 68.4% and specificity of 75%, however 
38/115 cases of CC had levels less than 37 U/ml.  Furthermore, some people do not 
express Ca 19.9 at all, and it is reported that up to 10% of the Japanese population do 
not express Ca 19.9 due to their genotype (Enjoji et al. 2004). 
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Table 5: Sensitivity and specificity of proposed cut-off level of Ca 19.9 for 
diagnosis ad CC in PSC 
Study Ca 19.9 cut-off (U/ml) Sensitivity Specificity 
Ramage > 200 60% 91% 
Levy > 129 78.6% 98.5% 
Siqueira > 180 66.7% 97.7% 
 
 
1.4.2.5.2 CEA 
Carcinoembryonic antigen (CEA) was identified in 1979 by Koprowski et from 
hybridoma antibody experiments (Koprowski et al. 1979). 
 
Similarly to Ca 19.9, CEA is a suggestive, but not diagnostic tumour marker for CC.  
It is expressed at high levels in colorectal carcinoma, and other gastrointestinal 
malignancies (Hammarstrom 1999).  Ramage and Siqueira measured CEA levels in 
PSC patients in the above mentioned studies, and found a median level of 7 - 68.4 
ng/ml (range 0.1 - 959 ng/ml) with CC and concurrent PSC, and 2.2 – 3.5 ng/ml 
(range 0.5 - 16.7 ng/ml) with PSC only (Ramage et al. 1995, Siqueira et al. 2002).  
Ramage suggested a cut off of greater than 5 ng/ml for CC with a sensitivity and 
specificity of 53.3% and 86.1%.  Siqueira suggested a level greater than 5.2 ng/ml 
with a sensitivity and specificity of 68.0% and 81.5%. 
 
Ramage et al proposed the use of the following formula to distinguish patients with 
CC and PSC from PSC alone: 
Ca 19.9 + (CEA x 40) 
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A value of greater than or equal to 400 was classed as positive for CC, and gave a 
specificity and positive predictive value of 100% and a sensitivity of 66% (Ramage et 
al. 1995).   
 
1.4.2.5.3 Ca 125 
Carbohydrate antigen 125 or cancer antigen 125 (Ca 125) was identified in 1981 by 
Bast et al using hybridoma antibodies developed from ovarian cancer cell lines, and it 
is expressed in several gastrointestinal and reproductive malignancies (Bast et al. 
1981, Jacobs and Bast 1989). 
 
Haglund et al examined Ca 125 levels from 162 patient with digestive tract 
malignancy (including 13 patients with CC) and 155 patients with benign digestive 
tract disease (Haglund et al. 1991).  They found Ca 125 levels to be elevated in 62% 
of CC, however levels were also raised in benign biliary disease, and other 
malignancies of the digestive tract. 
 
 
In summary Ca 19.9 remains an informative yet imperfect tumour marker for CC, and 
at present a raised level greater than 100 U/ml is considered suggestive of CC (Khan 
et al. 2002a).  Serum CEA, and Ca-125 levels are also used in the assessment of CC, 
but have poor sensitivity and specificity.  
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1.4.2.5.4 Novel Tumour Markers 
Several novel tumour markers have been proposed for CC.  One such serum tumour 
marker is human telomerase (hTERT) mRNA (the role of telomerase is discussed in 
section ‘Telomerase Length’).  In a study of 84 patients including 33 CC, 41 benign 
biliary disease, and 10 healthy controls, Leelawat et al measured hTERT mRNA 
levels using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
(Leelawat et al. 2006).  There was no detectable hTERT mRNA in the healthy control 
group, however it was detectible in the CC group, with a sensitivity and specificity of 
84.85% and 78.05% for CC.  Ca 19.9 levels were measured in the same patients, with 
a cut off of >100 U/ml as positive, and the sensitivity and specificity for CC was 
60.0% and 80.49%.  Therefore measurement of hTERT mRNA for diagnosing CC is 
more sensitive than Ca 19.9 in this study, but no more specific, and is unlikely to 
represent a significant clinical advantage over Ca 19.9 for diagnosis.  
 
Enjoji et al proposed RCAS1 antigen (Receptor-binding Cancer Antigen expressed 
on SiCo cells) as a novel tumour marker (Enjoji et al. 2004).  They compared RCAS1 
levels using an ELISA assay (with a cut off of 17.5 U/ml) with Ca 19.9 (with a low 
cut-off of 32 U/ml) in 38 patients with malignancy (27 CC, 4 gallbladder carcinoma, 
7 ampullary carcinoma) and 100 patients with benign biliary disease.  The sensitivity 
and specificity of RCAS1 for malignancy was 74.4% and 91.0%, compared to the 
sensitivity of Ca 19.9 of 59.0%.  RCAS1 levels are stable with benign biliary 
obstruction, however Ca 19.9 levels rise.  However it should be noted that the data for 
RCAS1 was not more specific or sensitive than Ca 19.9 when using the standard 
higher cut off levels (>100). 
 
Chapter I: Introduction 
 
 
1-61 
Interleukin-6 (IL-6) serum levels are raised in many diseases, including 
cardiovascular disease, type II diabetes mellitus, and malignancy (Heikkila, Ebrahim 
and Lawlor 2008).  Tangkijvanich et al measured IL-6 and Ca 19.9 serum levels in 45 
CC, 15 HCC, 15 metastatic liver cancers, 10 benign biliary disease, and 10 healthy 
controls (Tangkijvanich et al. 2004).  Using a cut-off of >50 pg/ml for IL-6, and 
>100U/ml for Ca 19.9 gave a sensitivity and specificity of 55.6% and 80.0% for IL-6 
and 62.2% and 76.6% for Ca 19.9.  Combining the data from the two markers 
increased the sensitivity from 55.6 - 62.2% to 80.0%, however it decreased the 
specificity from 80.0 - 76.6% to 70.0% 
 
1.4.3 Treatment 
The outlook once diagnosed with CC is dismal, with reported 5-year overall survival 
rates of only 3% (Carriaga and Henson 1995), however, this improves to 15-67% 
following resection for ICC (DeOliveira et al. 2007, Thanasai et al. 2006, Jan et al. 
2005, Uenishi et al. 2001, Inoue et al. 2000, Yamamoto, Takasaki and Yoshikawa 
1999, Madariaga et al. 1998),  and to 23-62% for ECC (DeOliveira et al. 2007, Cheng 
et al. 2007, Murakami et al. 2007, Yoshida et al. 2002, Fong et al. 1996).   
Unfortunately the majority of patients with CC present at a late stage, and are unable 
to be offered a curative resection.  Memorial Sloan Kettering presented data from 352 
consecutive cases of PHCC from 1991-2008 (Rocha et al. 2010).   Eighty-one patients 
were unresectable at presentation, and a further 125 patients were found to be 
unresectable at exploration; therefore 59% of patients had unresectable disease at 
presentation or exploration (206/352 patients).  For the 146 patients resected, 111 had 
a potentially curative operation (R0; complete removal of tumour), therefore for all 
cases presenting with PHCC only 35% received potentially curative treatment.  The 
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median disease-specific survival for R0 resections was 74.3 months, compared to 13.1 
months for unresectable disease.  Unfortunately an R0 resection does not guarantee 
cure, and this has been further demonstrated in a series of 79 cases of PHCC with R0 
resection, where there was a recurrence rate of 53% in the 4-years after surgery.  In 
this study, recurrence in R0 disease was associated with high T-stage (TNM 
classification) and lymph node involvement (Kobayashi et al. 2010). 
 
A recent multicentre study from the AFC-IHCC 2009 Study Group reported data for 
ICC R0 and R1 resections (Farges et al. 2011).  Only mass-forming tumours were 
included in the study, to remove the variation in survival caused by the PI and IF 
subtypes.  There were 212 R0/R1 cases were included, and 78 controls (R2 or no 
resection).  Median survival in the control group was 6 months, with 1- and 3-year 
survival of 26% and 0%. In R0/R1 group the median survival was 28 month, with 1-, 
3-, and 5-year survival of 77%, 43%, and 28%.  In R0/R1 group, if they were N1 
(lymph node positive), then resection status (R0 vs R1) did not significantly affect 
survival (median survival 18 vs 13 months). However in the N0 (lymph node 
negative) group, resection status was significant with R0N0 median survival of 58 
months, versus 12 months for R1N0 cases.  Furthermore, in lymph node negative R0 
resections, an increased distance of margin clearance also correlated with improved 
survival. 
 
1.4.3.1 Adjuvant chemotherapy 
Following surgical resection there is no clear evidence for adjuvant chemotherapy in 
CC.  To date there have been no definitive randomised controlled trial for adjuvant 
chemotherapy for CC. 
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A randomised controlled phase III study of mitomycin C and 5-FU in 
pancreaticobiliary carcinoma was reported in 2002 by Takada et al (Takada et al. 
2002).  It included 445 patients: 118 CC; 158 pancreatic carcinoma; 112 gallbladder 
carcinoma; and 48 ampullary carcinoma.  The study was for adjuvant treatment for 
advanced tumours (stage II-IV) following surgical resection (R0 and R1).  For CC, 58 
patients were in the treatment group and received chemotherapy, and 60 patients were 
in the control group receiving no drug or placebo.  Adjuvant chemotherapy produced 
a survival benefit for patients with gallbladder carcinoma.  There was however no 
survival benefit for CC, with 5-year survival rates of 26.7% and 24.1% in treatment 
and control groups.  
 
Due to the success of adjuvant chemotherapy with gemcitabine in pancreatic cancer 
demonstrated by the CONKO-001 trial several trials have focused on gemcitabine for 
hepatobiliary disease (Oettle et al. 2007, Burris et al. 1997, Rothenberg et al. 1996).  
The CONKO-001 trial enrolled 368 patients with pancreatic adenocarciinmoa 
following R0/R1 resection.  The treatment group received gemcitabine, and 
demonstrated and median disease free survival of 13.9 months, compared to 6.9 
months in the control group.  However, there was no difference in overall survival, 
22.1 months in the treatment group, and 20.2 months in the control group.   
 
Gemcitabine and S-1 (5-FU prodrug) were used in a phase II study with 103 patients 
with advanced biliary tract cancers, classified as UICC stage IIA or IIB, with both R0 
and R1 resections (Murakami et al. 2009).  The study included 21 PHCC, 14 ECC, 9 
ampullary carcinoma, and 6 gallbladder carcinomas.  Fifty patients received 
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chemotherapy, and 53 were controls; there were no significant differences in patient 
demographics or pathological characteristics between groups.  Overall survival at 5-
years was 57% in the chemotherapy group, and 27% in the control group.  Positive 
surgical margins (R1) was a negative prognostic factor, nevertheless chemotherapy 
improved survival in both margin positive and negative cases.  Chemotherapy also 
improved survival in node positive, but not node negative cases.  This was a small 
non-randomised study, and requires phase III validation, however it does suggest that 
gemcitabine and 5-FU would offer survival advantage following R0 and R1 resection.   
 
The BILCAP trial (Clinicaltrials.gov identifier NCT00363584) is currently ongoing in 
the UK, with results anticipated this year.  It is a randomized trial of adjuvant 
capecitabine following macroscopically clear resection of CC, versus observation, 
however no interim data has been released.   Therefore at present there is no definitive 
proven survival benefit with adjuvant chemotherapy following resection. 
 
1.4.3.2 Palliative chemotherapy 
The majority of cases are unresectable at presentation.  A recent case series by Endo 
et al at Memorial Sloan Kettering reported outcomes of a series of 238 cases of ICC 
(Endo et al. 2008).  One-hundred and twenty-eight patients were unresectable at 
presentation, and a further 33 patients were unresectable at surgical exploration, 
therefore 67.8% patients had unresectable disease (161/238). 
 
Until recently there has been a lack of evidence supporting a substantial benefit from 
chemotherapy for palliative disease. Gemcitabine is of interest following the 
CONKO-001 trial, and the use of gemcitabine plus platinum-containing 
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chemotherapeutic agents e.g. cisplatin or oxaliplatin, has been trialed due to their 
synergistic effect.   
 
Andre et al. performed a phase II trial with 56 patients with histologically confirmed, 
unresectable, locally advanced or metastatic biliary tract carcinoma (34 CC; 19 
gallbladder carcinoma; 3 ampullary carcinoma) in the GERCOR trial (Andre et al. 
2004).  All patients received gemcitabine and oxaliplatin (GEMOX), but were divided 
into two groups: group A had a performance status 0-2 and it was their first-line 
therapy; group B had performance status >2 and it was their second- or third-line 
therapy.  There was no control group.  Median progression-free survival (PFS) for 
group A was 5.7 months, compared to 3.9 months in group B.  Overall survival with 
GEMOX was 15.4 months for group A, and 7.6 months for group B.   
 
The ABC-01 phase II randomised trial of gemcitabine versus gemcitabine plus 
cisplatin (GEMCIS) included 86 patients with histologically or cytologically proven 
locally advanced or metastatic biliary tract carcinoma (59 CC; 22 gallbladder 
carcinoma; 5 ampullary carcinoma) (Valle et al. 2009).  The gemcitabine group 
included 44 patients, and there were 42 patients in the GEMCIS group.  The GEMCIS 
group showed an improvement in 6-month PFS, of 45.5% vs 57.1% for gemcitabine 
and GEMCIS respectively.  The median PFS was significantly different, 4.0 vs 8.0 
months for gemcitabine and GEMCIS respectively.  The trial was extended to a phase 
III trial to assess overall survival (ABC-02 trial), including 410 patients (241 CC; 149 
gallbladder carcinoma; 20 ampullary carcinoma) (Valle et al. 2010a).  There were 206 
patients in the gemcitabine-alone group, and 204 patients in the GEMCIS group.  The 
PFS was significantly better in the GEMCIS group, of 5.0 vs 8.0 months.  The 
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GEMCIS group also showed a survival benefit of 3.6 months compared to 
gemcitabine alone, with an overall median survival of 8.1 vs 11.7 months for 
gemcitabine and GEMCIS respectively.  This trial established GEMCIS as a new 
standard of care for the palliative treatment of CC.   
 
Despite this modest benefit with conventional chemotherapy in the palliative 
treatment of CC, the survival is still disappointingly poor.  It is well established that 
with effective medical treatment it is possible to downstage inoperable colorectal liver 
metastases and subsequently perform curative resections, first reported by Bismuth et 
al. (Bismuth et al. 1996).  There is an urgent need to find new effective treatments for 
cholangiocarcinoma, in order to downstage unresectable cases, to be able to then offer 
a curative resection.  Targeted cancer therapies used either as neoadjuvant agents to 
downstage disease, or in the adjuvant setting to prevent relapse are an attractive 
option in CC.  There is, however, a paucity of identified targets for known molecular 
agents in CC. 
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1.5 Targeted Treatment 
Targeted treatment is defined as:  
‘a new generation of cancer drugs designed to interfere with 
a specific molecular target (typically a protein) that is 
believed to have a critical role in tumour growth or 
progression’ (Sawyers 2004).   
 
Targeted therapies can be broadly categorized into: small molecule inhibitors or 
tyrosine kinase inhibitors (TKI); monoclonal antibodies (mAb); and therapeutic 
cancer vaccines.  Recent advances in targeted cancer therapies, in particular the 
development of mAb and TKI have brought about significant changes to oncology 
practice.  There has been a surge in the development of such agents, many of which 
have now been licensed for clinical use in a variety of tumours, with dozens of further 
agents in the pipeline at various stages of development.   
 
Receptor tyrosine kinases are a family of membrane spanning cell surface receptors.  
They comprise of an extracellular ligand-binding domain, connected via a single 
transmembrane helix, to an intracellular cytoplasmic tyrosine kinase domain.  They 
are normally monomers, and dimerise when ligand-bound causing receptor 
autophosphorylation and activation of the tyrosine kinase domain (Figure 3a).   
 
Monoclonal antibodies (mAb) function by preventing ligand-binding to the 
extracellular domain of the tyrosine kinase receptor, by binding to either the ligand or 
the receptor (Figure 3b and d).  Tyrosine kinase inhibitors (TKI) function by acting on 
the intracellular tyrosine kinase domain of receptor (Figure 3c). These small 
molecules are generally reversible competitors with ATP for binding to the internal 
catalytic domain of the tyrosine kinase.  
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Figure 3: Tyrosine kinase receptors and targeted therapy:  
(A- normal mechanism of action; B- Monoclonal antibody to receptor; C- Tyrosine 
kinase inhibitor; D- Monoclonal antibody to ligand) 
 
Due to the disappointing effectiveness of conventional chemotherapy in CC, targeted 
cancer therapies represent an appealing potential treatment option for this resistant 
tumour.  To date, however, no targeted agent has been effectively tested and licensed 
for clinical use for CC. Experience from other tumour types suggests that 
considerable heterogeneity exists amongst tumours of the same pathological type in 
the same tissue.  Therefore, blind treatment of all CCs could lead to a reduced 
efficiency of response in many patients when targeted treatments are used.  As the 
experience in breast cancer using trastuzumab has already shown, pre-screening of the 
patient population to identify those that express the target can potentially lead to the 
identification of patients who will benefit most from these expensive treatments. 
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1.6 Molecular Pathogenesis of Cholangiocarcinoma 
Cholangiocarcinogenesis is presently poorly understood, however it is evident that it 
involves a number of changes resulting from inflammation of the biliary tree.  
Alterations in: cholangiocyte proliferation signaling; cell cycle progression; 
apoptosis; telomere length; angiogenesis; and tissue invasion have been implicated in 
cholangiocarcinogenesis.   
 
1.6.1 Cholangiocyte Proliferation Signaling 
Cholangiocarcinoma exhibits abnormal cell proliferation signaling, with sustained 
autocrine and paracrine signaling unregulated by normal cellular feedback.  Chronic 
inflammation and cholestasis leads to the generation of cytokines and growth factors, 
up regulating proliferation signaling.  Key mediators of cholangiocyte proliferation 
signaling include: ErbB-2; EGFR; COX-2; K-ras; nitric oxide; HGF; c-met; IL-6; and 
gp80/gp130. 
 
The key cellular signaling pathways and their alterations in cholangiocarcinogenesis 
are discussed in the following section. 
 
1.6.1.1 Signaling pathways 
Receptor tyrosine kinases are cell-surface receptors, key in many cellular processes, 
with a critical role recognised in the development and progression of cancer.  
Receptor tyrosine kinases have an extracellular ligand binding domain, a single 
transmembrane helix, and a cytoplasmic tail.  They either function as a receptor with 
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intrinsic kinase activity e.g. the erbB-family, or a receptor that recruits a separate 
tyrosine kinase e.g. the IL-6 receptor.   
 
ErbB are a family of Class I growth factor receptor tyrosine kinases, including: ErbB-
1, known as Epidermal Growth Factor Receptor (EGFR); ErbB-2 (also known as c-
ErbB-2, Her2, or neu); ErbB-3; and ErbB-4.  Numerous molecules act as ligands for 
ErbB tyrosine kinases, including EGF and TGF-α, however to date no ligand for 
ErbB-2 has been identified.  Following ligand binding (except with ErbB-2) ErbB 
receptors undergo homo- or heterodimerisation, and ErbB-2 is the preferred 
dimerisation partner for all ErbB receptors.  Autophosphorylation of the cytoplasmic 
tyrosine residues enables them to function as ‘docking sites’ for signaling molecules, 
activating intracellular signaling cascades (Figure 4).   
 
Figure 4: ErbB Receptor Tyrosine Kinase Activation (with intrinsic kinase 
activity) 
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The IL-6 receptor does not have intrinsic tyrosine kinase activity, however, on 
activation it recruits kinases.  IL-6 binds to the IL-6-receptor, which forms a complex 
with membrane protein gp130, activation of this complex causes a conformational 
change, and cytoplasmic kinases are recruited e.g. Janus Kinase (JAK), which binds 
as a pair, and phosphorylate each other, creating a docking site for subsequent 
signaling proteins (Figure 5). 
 
Figure 5: IL-6 receptor activation (with recruited Janus Kinase activity) 
 
 
Common signaling pathways that can be activated by tyrosine kinase receptors 
include the Mitogen-Activated Protein Kinase cascade (MAPK), the Phosphoinositol-
3’-kinase/Akt pathway (PI3K/Akt), and the STAT3 pathway, as shown in Figure 6. 
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Figure 6: Signaling pathways 
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The MAPK pathway is the major signaling pathway associated with the ErbB family, 
driving cell proliferation (Sirica 2008).  Grb2 and SOS are recruited to the tyrosine 
kinase docking site, which activates membrane G-protein Ras, which in turn activates 
cytoplasmic Raf.  The MAPK pathway continues via a combination of MAPKs, 
including: extracellular signal-regulated kinases1/2 (ERK 1/2); c-Jun amino (N)-
terminal kinases 1/2/3 (JNK 1/2/3); and p38 isoforms (α, β, δ, and γ) (Cargnello and 
Roux 2011). Transcription factors are subsequently phosphorylated in the nucleus, 
initiating cell differentiation, cell proliferation, cell survival, cell migration and 
angiogenesis (Davis 2000, Cargnello and Roux 2011). For example, activation of 
ERK1/2, leads to nuclear accumulation of c-myc and STAT3, and cytoplasmic 
accumulation of death-associated protein kinase (DAPK), controlling cell 
proliferation (Cargnello and Roux 2011).  ERK1, one of the phosphorylated 
Chapter I: Introduction 
 
 
1-73 
transcription factors, causes the disassociation of Grb-SOS complex on the ErbB 
receptor, inactivating the signal cascade as part of a feedback loop (Knowles and 
Selby 2005). 
 
The PI3K/Akt pathway is also associated with ErbB signaling, activated primarily by 
EGFR, although it can also be indirectly activated by IL-6 (Hynes and MacDonald 
2009).  PI3K is a dimer of subunits p85 and p110, which phosphorylates the tyrosine 
kinase receptor and activates AKT, which is inhibited by increased levels of PTEN.  
Activation of AKT leads to increases in MDM2, NF-κB, and mTOR signaling, and 
inhibition of FKHR, BAD and GSK3β.  PI3K/AKT signaling promotes cell 
proliferation, cell cycling and inhibits apoptosis (Hennessy et al. 2005, Sirica 2008). 
 
 
1.6.1.2 Alteration of signaling pathways in CC 
The ErbB family has been implicated in cholangiocarcinogenesis, with an emphasis 
of dysregulation of ErbB-2 and EGFR signaling. 
1.6.1.2.1 ErbB-2 
As described above, ErbB-2 is a cell surface receptor tyrosine kinase, and it’s 
activation on dimerisation leads to auto-phosphorylation of its tyrosine residues, and 
initiation of downstream signaling pathways, leading to cell proliferation, migration, 
and survival.  ErbB-2 is a recognised proto-oncogene, and ErbB-2 gene amplification 
and ErbB-2 protein over expression are detected in many human malignancies, and 
are associated with a poor prognosis in breast and lung carcinoma (Croce 2008a, 
Croce 2008b, Sirica 2008).   
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Many studies have examined ErbB-2 protein expression using immunohistochemistry 
(IHC), and ErbB-2 gene amplification using fluorescence in situ hybridisation (FISH) 
and chromogenic in situ hybridisation (CISH) techniques in normal, biliary 
proliferative disorders associated with CC, and CC cases.  ErbB-2 protein is not 
expressed in normal cholangiocytes (Zheng and Zhu 2007, Pignochino et al. 2010).  
However ErbB-2 protein is over-expressed in some cases of PSC and hepatolithiasis, 
risk factors for the development of cholangiocarcinoma.  For example, Aishima  
examined 23 livers with hepatolithiasis, and found ErbB-2 over-expression in 87% of 
proliferating peribiliary glands, and 61% of dysplastic regions, however it was mostly 
cytoplasmic rather than membranous staining (Aishima et al. 2002).  Terada found 
that 75% of hepatolithiasis cases over-expressed ErbB-2, compared to 70% of ICC, 
but it was not expressed in normal or fetal liver, indicating a role for ErbB-2 in non-
malignant biliary proliferative lesions, as well as cholangiocarcinogenesis (Terada et 
al. 1998).  
 
The effect of ErbB-2 has been studied in vitro using CC cell line experiments.  ErbB-
2 was suppressed by an ErbB-2 kinase inhibitor AG825, and also by using silencing-
RNA in three CC cell lines (HUCCA-1, KKU-100, and KKU-M13) 
(Treekitkarnmongkol and Suthiphongchai 2010).  Both methods of inhibiting ErbB-2 
reduced cell invasion, motility, and proliferation of the cell lines.  ErbB-2 inhibition 
deceased downstream AKT and p70S6K phosphorylation, both members of the PI3K-
AKT-mTOR-p70S5K pathway involved in processes such as proliferation, apoptosis 
and growth (Vivanco and Sawyers 2002).   
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In vivo studies using rat and mouse models have also been performed in CC to 
investigate aberrant ErbB-2.  In the rodent, ErbB-2 is known as ‘neu’, and four rodent 
models are described below:  
1. The furan rat model was created by long-term feeding furan to rats, and neu 
over-expression was detected in the CC lesions, especially in the early stages 
of furan-induced cholangiocarcinogenesis (Elmore and Sirica 1993, Sirica, 
Radaeva and Caran 1997).   
2. The addition of thioacetamide to the drinking water of rats induced CC in all 
cases by 22 weeks, all with over-expression of neu (Yeh et al. 2004).   
3. Cholangiocarcinoma was induced in the p53 deficient/CCI4 mouse model by 
chromic intermittent toxin exposure, inducing cirrhosis, and subsequently CC, 
demonstrating strong over-expression of neu (Farazi et al. 2006).   
4. In the rat BDEneu orthotopic cell transplant model, immortalised non-
malignant rat cholangiocytes, BDE1 cells, were transfected to over-express 
neu, developing a highly tumourigenic phenotype when transplanted into 
isogenic rats (Lai et al. 2005, Sirica et al. 1997).   
 
The furan rat model, thioacetamide rat model, p53 deficient/CCI4 mouse model, and 
rat BDEneu orthotopic cell transplant model produce CC via different 
stimuli/mechanisms, however all exhibit neu protein over-expression, emphasising 
the importance of ErbB-2 in cholangiocarcinogenesis, at least in the rodent (Sirica 
2008). 
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1.6.1.2.2 EGFR 
EGFR is a cell surface receptor tyrosine kinase from the same family as ErbB-2, with 
a key role in cell proliferation, migration and survival following activation. 
 
A study by Yoshikawa et al examined EGFR protein over expression using 
immunohistochemistry of 236 ICC and ECC (Yoshikawa et al. 2008).  They found 
22.9% cases were positive for EGFR over expression, and it was mostly expressed in 
the moderately and poorly differentiated tumours.  EGFR expression was associated 
with lymph node metastasis, higher UICC tumour stage, lymphatic vessel invasion, 
and perineural invasion.  EGFR-positive cases were also found to have poorer 
survival.  The 5-year survival for ICC was 47.1% for EGFR-negative cases, compared 
to 17.7% for EGFR-positive.  The 5-year survival for ECC was similar, at 45.6% for 
EGFR-negative, and 26.4% for EGFR-positive.  Similar data were reported by Gu et 
al with 46/83 (55.4%) ICC over expressing EGFR, associated with poorly 
differentiated tumours (Gu and Choi 2012).  Further confirmed with a study by 
Harder et al in 56 patients with advanced biliary tract cancer (Harder et al. 2009).  
Using immunohistochemistry positive expression, which was classed as 2+/3+, was 
found in 22 cases (39.3%).  This small study found no association between EGFR 
expression and pathological features or survival.   
 
In summary, EGFR expression is a frequent finding in CC, with 22.9% - 55.4% cases 
of CC found to over express EGFR, associated with poorly differentiated tumours, 
lymph node metastasis, perineural invasion, and worse survival in the largest study. 
 
 
Chapter I: Introduction 
 
 
1-77 
1.6.1.2.3 IL-6 
IL-6 is an acute inflammatory cytokine that plays a major role in cell 
survival/proliferation signaling in CC.  Chronic inflammation plays a key role in the 
development of CC, and IL-6 is thought to mediate this.  IL-6 binds to the IL-6-
receptor, activating it, which in turn can activate the MAPK, PI3K/Akt, and STAT3 
signalling pathways: increasing cellular proliferation, and inhibiting apoptosis. 
 
IL-6 is not only produced by inflammatory cells, but also by CC cells in an autocrine 
and paracrine fashion, demonstrated in clinical specimens and cell line experiments 
(Sugawara et al. 1998).  Cholangiocarcinoma cell line KMCH-1 constitutively 
produces IL-6, and production is significantly increased following stimulation with 
inflammatory cytokines IL-1ß and tumour necrosis factor-α (TNF-α) (Park et al. 
1999).  In the same cell line experiments, IL-6 significantly increased proliferation, an 
effect that was inhibited by pre-incubation with an IL-6 inhibitor.  IL-6-mediated 
increased proliferation was via the MAPK signaling pathways.    
 
IL-6 also inhibits apoptosis via PI3K/Akt signaling in CC.  Kobayashi et al incubated 
CC cell lines with IL-6, and demonstrated increased Akt activation, and up regulation 
of anti-apoptotic factor Mcl-1 (Kobayashi et al. 2005).  Mcl-1 is a member of the anti-
apoptotic Bcl-2 family, which inhibits apoptosis via tumour necrosis factor-related 
apoptosis inducing ligand (TRAIL) resistance.   
 
Binding of IL-6 to the IL-6 receptor, causes Janus Activated Kinases (JAKs) to 
phosphorylate Signal Transducer and Activator of Transcription (STAT) proteins, 
particularly STAT3.  Phosphorylated cytosolic STAT3 dimerises, and translocates to 
Chapter I: Introduction 
 
 
1-78 
nucleus where functions as a transcription factor, activating Mcl-1 transcription 
(Isomoto et al. 2005).  Isomoto et al found STAT3 to be constitutively activated in 
CC cells, but not in normal cholangiocytes (Isomoto et al. 2005).  Normally 
Suppressor Of Cytokine Signalling 3 (SOCS-3) terminates IL-6/STAT3 signaling.  
However, in CC there is sustained IL-6/STAT3 signaling (Isomoto et al. 2006, 
Isomoto et al. 2007).  Isomoto et al identified that SOCS3 promoter was methylated, 
and treating CC cells with a demethylating agent reversed SOCS3 methylation, and 
reactivated SOCS3 inhibitory function (Isomoto 2009).  Furthermore, IL-6 over-
expression up regulates microRNA let-7a in CC cell lines transfected to over-express 
IL-6, let-7a in turn increased phosphorylation of STAT3 (Meng et al. 2007a).   
 
Over expression of IL-6 enhances cell survival and transformed cell growth in CC cell 
lines and mouse xenograft models, and in cell lines IL-6 increases telomerase activity, 
promoting growth (Meng et al. 2006b).  Also, increased IL-6 production reduced 
EGFR promoter methylation in CC cells, enhancing EGFR protein expression 
(Wehbe et al. 2006).   
 
IL-6 plays a multifactorial role in cholangiocarcinognesis, not only promoting cellular 
proliferation through the mechanisms described above.  IL-6 also promotes epigenetic 
modulation of CC cells, by down regulating several microRNAs (miR-148a, miR-
152, miR301), which in turn increased the expression of DNA methyltransferease-1, 
consequently decreasing methylation-sensitive tumour suppressor genes Rassf1a and 
p16INK4a (Braconi, Huang and Patel 2010).   
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Infection with liver flukes causes a severe inflammatory reaction within the biliary 
tree.  Ninlawan et al exposed a normal cholangiocyte cell line H69 to O. Viverrini 
excretory/secretory products, and found significantly increased IL-6 production 
(Ninlawan et al. 2010). Liver flukes are classified as a Group I carcinogen, with 
exposure being directly linked to the development of CC. 
 
Elevated serum IL-6 levels were detected in 100% of patients with CC (15 cases), 
levels correlated with tumour burden, and dropped sharply after CC resection 
(Goydos et al. 1998). 
 
1.6.1.2.4 Cyclooxygenase-2 
Cyclooxygenase (COX) is an enzyme that catalyses the formation of prostaglandin 
endohydroperoxidase from arachidonic acid, a mediator for signal transduction and 
cell proliferation.  COX-2 is an inducible isoform of the enzyme, which exhibits 
aberrant expression in many human malignancies.  ErbB-2 is a transcriptional 
regulator of COX-2.  PGE2, a product of COX-2, positively regulates ErbB-2.  
Increased levels of COX-2 are associated with over expression of ErbB-2 (Sirica et al. 
2002, Endo et al. 2002).  Exposure of cholangiocytes to bile acids increases COX-2 
levels via the EGFR signalling cascade (Yoon et al. 2002).  Over expression of 
nuclear receptor PPARδ induces COX-2 gene expression and subsequent PGE2 
production via EGFR.  PGE2 stimulates growth in CC cell lines (Wu et al. 2002).  
There is evidence of ‘cross-talk’ between COX-2 and IL-6 pathways in CC, with 
PGE2 also inducing IL-6 production via activation of EP4 receptor (Han, Demetris 
and Wu 2006).  COX-2 over expression is found in early and late stages of CC, 
suggesting a role in early cholangiocarcinogenesis (Chariyalertsak et al. 2001).  
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Strong COX-2 over expression in ICC is associated decreased apoptosis and increased 
proliferative activity, and a significantly poorer overall survival in ICC (Schmitz et al. 
2007). 
 
1.6.1.2.5 Nitric Oxide 
Nitric oxide (NO) is synthesised by nitric oxide synthase (NOS).  There are three 
isoforms of NOS: neuronal NOS, endothelial NOS and inducible NOS (iNOS).  iNOS 
is controlled at a transcriptional level by inflammatory cytokines and 
lipopolysaccharide, and is expressed by macrophages and epithelial cells during 
inflammation (Jaiswal, LaRusso and Gores 2001).   
 
During chronic inflammation, NO reacts with superoxide, producing reactive oxygen 
species, which are directly damaging to DNA, causing DNA strand breaks and DNA 
cross-links.  NO nitrosylates thiol residues of proteins, causing a loss of catalytic 
activity of caspases disabling apoptosis, and of DNA repair enzymes, promoting 
accumulation of oncogenic mutations.   
 
iNOS with high levels of activity has been demonstrated in CC tissue.  Inflammatory 
cytokines stimulate iNOS expression and NO production in CC cell lines (Jaiswal et 
al. 2000).  iNOS induced COX-2 expression promotes cell growth in mouse CC cell 
lines (Ishimura, Bronk and Gores 2004). 
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1.6.2 Augmented Cell Cycle Progression 
Increased cholangiocyte exposure to biliary toxins through cholestasis, and 
inflammatory mediators through chronic inflammation is thought to lead to DNA 
damage.  Altered function of key genes regulating the cell cycle in cholangiocytes 
leads to unchecked cell cycle progression, with accumulation of DNA mutations, 
leading to cholangiocarcinogenesis.  Alterations in p53 and k-ras function are key 
features in carcinogenesis. 
 
1.6.2.1 p53 
p53 is a tumour suppressor gene, known as the ‘guardian of the genome’, as it stops 
cell proliferation by halting the cell cycle, enabling repair of damaged DNA, or 
apoptosis if beyond repair.  Also known as TP53, it encodes p53 protein.  Wild-type 
p53 is a transcription activator of mdm-2 gene, whose protein interacts with p53 
protein, promoting its conjugation to ubiquitin, and thus degradation by the 
proteasome.  Hence under normal conditions p53 protein is highly unstable, with a 
half-life of less than two and a half minutes, not accumulating enough to activate 
transcription. Damaged DNA stabilises p53 protein, leading to increased cellular 
levels of p53, stimulating transcription of several genes, including p21CIP/WAF1, 
which in turn inhibits cyclin-dependent kinase (CDK) complexes.  CDKs regulate the 
passage of the cell through the cell cycle, and inhibition causes cell arrest in G1 (and 
G2) until the damaged DNA is repaired.  If damaged DNA cannot be repaired p53 
induces cell apoptosis, as it controls Bax protein, which binds to the anti-apoptotic 
protein Bcl-2 promoting apoptosis. 
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p53 is altered in more than 50% of human malignancies (Greenblatt et al. 1994).  
Aberrant expression of p53 protein is frequent in CC, ranging from 18 to 100% cases 
(Ashida et al. 1998, Kang, Kim and Jang 2002, Furubo et al. 1999, Khan et al. 
2005b).  p53 protein expression is differentially altered along the biliary tract, with 
altered expression in 9% ICC, 25% PHCC and 51% ECC (Argani et al. 2001). 
Expression also alters according to differentiation, with 100% well differentiated CC, 
and 50% of poorly differentiated CC exhibiting aberrant expression (Furubo et al. 
1999).   
 
Although altered levels of p53 protein are frequently detected in CC, mutations of p53 
gene are much less frequent than expected.  10.7% cases ICC exhibit p53 mutation, 
whereas amplification of mdm-2 gene was shown in 31.8%, and 18.2% had MSI-
positive phenotype.  Almost all cases had wild type p53 gene, therefore loss of p53 
function is not through p53 gene mutation, rather via mdm-2 over expression.  Over 
expression of mdm-2 was observed in less differentiated tumours, suggesting its role 
in the later stages of cholangiocarcinogenesis (Momoi et al. 2001).   
 
Other components of the cell cycle are also altered in CC.  Cyclin-D1 over expression 
had been shown with immunohistochemistry in 61.9% ICC and PHCC.  Cyclin D1 
complexes with CDK6 or CDK4 phosphorylating Rb protein, moving the cell into S-
phase of the cell cycle (Kang et al. 2002).  p16INK4/CDKN2 blocks G1 to S transition 
of cell cycle by inhibiting Cyclin-D and CDK4.  p16INK4/CDKN2 mutations have been 
found in 63% PHCC and 33% ICC (Yoshida et al. 1995).  
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1.6.2.2 K-ras 
K-ras is a member of the ras proto-oncogene family involved in mitogenic signal 
transduction.  K-ras is a GTPase that is downstream of EGFR, and following EGFR 
activation K-ras is active for a short period, activating further members of the 
signaling cascade.  K-ras drives cell proliferation by enabling cell growth and 
inhibiting apoptosis. 
 
Figure 7: Activated K-ras: proliferation signaling  
(Adapted from (Pylayeva-Gupta, Grabocka and Bar-Sagi 2011)  
 
 
Mutations of K-ras enable mitogenic signal transduction in the absence of growth 
factor stimulation, being permanently activated (Knowles and Selby 2005).  Mutated 
K-ras promotes cell motility, invasion, and cell survival (Pylayeva-Gupta et al. 2011).  
Levi et al examined 15 ECC for mutations of codon 12 of K-ras, and found all cases 
were positive for K-ras mutation (Levi et al. 1991, Ohashi et al. 1995).  A larger study 
was performed by Ohashi et al, including 22 ICC, 36 ECC, and 19 GBCC (Ohashi et 
Chapter I: Introduction 
 
 
1-84 
al. 1996).  Mutations were identified in 34/56 cases of CC (60.7%) at codon 12, with 
no mutations at codon 13 or 61.  Chen et al examined 86 resected cases of ICC for K-
ras mutations using direct-sequencing (Chen, Jan and Yeh 2012b).  K-ras mutations 
were present in 19 cases (22.1%).  The most frequent region of mutation was codon 
12 (17 cases), with 1 case with mutation at codon 13, and one at codon 61.  
Multivariate anaylsis revealed K-ras mutation to be an independent prognostic factor, 
and was associated with perineural invasion.  Median overall survival was worse in 
those with k-ras mutation, 5.7 months vs 19.0 month with and without K-ras mutation 
respectively.  Overall, in the studies presented, K-ras mutations are most frequently 
identified at codon 12 in CC, with a frequency of 22.1% to 100%. 
 
Alterations of p53, cyclin D1 and K-ras suggest abnormalities of cell cycle 
progression are major events in cholangiocarcinogenesis. 
 
1.6.3 Dysregulation of Apoptosis 
Apoptosis is an essential process to ensure damaged and mutated cells do not survive, 
ensuring malignant and premalignant cells do not replicate.  Apoptosis can be 
initiated either by the death inducing receptor pathway, or the mitochondrial pathway 
with release of cytochrome C.  Fas-mediated apoptosis is induced by the Fas receptor 
(FasR) binding to Fas ligand (FasL), producing death-inducing signalling complex 
(DISC).  DICS includes pro-caspase 8, which is activated inducing apoptosis.  I-
FLICE inhibits caspase 8, thus inhibiting Fas-mediated apoptosis.  Normal 
cholangiocytes only express FasL, whereas CC cell lines express FasR, FasL and I-
FLICE.  I-FLICE inhibits apoptosis in CC cells (Que et al. 1999).  In the 
mitochondrial pathway, caspase 9 is activated following the release of cytochrome C, 
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inducing apoptosis.  CC cells transfected with the iNOS gene showed inhibition of 
apoptosis, by inhibiting caspase 9 activation (Torok et al. 2000). 
 
Bcl-2, Bcl-XL and Mcl-1 are anti-apoptotic proteins that block apoptosis, and they are 
all members of the Bcl-2 protein family.  Over expression of Bcl-2 confers resistance 
to apoptosis in CC cell lines (Harnois et al. 1997).  It has been reported that up to 
72.2% CC cases are positive for Bcl-2 protein expression (Charlotte et al. 1994), 
however, other studies have disputed this and suggest that in the biliary tree cell 
survival is governed by Bcl-XL and Mcl-1, not Bcl-2.  Expression of Bcl-XL and 
Mcl-1 proteins is reported in 60 to 100% cases of CC, but has also been found in 
normal and dysplastic cholangiocytes (Okaro et al. 2001).  This supports the view that 
apoptosis forms part of a normal balance of cell growth, and over expression of 
proteins inhibiting apoptosis is important in tipping the balance in favour of 
cholangiocarcinogenesis. 
 
Alteration of p53 function and COX-2 expression also play a role in dysregulation of 
apoptosis, as commented previously.   
 
1.6.4 Stimulation of Angiogenesis 
Angiogenesis is necessary for tumour growth and metastasis.  Vascular endothelial 
growth factor (VEGF) is a mitogen for vascular endothelial cells, and induces 
endothelial cell migration, proliferation, inhibition of apoptosis, and consequently 
angiogenesis of new tumour blood vessels (Neufeld et al. 1999).  The VEGF gene 
codes for 5 isoforms of VEGF (VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PIGF), 
which are produced through alternate splicing.   
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In a study by Mobius et al of 51 ECC, they found that normal cholangiocytes did not 
stain for VEGF-A using immunohistochemistry, however there was weak VEGF 
expression in normal endothelial cells.  Conversely, in malignant cholangiocytes 
VEGF-A expression was demonstrated, and it was strongly expressed at the invasive 
edge of CC samples, demonstrating it’s role in angiogenesis and tumour invasion 
(Mobius et al. 2007): 24 cases demonstrated low-expression, and 27 cases 
demonstrated high-expression of VEGF-A.  VEGF over-expression in CC was also 
investigated by Yoshikawa et al using immunohistochemistry for 236 cases of ICC 
and ECC (Yoshikawa et al. 2008).  They found VEGF over expression was frequent, 
demonstrated in 134 cases, i.e. 56.8%.  Furthermore, TGFß has been shown to induce 
VEGF expression in CC cell lines, causing an ‘angiogenic switch’ in CC (Benckert et 
al. 2003). 
 
1.6.5 Tissue Invasiveness 
Cholangiocarcinoma is a highly infiltrative tumour with ability for local invasion.  
Alterations in the expression of cellular adherence molecules such as E-cadherin and 
increased expression of matrix metalloproteinases are found in CC, enabling 
infiltration.  E-cadherin gene mutations in ICC are associated with decreased 
expression of E-cadherin protein, and subsequent reduction in cell adhesiveness.   
Reduced E-cadherin expression is associated with high grade ICC (Endo et al. 2001, 
Ashida et al. 1998, Settakorn et al. 2005).  Bile acids induce Snail expression in CC 
cell lines, reducing E-cadherin expression, resulting in cell migration and invasion 
(Fukase et al. 2008). 
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Epithelial cells secrete gel-forming mucins.  Mucins play a key role in protecting cells 
from harsh environments, and aiding cell survival, and enable signal transduction 
from the environment to the cell via membrane-associated mucins (Hollingsworth and 
Swanson 2004).   
 
MUC1 and MUC4 are members of the mucin family, encoding membrane bound 
glycoproteins.  Both MUC1 and MUC4 have been found to be over expressed in CC.  
Zhao et al used immunohistochemistry to investigate MUC1, MUC2, MUC5AC, and 
MUC6 in 100 ICC.  They found MUC1 to be over expressed in 61% cases ICC, and 
22% over expressing MUC5A (Zhao et al. 2008).  Tamada et al and Shibahara et al 
investigated MUC4 expression in CC, as MUC4 is a known ligand for ErbB-2.  They 
found 51.4% ECC and 37% of ICC express MUC4 (Tamada et al. 2006, Shibahara et 
al. 2004).  Furthermore, strong MUC1 and MUC4 expression are associated with 
significantly poorer survival (Tamada et al. 2006, Tamada et al. 2002, Higashi et al. 
1999).   
 
1.6.6 Telomere Length 
Telomeres are simple tandem repeats at the ends of chromosomes. For telomeres to 
function effectively, they require a minimum length of DNA and associated capping 
proteins. In normal somatic cells with each cell division/replication telomeres are 
progressively shortened (by approximately 40-50 base pairs).  Eventually a critical 
telomere length in reached, limiting growth by irreversible growth arrest. This 
irreversible growth arrest is termed cellular senescence.  The initial telomere length is 
different for different cell types, directly correlating with the replicative capacity of 
the cell. 
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As telomeres become progressively shortened, the end lengths of DNA are 
susceptible to fusion and subsequently abnormal cell division, as they are not 
adequately protected (Londono-Vallejo 2004).  Der-Sarkissian et al used subtelomeric 
markers and karyotype analysis to demonstrate that chromosomes with short 
telomeres are more susceptible to breakage-fusion-bridges, and show high levels of 
chromosomal instability (der-Sarkissian et al. 2004).  Excessively short telomeres 
lead to breakage-fusion-bridge cycles, where chromosomes break at weak points, and 
then fuse again leading to regions of deletion or gain within the chromosome.  This 
generates genomic instability, and can lead to abnormal cell survival and 
proliferation, as cells develop a malignant phenotype.  Cells with mutations enabling 
them to avoid apoptosis continue to replicate further increasing the tumour cells 
genomic instability. 
 
Telomerase is a reverse transcriptase enzyme, whose activity lengthens telomeres, 
increasing the cells replicative capacity (Hiyama and Hiyama 2003).  Many malignant 
cells have acquired the ability to reactivate telomerase. Telomerase activity has been 
demonstrated in malignant and dysplastic, but not in normal cholangiocytes, and IL-6 
has been shown to increase telomerase expression in CC cell lines (Yamagiwa, Meng 
and Patel 2006).  Telomerase reverse transcriptase mRNA was detected in the serum 
in 84.9% CC cases, and 21.9% cases with benign biliary tract disease, however none 
was detected in the serum of healthy volunteers (Leelawat et al. 2006).   
 
Chen et al transfected biliary epithelial cells with the gene encoding Hepatitis C core 
antigen (Chen et al. 2007).  Hepatitis C transfected cells produced tumours when 
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inoculated into the flank of nude mice, unlike the normal biliary epithelial cells or 
plasmid-control cells.  Hepatitis C transfected cells also showed significantly 
increased telomerase mRNA and protein expression, with barely detectable levels in 
normal biliary epithelial cells or plasmid-control cells.  Telomerase activity has also 
been induced in human cholangiocytes by transfection with human hepatitis B virus X 
gene, supporting the role of Hepatitis B and C virus in cholangiocarcinogenesis (Zou 
et al. 2004). 
 
As telomeres shorten, normal cells become more susceptible to malignant 
transformation as genomic instability increases.  Furthermore, inflammatory 
mediators, pre-malignant inflammatory biliary conditions, and infection with viral 
hepatitis, aetiological factors for the development of CC, have been shown to 
reactivate/increase telomerase activity.  Lengthening of telomeres by telomerase 
enables malignant cells to avoid cellular senescence and apoptosis. 
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1.7 Present Work and Hypotheses 
Cholangiocarcinoma is a deadly tumour that presents late and is therefore often not 
amenable to surgical resection.  Despite increased activity in the field of 
cholangiocarcinoma research, there have been no significant breakthroughs in our 
ability to treat this tumour, and surgical resection offers the only chance of cure. 
 
Molecular targeting agents offer a potential treatment breakthrough for this 
chemoresistant tumour, however research to date has failed to identify targets that can 
be significantly utilised.  Genomic copy number alteration in cholangiocarcinoma 
leads to amplification and deletion of genes.  Detailed analysis of copy number 
alteration in this tumour may identify amplified genes that can be treated successfully 
with targeted agents. 
  
The molecular biology of a tumour is related to a number of different factors 
including its cellular and anatomical origin, its aetiology and the stage of disease at 
the time the tissue was taken for molecular analysis.  We have therefore analysed the 
relationship between the molecular biology of CC and these factors. 
 
The aetiology of CC is well characterised in Asia, related to liver fluke infestation.  
However, there is no clear aetiological agent for cholangiocarcinoma in the western 
world.  We therefore hypothesised that Asian and UK cholangiocarcinoma may 
exhibit different molecular alterations due to differing aetiological agents.  We have 
therefore compared genomic alterations between UK and Thai cholangiocarcinoma 
cases to identify if they exhibit common or different alterations. 
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Improved understanding of the molecular pathogenesis of cholangiocarcinoma, will 
identify key molecular pathways involved in chlangiocarcinogenesis, which can be 
potentially altered by targeted agents.  MicroRNAs are small non-coding RNAs that 
influence gene  expression.  To date there have been only a handful of miRNA studies 
in cholangiocarcinoma, the majority of which used cell lines as their experimental 
model.  We have analysed miRNA alteration in cholangiocarcinoma samples, to 
identify key molecular pathways in cholangiocarcinoma. 
 
Through the creation of an accurate and detailed clinical database of 
cholangiocarcinoma cases presenting to major hepatobiliary centres, it will be 
possible to assess the survival following diagnosis with cholangiocarcinoma, treated 
both medically and surgically.  Previous array-CGH studies have not assessed CNA in 
relation to survival.  Using our comprehensive clinical data we can assess genomic 
and miRNA alterations for prognostic signatures. 
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1.8 Aims of Thesis 
• To create a detailed and accurate clinical database of CC samples for survival 
analysis. 
• To characterise genomic copy number alteration in cholangiocarcinoma. 
• Assess genomic copy number alteration in cholangiocarcinoma from a 
population with a clear aetiological factor (Thai cases), and UK samples 
without a clear aetiological factor.  
• To characterise microRNA alterations in cholangiocarcinoma. 
• To identify prognostic DNA and microRNA signatures in 
cholangiocarcinoma. 
• To identify treatment targets or molecular agents in cholangiocarcinoma. 
• To identify genes of interest altered in CC for further investigation.
 2-93 
CHAPTER II 
2 Materials and Methods 

Chapter II: Materials and Methods 
 
 
2-95 
2.1 Materials 
All chemicals used were of Molecular Biology grade and were obtained from either 
the Sigma-Aldrich Company Ltd. (Poole, Dorset, UK) or VWR International Ltd. 
(Lutterworth, Leicestershire, UK), unless otherwise stated. 
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2.2 UK Clinico-pathological database 
A large clinico-pathological database of UK cholangiocarcinoma cases was created.  
This identified tissue samples that could be used in the study, and recorded clinical, 
pathological and survival data for subsequent analysis.  
 
Cases were collected from five London-based hepatobiliary units: The Hammersmith 
Hospital (Imperial College NHS Trust); The Royal London Hospital (Barts and The 
London NHS Trust); The Royal Marsden Hospital; The London Bridge Hospital; and 
The London Independent Hospital. 
 
A retrospective review of all cases of all histologically and cytologically proven cases 
of CC presenting to two institutions were complied: from 1990-2009 for 
Hammersmith Hospital; from 2001-2010 for The Royal London Hospital.  
Consecutive cases presenting to the institutions were evaluated.  Cases with tissue 
available were recorded from the remaining units. 
 
Cases of cholangiocarcinoma were identified by three methods: from the 
histopathology computer archive; via hepatobiliary multi-disciplinary team (MDT) 
meeting minutes (Hammersmith Hospital); or from the surgeon’s personal record 
(London Bridge Hospital and The London Independent Hospital).  The MDT meeting 
minutes detailed all cases of cholangiocarcinoma, or potential cholangiocarcinoma, 
referred to and seen by the hepatobiliary unit.  All identified cases were cross-
validated using histopathology reports, medical records, clinic letters and radiology.  
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Inclusion criteria for the clinical database included: 
• Cholangiocyte origin of tumour 
• Histologically or cytologically proven 
 
Exclusion criteria included: 
• Mixed hepatocelluar/cholangiocyte origin 
• Ampullary tumours 
• Gallbladder tumours (with one exception) 
 
A more detailed clinical database was created for cases from Hammersmith Hospital 
and The Royal London Hospital.  Histopathology and cytology reports were reviewed 
for each case to confirm the diagnosis.  All imaging reports, including CT, MRI, PET-
CT, ultrasound, and cholangiographic imaging were reviewed at MDT to confirm 
diagnosis, anatomic subtype, and presence of metastasis. The multidiscipliniary team 
record (MDT) for all cases were reviewed for Hammersmith Hospital to identify any 
disparity in assessment of printed reports and clinician consensus of data. 
 
For operatively managed patients all operation notes were reviewed to confirm the 
operation performed, and where complete resection was not possible the reason for 
incomplete resection.  Histopathology reports were assessed in combination with the 
operation findings by myself and a consultant surgeon (DS) to confirm the resection 
status (R0, R1, R2) for each case.  
 
‘Resection status’ (R-classification or R-status) is an assessment of the completeness 
of surgical resection of the tumour.  It was first introduced in 1977 by the American 
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Joint Committee on Cancer (American Joint Committee on Cancer Staging and End 
Results Reporting. and American Cancer Society. 1977), and adopted by the 
International Union Against Cancer into the TNM Classification of Malignant 
Tumours in 1987 (Hermanek, Sobin and International Union against Cancer. 1987).  
There is some disparity in classification internationally in the exact definition of R-
status, and the UK definition used by the Royal College of Pathologists is used in this 
thesis, see Table 6. 
 
Table 6: Resection Status Definition 
Resection-Status Presence of Tumour 
R0 No residual tumour, ≥1mm between tumour and resection 
margin 
R1 Microscopic residual tumour, <1mm from resection margin 
R2 Macroscopic residual tumour  
 
Oncology letters, imaging and blood tests were reviewed to assess the medical 
treatment patient received (chemotherapy and radiotherapy) and to assess tumour 
recurrence. 
 
The hospital computer database was used to follow-up patient survival, listing date of 
death, or recently attended clinic appointments, which were cross-validated by 
reviewing clinic letters for those still alive.  For patients with no recent clinical record 
on the hospital computer database, general practitioners were contacted where 
possible to determine the survival status of patients. 
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All cases required histopathological or cytological confirmation of the diagnosis for 
inclusion. Date of diagnosis was defined as the date the tissue diagnosis was made.  
Survival data was recorded for all cases, as time from diagnosis to date of death.   
 
The Hammersmith Hospital cohort included survival data for cases that received 
operative and non-operative treatment.  This cohort was analysed to assess the 
survival from cholangiocarcinoma comparing medical and surgical treatment to 
ensure the study group was consistent with other published studies.  The Royal 
London cohort included survival data for 43 resected cases. 
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2.3 Tissue Samples and Cell Lines 
2.3.1 Tissue Samples 
Tissue was obtained from UK samples of cholangiocarcinoma.  UK Tissue was 
obtained from the Hammersmith Biological Resource Centre, an NRES approved 
Research Tissue Bank, or from four other centres with Research Ethics Committee 
approval for the study outlined in the ethics application 09/H0718/41.  All samples 
were from the diagnostic archive, stored as formalin-fixed paraffin embedded samples 
(FFPE).  All samples were assigned a unique identifier to maintain patient 
confidentiality.   
 
A haematoxylin and eosin (H&E) stained section of tissue for each case was reviewed 
by a histopathologist (GS and JCA): to confirm the diagnosis; and to select the best 
block of tissue to use (that containing the highest proportion of tumour).  
Haematoxylin and eosin reference slides were marked to define the area of tumour, to 
enable macroscopic dissection of the tissue sample to obtain a high proportion of 
tumour cells, and to remove normal tissue.  
 
Cases of cholangiocarcinoma (ICC, PHCC, and ECC) were included in the study.  
Gallbladder carcinoma (with one exception where PHCC was reclassified as 
gallbladder carcinoma after initial analysis when the imaging and histopathology were 
re-reviewed, and remained in the study), mixed hepatocellluar-cholangiocarcinoma, 
and ampullary carcinoma were excluded.   
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All UK cases were adenocarcinoma.  Age, sex, operative resection, and 
completenesss of resection, post-operative complications, survival and 
histopathological characteristics were recorded for all cases. 
 
Thai cholangiocarcinoma samples were obtained with ethical approval through 
collaboration with The Centre for Research and Development of Medical Diagnostic 
Laboratories, Khon Kaen University, Thailand.  Clinicopathological data, including 
age at initial diagnosis, gender, gross types, histological grades and the overall 
survival time were collected.  All cases with survival less than 4 weeks post-resection 
were excluded by the collaborating centre, to reduce the bias of reduced survival 
related to post-operative complications.  All samples were from fresh-frozen tissue, 
and were supplied as extracted aliquots of DNA.  DNA had been extracted from 
frozen liver tissues using DNeasy Tissue Kit (Qiagen, Hercules, CA, USA) according 
to the manufacturer's protocols.  
 
2.3.2 Cell lines 
Cell lines were used for several different experimental purposes: 
• Positive controls for DNA and RNA extractions; 
• Positive controls for PCR; 
• For validation of the array-CGH platform comparing fresh-frozen with FFPE 
tissue. 
 
The HuCC-T1 and SkChA1 cell lines were used.  HuCC-T1 cells were originally 
derived from malignant cholangiocarcinoma cells obtained from malignant ascites 
from a moderately differentiated ICC (adenocarcinoma) of a male patient (Miyagiwa 
Chapter II: Materials and Methods 
 
 
2-102 
et al. 1989).  SK-ChA-1 cells were derived from malignant cholangiocarcinoma cells 
obtained from malignant ascites from an undifferentiated ECC (adenocarcinoma) of a 
female (Knuth et al. 1985).   
 
Cells were stained with using immunofluorescent markers for Epithelial Membrane 
Antigen, CK7 and CK19 at the beginning of the study (by SP) to confirm their 
cholangiocyte origin, and to ensure they were not colonized by fibroblasts. Cell lines 
were also tested for Mycoplasma infection at the beginning of the study (by SP) and 
were both negative.   
 
Cell lines were grown as per original articles (Miyagiwa et al. 1989, Knuth et al. 
1985).  Both HuCC-T1 and SK-ChA-1 cholangiocarcinoma cell lines were cultured in 
RPMI 1640, with L-Glutamin, Streptomycin 100 µg/mL and Penicillin 100 IU/mL 
with 10% fetal calf serum, incubated at 37°C in 5% CO2 and 95% humidity.  
Confluent cells from 5 x T150 flasks were suspended with trypsin-versene, and spun 
down, washed three times in PBS, and the supernatant removed.   
 
Cell pellets were either frozen immediately, to create fresh-frozen cell pellets, or 
formalin fixed and paraffin embedded.   
 
To create FFPE pellets the following method was used: the pellet was resuspended 
with 200 µL human plasma, and 350 µL human thrombin was added, mixed, and left 
to agglomerate.  The pellet was placed in a biopsy capsule and incubated in 4% 
buffered formalin overnight.  The pellet was then embedded in paraffin following 
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dehydration with ethanol.  Fresh-frozen and FFPE pellets were created from the same 
passage of cell lines to reduce inter-experimental variability. 
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2.4 DNA extraction, quality assessment and preparation 
2.4.1 DNA extraction  
The protocol was adapted from VUMC, Microarray Facility, Amsterdam (van Beers 
et al. 2006).  A 10 µm section of FFPE tumour tissue on a slide was obtained.  A 4 
µm section stained with haematoxylin and eosin (H&E) with and the presence of 
tumour epithelium was verified by a histopathologist (GS and JCA), and the diagnosis 
confirmed.  In cases where the FFPE section contained normal and tumour tissue the 
H&E reference slide was marked by the histopathologist (GS), circling the area of 
tumour (and also tumour associated stroma in some cases), excluding normal tissue. 
The FFPE section was macroscopically dissected to enrich for tumour cells, this 
enabled macrodissection of the tumour tissue to exclude normal cells.  
 
Using the H&E reference slide, the area of tumour was marked onto the underside of 
the slide containing the 10 µm section of tissue.  The unwanted tissue was scraped off 
with a clean scalpel and discarded.  The 10 µm section was deparaffinised three times 
in xylene at room temperature, washed in absolute, 96%, and 70% ethanol for 30 
seconds each.  The tissue was allowed to dry briefly, to allow the ethanol to 
evaporate, the tissue was moistened with nuclease-free water, and scraped into a 
1.5ml eppendorf, then air-dried for 10-15 minutes.   
 
One millilitre of 1M Sodium thiocyanate (NaSCN) was added to the eppendorf, 
vortexed and then incubated overnight at 38°C to breakdown DNA cross-links.  The 
following day, the sample was centrifuged, the supernatant removed, then washed 
twice with PBS to remove the NaSCN.   
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The DNA extraction then followed the Qiagen QIAmp DNA Microkit (QIAGEN) 
standard protocol: adding 60 µl ATL buffer, and 60 µl proteinase K, and incubating at 
55°C until the tissue was digested; incubated at 98°C for 10 minutes; 100 µl ATL 
buffer was added, then 200 µl AL buffer; the sample was vortexed, then 200 µl 
ethanol was added and incubated at room temperature for 5 minutes.  The lysate was 
transferred to the QIAamp MinElute Column (300ul each time), and spun at 8,000 
rpm for 1 minute (300 µl of sample was added and spun-down until all the sample 
transferred to the column).  500 µl AW1 buffer was added and spun at 8,000 rpm for 
1 minute, then 500 µl AW2 buffer was added and spun for 1 minute at 8,000 rpm, and 
3 minutes at full speed to dry the membrane.  20-30 µl of AE buffer (depending on 
initial sample tissue size) was added to the   column to elute the DNA, incubating for 
5 minutes, then spun at 8,000 rpm into a clean eppendorf to collect the DNA sample.  
The sample was then quantified using the NanoDrop spectrophotometer (ND-2000), 
blanked with AE buffer, and subsequently stored at 4°C.   
 
DNA was extracted from a 10 µM section of cell pellet by the same method with each 
extraction, as a positive control for the DNA extraction.  
 
2.4.2 NanoDrop Spectrophotometer 
The NanoDrop spectrophotometer (ND-2000, Thermo Scientific) was used in many 
of the experiments.  It was used for the assessment of DNA, RNA and microRNA.  
The yield and purity of nucleic acid was measured after nucleic acid extraction.  The 
degree of Cy3/Cy5 labeling and yield for array-CGH experiments were also measured 
using the NanoDrop.   
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The NanoDrop measures the absorbance of all molecules in a given sample at specific 
wavelengths, giving an optical density (OD) measurement.  Furthermore, the 
NanoDrop measures the OD of a sample in microvolume quantities.  This is 
especially important with the use of archival samples, as the yield and volume is 
small, and the NanoDrop can assess the nucleic acid content with only 0.5-2 µL of 
sample (Desjardins, 2011, current protocols in molecular biology). 
 
For nucleic acid yield and purity the OD is measured at 230, 260, and 280 nm.  
Nucleic acids absorb at 260 nm.  The concentration of nucleic acid is calculated by 
assuming that 50 ng/µl of double stranded DNA has an OD260nm of 1.0, and 40 ng/µl 
of RNA has an OD260nm of 1.0 (Glasel, J.A. 1995. Validity of nucleic acid purities 
monitored byA260/A280 absorbance ratios. Biotechniques 18:62-63). 
 
Measuring the OD280nm and OD230nm assesses the purity of the nucleic acid sample.  
Contaminants such as protein and phenol absorb at 280, and thus a OD260nm/ OD280nm 
ratio of 1.8-2.0 represents a pure sample, however if the level is lower than 1.8 it 
suggests contamination.  Contaminants such as EDTA, TRIzol and phenol absorb at 
230, and thus a OD260nm/ OD230nm ratio of 2.0-2.2 represents a pure sample, however 
if the level is lower than 1.8 it also suggests contamination. 
 
The NanoDrop was also used to assess the degree of Cy3/Cy5 labeling of samples, 
and is described in more detail in the methodology for each application. 
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2.4.3 Reference DNA 
Reference DNA was purchased from Promega (Catalogue no. G1521 and G1471).  
The DNA was purchased as aliquots of male and female human DNA.  DNA was 
pooled according to sex from multiple anonymous donors.  The DNA was supplied 
with greater than 90% of the DNA having fragment length greater than 50Kb size, 
which was verified by gel electrophoresis using a 1% agarose gel stained with a non-
toxic fluorescence stain (SYBR Safe, Invitrogen) and 1Kb ladder (Metabion GmbH). 
The electrophoresis was run at 150V for 30 minutes and imaged using a gel 
documentation system (GelDoc), showing intact, non-degraded DNA.    
 
2.4.4 Whole Genome Amplification (WGA) 
This was performed on 4 samples in a validation experiment comparing invasive 
tumour and tumour-associated stroma copy number alteration profiles.  Two FFPE 
tumour samples were laser-capture microdissected into two separate components 
(invasive tumour cells vs stroma) through collaboration with Biotheranositics.  The 
total yield of DNA was low for each sample (3.81-12.73 ng) therefore WGA was 
performed to provide enough DNA for array-CGH.  The GenomePlex Single Cell 
Whole Genome Amplification Kit (WGA4-10RXN, Sigma Aldrich) was used as per 
manufacturers instructions.  This encompassed three steps: lysis and fragmentation; 
OmniPlex library generation; and PCR amplification.  Pooled genomic DNA 
(Promega, Mannheim, Germany) was used as a positive control for the amplification.   
 
In summary, 1 µL Proteinase K Solution-10’ Single Cell Lysis and Fragmentation 
Buffer was added to 9 µL DNA and incubated at 50°C for 1 hour.  2 µL 1’ Single Cell 
Library Preparation Buffer and 1 µL Library Stabilization Solution were added, and 
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incubated at 95°C for 2 minutes, followed by ice cooling.  1 µL Library Preparation 
Enzyme was added then the sample was incubated as follows: 
16°C 20 minutes 
24°C 20 minutes 
37°C 20 minutes 
75°C 5 minutes 
4°C Hold 
 
For the amplification step the following components were added:  
10’ Amplification Master Mix 7.5 µL 
Water 48.5 µL 
WGA DNA Polymerase 5.0 µL 
 
The samples were then incubated on the following program in a thermal cycler: 
95°C 3 minutes  
94°C 30 seconds 
65°C 5 minutes 
For 25 cycles 
4°C Hold  
 
The quality of the amplified DNA is then assessed by gel electrophoresis on a 1.5% 
agarose gel stained with a non-toxic fluorescence stain (SYBR Safe, Invitrogen).  4 
µL sample was loaded onto the gel with 2x loading dye (BlueJuice, Invitrogen).  A 
100bp ladder (Metabion GmbH) was used as a fragment length standard. The 
electrophoresis was run at 150V for 30 minutes and imaged using a gel 
documentation system (GelDoc).   The mean amplification product size should be 
approximately 400 base pairs (ranging form 100-1000 base pairs). 
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Samples were then purified using the QIAquick® PCR Purification Kit (28104, 
Qiagen) as per manufacturers instructions.  In summary 5 volumes of PB buffer were 
added to the sample, then transferred to the QIAquick column and centrifuged at 
13,000 rpm.  The column containing the sample was then washed with 750 µL PE 
buffer and spun, then the sample was eluted with 30 µL EB buffer.  The yield and 
purity of amplified and purified DNA sample was then determined using the 
NanoDrop-2000, recording the concentration (ng/ul), 260/230 and 260/280 ratios.  
 
2.4.5 Size-Multiplex PCR 
DNA isolated from FFPE tissues is fragmented as a result of both the fixation and 
processing required to generate the paraffin embedded tissue block used for 
diagnostic histopathology. Severely fragmented DNA leads to unspecific cross 
hybridization, and subsequently to distortion of the resulting copy number data.  
Therefore a quality assurance method is required which enables identification and 
exclusion of samples severely fragmented DNA.  Van Beers et al. demonstrated that 
DNA should contain fragment lengths of greater than or equal to 200 base pairs (bp) 
for downstream array comparative genomic hybridization, and this was used as a cut-
off in our study.  A gene-specific multiplex PCR (van Beers et al. 2006) was used 
with PCR primers (housekeeping-gene GDP, Metabion International GmbH 
MUNICH) resulting in 100bp-, 200bp-, 300bp- and 400bp non-overlapping 
amplicons, respectively (Table 7).  
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Table 7: Multiplex PCR Primer Sequences 
  Name  Sequence  Number of 
bases 
100bp-fragment   
  100F 5'- gttccaatatgattccaccc -3' 20 
  100R 5'- ctcctggaagatggtgatgg -3' 20 
200bp-fragment   
  200F 5'- aggtggagcgaggctagc -3' 18 
  200R 5'- ttttgcggtggaaatgtcct -3' 20 
300bp-fragment   
  300F 5'- aggtgagacattcttgctgg -3' 20 
  300R 5'- tccactaaccagtcagcgtc -3' 20 
400bp-fragment   
  400F 5'- acagtccatgccatcactgc -3' 20 
  400R 5'- gcttgacaaagtggtcgttg -3' 20 
 
 
For each PCR reaction normalised human male genomic DNA (Promega, Mannheim, 
Germany) was used a positive control.  DNA from a cell pellet (cell line HuCC-T1) 
was extracted in the same run of extraction as the samples as a positive control for the 
DNA extraction. To exclude contaminating human DNA of any of the components 
used in the PCR reactions nuclease free water was used instead of DNA template as 
negative no-template control.  PCR amplifications were performed using the FastStart 
High Fidelity PCR System kit (Roche) in a 96-well thermocycler (GeneAmp PCR 
System 9700, Applied Biosystems) according to the pipetting scheme in Table 8 and 
amplification products were subsequently analysed by gel electrophoresis. 
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Table 8: PCR Reagents (per reaction) 
FastStart High Fidelity Reaction Buffer, 10 x conc. (without MgCl2) 3 µL 
MgCl2 stock solution, 25mM 1.8 µL 
dNTP-mix (10mM each) 0.6 µL 
Primer-mix (1.25uM each) 3.2 µL 
FastStart High Fidelity Enzyme Blend (5U/uL) (Taq polymerase) 0.2 µL 
 
 
Table 9: Multiplex PCR Program 
96°C 9 minutes  
94°C 1 minute 
56°C 1 minute 
72°C 3 minutes 
 
For 35 cycles 
72°C 7 minutes  
4°C Hold  
 
 
Separation and analysis of PCR amplicons was by agarose gel electrophoresis.  From 
each PCR reaction 10 µl along with a 2x loading dye (BlueJuice, Invitrogen) were 
loaded on a 1.5% agarose gel which was stained using a non-toxic fluorescence stain 
(SYBR Safe, Invitrogen). A 100bp ladder (Metabion GmbH) was used as a fragment 
length standard. The electrophoresis was run at 150V for 30 minutes and imaged 
using a gel documentation system (GelDoc).  Samples, which exhibited amplification 
products of greater than or equal to 200 bp size, were selected for array-CGH. 
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2.5 Array Comparative Genomic Hybridisation (array-CGH)  
Two array Comparative Genomic Hybridization (array-CGH) platforms were used in 
the study: 
 
• 1Mb Bacterial Artificial Chromosome (BAC) array-CGH  
• 180K Oligonucleotide array-CGH 
 
The UK based study was performed using 1Mb BAC array-CGH.  The Thai based 
study was performed using 180K oligonucleotide array-CGH.  Both methods were 
tested with fresh frozen tissue and FFPE samples to prove that the sample stabilisation 
method did not alter the results.   
 
2.5.1 1Mb Bacterial Artificial Chromosome (BAC) array-CGH  
1Mb BAC arrays were used containing the Sanger 1Mb BAC array clone set which 
comprises approximately 3,400 BAC-clones covering the whole human genome in 
1Mb distances (Fiegler et al. 2003).  BAC-clones were spotted on the amino-active 
glass slides in triplicate (CodeLink, GE Healthcare, Buckinghamshire, England).  
 
For each experiment, 525 ng tumour DNA and 525 ng reference DNA (Promega, 
Mannheim, Germany) were labeled with Cy3-dCTP and Cy5-dCTP respectively 
(CyScribe kit, Amersham).  Reference DNA was sex-mismatched to the tumour 
sample to provide an internal hybridization control i.e. if the tumour sample was 
female, then male reference DNA was used, and at analysis the X chromosome would 
reveal a gain, and the Y chromosome a loss, demonstrating appropriate hybridisation. 
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2.5.1.1 DNA Labeling 
Fluorescence labeling of reference and tumour DNA was performed by random 
primed labeling using the CyScribe kit (CyScribe Array CGH Genomic DNA 
Labeling Kit, 28909726, Amersham). The manufacturers protocol used was used with 
slight amendments. 
 
The following components were added to a 1.5ml eppendorf on ice: 
Tumour DNA 525 ng (made up to vol 63uL with nuclease free water) 
Random Nonamers 35 µL 
Reaction buffer 35 µL 
 
 
The components were carefully mixed and incubated at 95°C for 5 minutes and 
cooled on ice for 5 minutes.  The following components were added: 
dCTP-labeling mix 28 µL 
Cy3-dCTP 10.5 µL 
Klenow (ExoFree) 3.5 µL 
 
 
The reaction was incubated at 37°C overnight.  The labeled DNA was purified from 
excess fluorescence coupled nucleotides and primers using spin-filter columns 
(Microcon, Millipore). The DNA was made up to a volume of 28 µL using EDTA 
reduced TE buffer (DNA suspension buffer, Teknova).  The yield of labeled DNA 
and the efficiency (incorporation rate of fluorescence dye) of the labeling reaction 
were determined spectrophotometrically using the Nanodrop Spectrophotometer (ND-
2000) and 1 µL of sample.  The sample was stored in the dark at -20°C until use. 
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As reference DNA, pooled genomic DNA (Promega) was used, as described 
previously. The reference DNA was labeled, using the above protocol but with Cy5 
coupled dCTP.  
 
2.5.1.2 DNA Hybridisation 
The following components were added to a 1.5ml eppendorf: 
Cy3-labelled tumour DNA 27 µL 
Cy5-labelled reference DNA (sex mismatched) 27 µL 
Cot-1 DNA (1.0mg/uL) 50 µL 
Agilent 10X Blocking Agent 26 µL 
Agilent 2X Hybridization Buffer 130 µL 
 
 
The samples were denatured at 95°C for 3 minutes followed by pre-hybridisation 
(binding of cot-1 DNA to repetitive sequences) for 30 minutes at 37°C.  Each sample 
was applied to a gasket slide (SureHyb, Agilent) as part of a hybridisation chamber. 
The active side of the microarray slide (Microarray Facility of Institute of Pathology, 
University of Cambridge) was placed on top of the gasket slide to form a “sandwich 
slide pair”, the chamber closed, and transferred to the hybridisation oven (Agilent) 
and rotated at 60°C for 60 hours at a rotational speed of 20 rpm. An air bubble in the 
hybridisation mix together with the rotation within the oven enables agitation of the 
solution, which increases hybridisation efficiency and improves evenness of 
hybridisation.  
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Washing and scanning of slides was performed as per Agilent protocol, using Oligo 
aCGH Wash Buffer 1 and 2. Slides were washed at room temperature with Agilent 
Oligo aCGH Wash Buffer 1 for 5 minutes and with Agilent Oligo aCGH Wash Buffer 
2 for 1 minute. 
 
Array slides were scanned using a microarray scanner with 5 µm resolution (Agilent) 
which generates a two-layer tiff file with one image of Cy3 and one of Cy5 
fluorescence. 
 
2.5.1.3 Analysis 
Tiff images were split into Cy3 and Cy5 using Tiff-splitting software.  The images 
were then loaded into the microarray image analysis software MAIA (Novikov and 
Barillot 2007) and intensity ratios extracted.  Initial image analysis involved multiple 
steps, listed in Figure 8.  
 
Figure 8: Steps in Initial Image Analysis 
• Gridding 
• Spot Addressing 
• Spot Segmentation 
• Spot Quantification 
• Outlier Detection 
• Normalisation 
• Triplicate Statistical Analysis (as BAC 
clones in triplicate) 
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For pre-screening the data was loaded on the web-based array-CGH evaluation 
platform CAPweb (Liva et al. 2006) which was installed on a local server.  Raw 
array-CGH data needed to be ‘normalised’ after import to reduce experimental 
artifact, to enable analysis of alterations with true biological origin.  Neuvial et al. 
proposed a spatial normalisation algorithm in 2006 for array-CGH data to ‘delineate 
and to eliminate and/or correct areas of spatial bias’ (Neuvial et al. 2006).  They 
defined two types of experimental artifact related to spatial effects: Continuous 
Spatial Gradient; and Local Spatial Bias.  Combining two algorithms, the 
Neighbourhood Expectation Maximisation (NEM), and Spatial Trend Estimation, a 
method for reducing and eliminating spatial artifact has been created.  This algorithm 
is integrated into R package Micro-Array NORmalisation (MANOR) and follows the 
three steps listed below in Figure 9 to identify and eliminate unreliable areas by 
segmenting the data. 
  
Figure 9: The Three Steps of Spatial Normalisation, adapted from (Neuvial et al. 
2006) 
 
 
 
 
 
 
 
 
 
 
STEP 1: Spatial trend estimation: Estimate the spatial 
trend on the array using 2-dimensional LOESS regression; 
 
STEP 2: Spatial Segmentation: Segmentation of the array 
into spatial areas with similar trend values using NEM, an 
unsupervised classification algorithm including spatial 
constraints; 
 
STEP 3: Identification and Elimination of Local Spatial 
Bias. 
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Array spots that had not been excluded following spatial normalisation were then 
subject to analysis for continuous spatial gradients, and subsequently normalised. 
Data normalisation was performed as summarised above in CAPweb using R package 
MANOR.  Default parameters were used: exclusion of data points with a replicate 
deviation of > 0.1; and/or a foreground to background signal ratio of < 3 (Neuvial et 
al. 2006).  
 
Data was exported to the array data visualisation tool VAMP (Visualisation and 
Analysis of Molecular Profiles) (La Rosa et al. 2006), which enabled visualisation of 
the data and first level analysis of the alteration profiles.  Regions of alterations of the 
analysed cases were determined using the minimal-alteration algorithm (Rouveirol et 
al. 2006) which is integrated into the VAMP software.  
 
Final analysis of array-CGH data was performed by KU using the R statistical 
platform (Team 2008, Team 2010).  Normalised profiles were segmented using the 
DNAcopy package, which utilises the Circular Binary Segmentation (CBS) algorithm 
to identify genomic locations of copy number transitions (Venkatraman and Olshen 
2007).  The DNAcopy data is then subjected to CGHcall, which converts the feature 
extraction data back to an absolute measure, ‘calling’ the data, as defined in Table 10 
(van de Wiel et al. 2007) as a region of loss, normal, gain or amplification.  Each 
called region is then integrated into a matrix with all clones on one axis, and all calls 
on the other axis.  This is created through the CGHregions program, which reduces 
the size and complexity of the matrix to enable simultaneous and efficient analysis of 
multiple samples.  CGHregions reduces the computational time required to analyse 
the data set, and reduces the biological complexity for interpretation of copy number 
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alterations, and improves the statistical power of the significant findings (van de Wiel 
and van Wieringen 2007).  Simplifying the data enables downstream analysis for 
testing, clustering and classification that incorporates correction of p-values due to  
multiple testing using a permutation-based calculation of the false discovery rate for 
each p-value as suggested by Benjamini and Hochberg (Benjamini Y 1995, Benjamini 
and Hochberg 1995).  The frequencies of calls per region for each group tested was 
subjected to a modified Benjamini-Hochberg FDR correction is applied as described 
by Gilbert et al (Gilbert 2005). Regions were considered significantly altered between 
groups if the p-value was less than 0.05, and its false discovery rate was less that 
20%. 
 
Table 10: CGHcall classification (‘calling’) 
Call Classification Number of DNA Copies 
Loss < 2 Copies 
Normal 2 Copies 
Gain 3-4 Copies 
Amplification > 4 copies 
 
Identified regions of significant copy number alteration were then further analysed in 
three ways: 
1. For the presence of genes that could be targeted with known molecular agents 
within regions gained. 
2. For alterations relating to specific phenotypes – through unsupervised and 
supervised hierarchical cluster analysis. 
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3. For key pathways and genes within the altered regions through the web-based 
bioinformatic analysis platform Database for Annotation, Visualization and 
Integrated Discovery (DAVID) (Huang da, Sherman and Lempicki 2009). 
 
Altered regions were defined by the beginning and end base pair location along the 
chromosome.  The web-based tool ‘Ensembl’ (http://www.ensembl.org) was used to 
identify the genes present within the altered regions (Hubbard et al. 2009).  Ensembl 
is a database that provides details of the genome of various species free to access 
online.  Using the ‘Ensembl Gene 66’ database and the ‘GRCh37.p6’ Homo Sapiens 
genome BioMart (a tool within the Ensembl platform) was used to produce gene lists 
of the genes present within the altered regions (Figure 10).  The beginning and end 
base pair location for each region were entered into BioMart, and gene lists were 
exported for further analysis. 
 
Figure 10: Biomart in Ensembl 
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DAVID is a web-based bioinformatic tool created by the Laboratory of 
Immunopathogenesis and Bioinformatics to support research from the National 
Institute of Allergy and Infectious Diseases (NIAID) (Figure 11).  It is a free-access 
tool providing functional annotation of genes to assist the biological understanding of 
a group of genes.  In this study we identified genes within altered regions using 
BioMart to create gene lists for the altered regions, we then input the gene lists into 
the DAVID platform for analysis.  DAVID version 6.7 was used to interrogate gene 
lists to: identify enriched biological themes using Gene Ontology (GO) Terms (Figure 
12); identify enriched functional-related gene groups; and visualise genes of interest 
using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway maps (Figure 
13). 
 
Figure 11: DAVID version 6.7 
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Figure 12: Gene Ontology Analysis in DAVID 
 
Figure 13: KEGG Pathway Analysis in DAVID 
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2.5.2 Oligonucleotide array-CGH 
DNA was labeled using random primer labeling (Enzo Life Sciences CGH Labeling 
Kit).  Tumour DNA was labeled with Cy3 and sex-mismatched reference DNA 
(Promega) with Cy5 fluorescence dye and hybridised to 180K Agilent 
Oligonucleotide array CGH slides for 24 hours. Microarray slides were scanned at 3 
µm (Agilent), fluorescence intensities extracted using the Feature Extraction Software 
(Agilent) and subsequently analysed within the statistical environment R using the 
CBS algorithm for segmentation of profiles and the CGHcall package for calling of 
copy number gains and losses. 
 
The method was adapted from three existing protocols: 
1. Agilent 44k aCGH arrays VUMC protocol Draft 1.1 04-10-2007 Alan Mršić: 
Adapted from Agilent Oligonucleotide Array-Based CGH for Genomic DNA 
Analysis: Agilent Microarray Hybridization Oven Version 4.0 
 
2. Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis 
Enzymatic Labeling for Blood, Cells or Tissues (with a High Throughput 
option) Protocol Version 6.2.1, February 2010 
 
3. Enzo life sciences CGH Labeling Kit for Oligo Arrays for preparation of 
Cyanine 3- and Cyanine 5-labeled DNA for hybridization to Agilent 
oligonucleotide arrays Instruction Manual ENZ-42671 
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2.5.2.1 DNA labeling (Enzo Labelling) 
The Enzo CGH Labelling Kit for Oligo Arrays (ENZ-42671) was used.  Firstly the 
DNA was denatured, and random primers annealed.  The following components were 
added to a 1.5ml eppendorf: 
Water 19 - X µl  
Primers/Reaction buffer 20 µl 
DNA X µl (500ng, max 19 µl) 
Total 39 µl 
 
 
The contents were then heated at 99°C for 10 minutes and placed on ice for two 
minutes.  The primers were extended using Klenow Exo-DNA Polymerase by adding 
the following components: 
To Test Sample 10 µl Cy3 (Vial 2) 
To Reference Sample 10 µl Cy5 (Vial 3) 
Klenow Exo-DNA Pol 1 µl (Vial 4) 
 
The contents were then incubated at 37°C for 4 hours.  5 µl of Stop Buffer (Vial 5) 
was then added to halt the reaction before the ‘clean-up’ step.  Clean-up/purification 
of the labeled DNA was performed using Amicon 30kDa filter columns.  430 µL of 
DNA suspension buffer to each reaction tube, then the sample was added to the 
Amicon 30kDa filter column, and spun for 10 minutes at 14,000 × g at room 
temperature. The sample was further purified by adding 480 µL of DNA suspension 
buffer and spinning for 10 minutes. The sample was recovered by inverting the filter 
into a fresh 1.5-mL eppendorf and spinning for 1 minute at 1,000 × g at room 
temperature.  The required volume of the purified sample is 39 µL: if < 39 µL it was 
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made-up to 39 µL using DNA suspension buffer; or if > 39 µL it was concentrated 
using a speedvac.   
 
The NanoDrop 2000 was used to measure the yield and specific activity using 1.5 µL 
of sample and the following calculations: 
 
Yield (µg) =       DNA concentration (ng/µL) x Sample Volume (µL) 
1000 ng/µg 
 
 
Specific Activity =                   pmol per µL dye     .       
      µg per µL genomic DNA 
!
 
According to the Array-based CGH for Genomic DNA Analysis Protocol acceptable 
values for hybridization of labeled DNA were: a yield of 5-7 µg; a specific activity of 
Cy-3 of 25-40 pmol/µg; and a specific activity of Cy-5 of 20-35 pmol/µg. 
 
2.5.2.2 DNA labeling (ULS Labeling) 
A validation experiment was performed comparing stromal and invasive elements of 
tumour tissue to ensure macroscopic dissection of the tissue did not significantly 
affect CGH profiles. The experiment is described in more detail later, however the 
ULS Labeling Kit (Agilent) was used to label the samples, and the label protocol is 
described here.  The Genomic DNA ULS Labeling Kit (5190-0419, Agilent) was used 
providing a non-enzymatic direct-labeling method, without an amplification step.  500 
ng DNA was made-up to 8 µL with nuclease-free water, denatured at 95°C for 5 
Chapter II: Materials and Methods 
 
 
2-125 
minutes, then ice-cooled for 3 minutes.  A labeling master mix was made-up as 
follows (per reaction): 
Nuclease-free water 0.5 µL 
ULS-Cy3 OR ULS-Cy5 0.5 µL 
10 x labeling solution 1 µL 
 
2 µL of master mix was added to each sample, then incubated at 85°C for 30 minutes, 
followed by ice cooling for 3 minutes.  10 µL of nuclease-free water was added to 
each sample then the excess Cy3/Cy5 was removed using Agilent KREApure 
columns.  Briefly, the KREApure columns were pre-spun for 1 minute at 16,000 x g 
and 100 µL of nuclease-free water was added followed by a further 1 minute spin.  
The labeled DNA sample was added to the column and spun at 16,000 x g for one 
minute, and the purified sample was collected in a 1.5 mL eppendorf beneath.  1.5 µL 
labeled DNA was then applied to the NanoDrop-2000 to determine the yield and 
specific activity (as calculated for Enzo-labeling protocol).  The yield should be the 
same as the input yield of DNA as there is no amplification step.  The specific activity 
should ideally be 20-70 pmol/µg for Cy5 and 50-100 pmol/µg for Cy3. 
 
2.5.2.3 DNA Hybridisation 
The Cy-5 and Cy-3-labelled samples were combined and the following components 
were added: 
Cot-1 DNA (1.0 mg/mL) 5 µL 
Agilent 10X Blocking Agent 11 µL 
Agilent 2X Hi-RPM Buffer 55 µL 
Hybridization Master Mix 71 µL 
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The sample was incubated at 95°C for 3 minutes, then immediately transferred to a 
heat block at 37°C for 30 minutes.  The sample was then applied to a gasket slide 
(Hybridization Gasket Slide Kit 4 microarrays per slide format, G2534-60011, 
Agilent). The active side of the microarray slide (SurePrint G3 Human CGH 
Microarray Kit, 4x180K, G4449A, Agilent) was placed on top of the gasket slide to 
form a “sandwich slide pair”, the chamber closed, and transferred to the hybridisation 
oven (Agilent) and rotated at 65°C for 24 hours at a rotational speed of 20 rpm.  
 
Washing and scanning of slides was performed as per Agilent protocol, using Oligo 
aCGH Wash Buffer 1 and 2. Slides were washed at room temperature with Agilent 
Oligo aCGH Wash Buffer 1 for 5 minutes and with Agilent Oligo aCGH Wash Buffer 
2 for 1 minute at 37°C, then air dried. 
 
Array slides were scanned using a microarray scanner with 3 µm resolution (Agilent), 
which generates a two-layer tiff file with one image of Cy3 and one of Cy5 
fluorescence. 
 
2.5.2.4 Analysis 
Fluorescence intensities were extracted using the Feature Extraction Software 
(Agilent) and subsequently analysed within the statistical environment R using the 
CBS algorithm for segmentation of profiles.  The CGHcall package for calling of 
copy number gains and losses and the CGHregions package for calculation of regions 
of copy number alterations. 
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2.6 ErbB-2 Copy Number Gain 
To verify copy number gains identified by array-CGH ErbB-2 status was assessed in a 
subset of cases.  ErbB-2 was assessed for gene amplification and protein over 
expression.  Explanation of why ErbB-2 was assessed is addressed in the results 
chapter. 
 
ErbB-2 gene amplification was assessed in a subset of 9 cases.  ErbB-2 copy number 
gain/amplification was measured using chromogenic silver in situ hybridization 
(SISH) using the INFORMTM HER2 DNA probe (Ventana Medical Systems’, Arizon, 
USA).  The method requires three sections of FFPE tissue, one stained with H&E to 
identify the invasive tumour, one for the INFORMTM HER2 DNA probe, and one for 
the INFORMTM Chromosome 17 Probe.  The probes use chromogenic silver in situ 
hybridization and stain either ErbB-2 gene or chromosome 17, visualised as black 
dots.  The number of copies of ErbB-2 gene can be calculated compared to the 
number of copies of chromosome 17 per cell, to give a ErbB-2/Ch17 ratio.  The 
grading criteria were standardised by the American Society of Clinical Oncology and 
the College of American Pathologists in the ‘Guidelines for Recommendations for 
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer’ (Wolff et al. 
2007).  The SISH protocol for INFORMTM HER2 DNA probe was based on the 
guideline recommendations for cancer, and scored the cases as positive for gene 
amplification if the ErbB-2/Ch 17 ratio was greater than or equal to 2.2.  However, in 
the ToGA study of advanced gastric adenocarcinoma, it was found that using breast 
cancer scoring systems for gastric adenocarcinoma grossly under called the number of 
cases that were positive for ErbB-2 gene amplification and protein over expression 
that would respond to Trastuzumab therapy due to the heterogeneity of gastric 
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tumours compared to breast (Ruschoff et al. 2010).  The guidelines from the trial take 
into account the heterogeneity of the tumour, and thus require less stringent 
conditions, with a ErbB-2/Ch 17 ratio of 2.0 classed as positive, rather than 2.2.  All 
cases were classified as: negative, equivocal, or positive, for gene amplification by a 
consultant histopathologist (GS), using the signal enumeration detailed in Figure 14, 
modified to the ToGA study criteria as in Table 11.   
 
Table 11: Modified Scoring for ErbB-2 Gene Amplification using SISH 
Average ErbB2/Chr17 ratio Reported Result 
ErbB-2/Chr17 < 1.8 Negative for ErbB-2 gene amplification 
ErbB-2/Chr17 1.8-2.0 Equivocal for ErbB-2 gene amplification 
ErbB-2/Chr17 > 2.0 Positive for ErbB-2 gene amplification 
 
 
Figure 14: SISH Signal Enumeration (from ‘Interpretation Guide INFORMTM 
HER2’, Roche) 
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ErbB-2 protein expression was also assessed using immunohistochemistry (IHC) in a 
subset of 21 cases.  The I-VIEW DAB Detection Kit (Catalogue no. 760-091; 
Ventana Medical Systems, Inc., Tucson, AZ, USA), using Her2 antibodies (Ventana 
Cat No. 800.2996), was used with standard dilutions using the benchmark XT.  Cases 
were scored by a consultant histopathologist (GS), using the ToGA study criteria for 
grading gastric carcinoma (Ruschoff et al. 2010).  The Ruschoff criteria (described in 
Table 12) have been proven to be predictive of response to trastuzumab therapy 
(Herceptin, Roche) in advanced gastric cancer.  The ToGA study criteria were 
modified from the standard breast cancer criteria for scoring, as gastric carcinoma, 
like cholangiocarcinoma, a very heterogeneous tumour. 
 
Table 12: IHC scoring of ErbB-2 over expression, adapted from (Ruschoff et al. 
2010) 
Staining 
Intensity 
Score 
Staining Pattern ErbB-2 Over 
expression 
Status 
0 No reactivity or membranous reactivity in < 10% of tumour cells Negative 
1+ 
Faint/ barely visible membranous reactivity in ≥ 10% of tumour 
cells; cells are reactive only in part of their membrane 
Negative 
2+ 
Weak to moderate complete, basolateral, or lateral membranous 
reactivity in ≥10% of tumour cells 
Equivocal 
3+ 
Strong complete, basolateral or lateral membranous reactivity in ≥ 
10% of tumour cells 
Positive 
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2.7 EGFR Copy Number Gain 
EGFR protein expression was assessed using immunohistochemistry (IHC) in a 
subset of 21 cases.  The I-VIEW DAB Detection Kit (Catalogue no. 760-091; 
Ventana Medical Systems, Inc., Tucson, AZ, USA), using EGFR antibodies (Ventana 
Cat No. 790-2988), was used with standard dilutions using the benchmark XT.  Cases 
were scored by a consultant histopathologist (GS). 
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2.8 microRNA Extraction and Quality Assessment 
2.8.1 microRNA Extraction 
To extract microRNA the RNeasy FFPE kit (Catalogue no. 74404, Qiagen) for Total 
RNA extraction was used, using the option that retains small RNAs including 
microRNAs.  As with DNA extraction, 10 µm sections of FFPE tissue on glass slides 
were used.  Macroscopic dissection was performed using a scalpel and a H&E 
reference slide.  
 
Using the H&E reference slide, the area of tumour was marked onto the underside of 
the slide containing the 10 µm section of tissue.  The unwanted tissue was scraped off 
with a clean scalpel and discarded.  The 10 µm section was deparaffinised three times 
in xylene at room temperature, washed in absolute, 96%, and 70% ethanol for 30 
seconds each.  The tissue was allowed to dry briefly, to allow the ethanol to 
evaporate, then the tissue was moistened with nuclease-free water, and scraped into a 
1.5ml eppendorf, then air-dried for 10-15 minutes.   
 
The air-dried tissue pellet was resuspended with 150 µL Buffer PKD and 10 µL 
Proteinase K, then incubated for 15 minutes at 55°C, the 15minutes at 80°C.  320 µL 
Buffer RBC was added, then the sample was transferred to a gDNA Eliminator spin 
column.  720 µL 100% ethanol was added to the flow-through, then 700 µL of sample 
was transferred to an RNeasy MinElute spincolumn and spun for 15 seconds at 
10,000 rpm until all the sample was transferred.  500 µL Buffer RPE buffer was 
added to the column ad spun, and repeated.  After drying of the column by spinning 
for 5 minutes, the sample was eluted using 20 µL RNase-free water.  The yield and 
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purity was assessed using 1 µL of sample on the NanoDrop-2000.  RNA was then 
stored at -80°C until use. 
 
2.8.2 microRNA Quality Assessment: qRT-PCR QA 
To ensure microRNA was present in each sample before the microRNA array was 
performed each sample underwent qRT-PCR for ‘house-keeping’ microRNA RNU24.  
If RNU24 expression was identified, the sample was deemed of sufficient quality to 
undergo array analysis.  The TaqMan® MicroRNA Assay was used as per the 
TaqMan® Small RNA Assays Protocol. 
 
2.8.2.1 Reverse-transcription 
Reverse transcription was performed using the TaqMan® RNU24 primer.  The master 
mix was prepared on ice as follows (per reaction): 
100mM dNTPs (with dTTP) 0.15 µL 
MultiScribe™ Reverse Transcriptase, 50 U/µL 1.00 µL 
10X Reverse Transcription Buffer 1.50 µL 
RNase Inhibitor, 20 U/µL 0.19 µL 
Nuclease-free water 4.16 µL 
 
Each sample was tested in duplicate.  7 µL master mix, 5 µL RNA sample, and 3 µL 
5X RT primer (RNU24, Assay ID 001001, part no. 4427975) were combined on ice in 
a 0.2 mL PCR reaction tube.  The sample was incubated on ice for 5 minutes, then 
transferred to the thermal cycler on the following program: 
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16°C 30 minutes 
42°C 30 minutes 
85°C 5 minutes 
4°C Hold 
 
2.8.2.2 qRT-PCR amplification 
On each assay plate a fresh frozen CC cell line was used as an endogenous control, 
and nuclease-free water was used as a no template control for the qRT-PCR.  Each 
sample was assayed in duplicate.  The following components were added to each well 
being used on a MicroAmp Fast 96-well Reaction Plate (Part no. 4346907, Applied 
Biosystems): 
TaqMan® Small RNA Assay (20X) (RNU24) 1.00 µL 
Product from RT reaction  1.33 µL 
TaqMan® Universal PCR Master Mix II (2X), no UNG 10.00 µL 
Nuclease-free water 7.67 µL 
 
The plate was sealed, and centrifuged to remove air bubbles, then applied to the 
7900HT Fast PCR System (Applied Biosystems) on the following program: 
 
Cycle (40 cycles) 
Hold 
Denature Anneal/extend 
95°C 95°C 60°C 
10 minutes 15 seconds 60 seconds 
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2.9 microRNA array 
The Human miRNA V3 Microarray kit (8 x 15K, G4470C, Agilent) was used.  Each 
array contained probes for 866 human and 89 human viral microRNAs represented 
from the Sanger miRBase (release 12.0).  Only those samples that showed expression 
of RNU24 were included in the study.  The labeling and hybridisation protocol 
‘miRNA Microarray System with Complete Labeling and Hyb Kit Protocol’ was used 
(Agilent).  We included the Spike-In Solution in the protocol to act as an internal 
control for assay processing.  The assay was followed as published, and will be 
briefly summarised below. 
 
2.9.1 microRNA labeling 
Calf Intestinal Alkaline Phosphate (CIP) master mix was made-up as follows (per 
reaction): 
10X CIP Buffer 0.4 µL 
Labeling Spike-In 1.1 µL 
CIP 0.5 µL 
 
On ice 2 µL CIP master mix was added to 100ng RNA, then incubated at 37°C for 30 
minutes to dephosphorylate the sample.  The sample was then denatured by adding 
2.8 µL 100% DMSO and incubating at 100°C for 7.5 minutes, then transferring to an 
ice-bath.  The ligation master mix was prepared as follows (per reaction): 
10X T4 RNA Ligase Buffer 1.0 µL 
Cyanine3-pCp 3.0 µL 
T4 RNA Ligase 0.5 µL 
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To each sample 4.5 µL Ligation master mix was added, then incubated at 16°C for 2 
hours.  The sample was then completely dried using a vacuum concentrator 
(SPD111V Speedvac, Thermo Savant). 
 
2.9.2 microRNA hybridisation 
The pellet was resuspended in 17 µL nuclease-free water, and the following 
components were added to each sample: 
Hyb Spike-In solution (3rd dilution) 1.0 µL 
10X GE Blocking Agent 4.5 µL 
2X Hi-RPM Hybridization Buffer 22.5 µL 
 
The samples were then incubated at 100°C for 5 minutes, the ice-cooled for 5 
minutes. Each sample was then added to the gasket- slide in a ‘drag and dispense’ 
manner to reduce air bubbles.  Once eight samples were loaded onto the gasket slide, 
the array slide was added to form a “sandwich slide pair”, the chamber closed, and 
transferred to the hybridisation oven (Agilent) and rotated at 55°C for 20 hours at a 
rotational speed of 20 rpm. 
 
Washing and scanning of slides was performed as per Agilent protocol, using Gene 
Expression Wash Buffer 1 with Triton X-102 and Gene Expression Wash Buffer 2. 
Slides were washed at room temperature with Gene Expression Wash Buffer 1 for 5 
minutes and with Gene Expression Wash Buffer 2 for 5 minute at 37°C, then air 
dried. 
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Array slides were scanned using a microarray scanner with 5 µm resolution (Agilent) 
using the profile ‘AgilentHD_miRNA’.   
 
2.9.3 Analysis 
The raw intensities were extracted using Agilent Feature Extraction Software and 
Data was analysed within the R statistical environment.  Significantly altered 
miRNAs were further assessed using the miRDB database (http://mirdb.org) (Wang 
and El Naqa 2008, Wang 2008).  The miRDB database is a free-access resource for 
‘target prediction and functional annotation’ of miRNAs.  It can be used in two ways, 
to identify computationally predicted targets for miRNAs, and to provide functional 
annotation for miRNAs.  We accessed the miRDB database 4.0, which uses miRNA 
information from ‘miRBase V18’ (Figure 15).  For humans miRDB includes 
information for 1,919 microRNAs with targets, 695,662 gene targets, and 16,851 
unique gene targets for analysis.  Altered miRNAs from the study were entered into 
the miRDB database, and gene targets are computationally predicted using the 
bioinformatics tool MirTarget2.  Predicted genes were assigned a prediction score, 
and an miRDB prediction score of >80 is considered significant.  All genes with 
prediction scores >80 were then assessed using DAVID for GO term enrichment, 
OMIM terms and KEGG pathways with biological significance as described in the 
1Mb BAC array-CGH analysis. 
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Figure 15: miRDB database 
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The material presented in this chapter has been presented as poster presentations at an international 
conference: 
 
Surgical Management of Cholangiocarcinoma.  
McKay SC, Pericleous S, Kent-Bramer J, Jiao L, Habib N, Spalding D.  
9th World Congress of the International Hepato-Pancreato-Biliary Association, 18-22nd April 2010. HPB Journal 2010, 
12(Suppl. 1):P354. 
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3.1 Methods 
A detailed explanation of the methodology can be found in the Methods Chapter (II). 
 
A clinical database of patients with CC was created.  The purpose of the clinical 
database was to: 
• Identify cases for array-CGH and miRNA-array analysis (as archival samples 
were used in the study); 
• To ensure that the study population was similar in survival and pathological 
characteristics to large scale published studies of CC, to validate the study 
population; 
• To assess the incidence and survival of CC at two large hepatopancreatobiliary 
(HPB) tertiary referral units; 
• To collect clinical data to enable identification of molecular alterations with 
prognostic significance. 
 
Two HPB units were studied: Hammersmith Hospital (Imperial College Healthcare 
NHS Trust), and The Royal London Hospital (Barts and The London NHS Trust).  A 
retrospective review of all consecutive cases of histologically or cytologically proven 
CC presenting to each institution was performed.  Cases from Hammersmith Hospital 
were assessed from 1990-2009.  Cases from The Royal London Hospital were 
assessed from 2001-2010.  Consecutive cases presenting to each institution were 
evaluated.   
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3.2 Results 
The Hammersmith Hospital (HH) is an established tertiary referral centre for HPB 
malignancy, covering the primary care trusts for Westminster, Hounslow, 
Hammersmith & Fulham, Kensington & Chelsea, Ealing, Brent, Harrow, Hillingdon 
and Berkshire East, with a catchment population of 2.26 million.  As the size of the 
catchment population is known, this figure was used to calculate the incidence of CC 
by region per 100,000 persons in the catchment population.  
 
The Royal London Hospital (RLH) is a tertiary referral centre   The for HPB 
malignancy, covering a large geographical area including North East London Cancer 
Network, Essex and Brighton with a catchment population of 3.3 million.  As the size 
of the catchment population is known, this figure was used to calculate the incidence 
of CC by region per 100,000 persons in the catchment population. 
 
The HPB unit at RLH was opened in 1999 and has steadily grown into a large 
established unit.  As the unit was growing and establishing itself over the study period 
data was assessed separately to HH, and later combined with data from HH to ensure 
the trends were not significantly altered by the growth of the unit. 
 
There were 155 cases fulfilling the inclusion criteria of histologically or cytologically 
proven CC presenting to HH from 1990-2009.  This included 151 histologically 
proven cases and 4 cytology-only proven cases.  For RLH there were 90 cases, 
including 88 histologically proven, and 2 cytology-only proven cases from 2001-
2010.  Therefore in total there were 241 cases of CC from 1990-2010, with the annual 
number of cases assessed at each institution shown in Figure 16. 
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The number of cases presenting to HH was stable from 1990-2000, however from 
2001 onward there was a significant increase in the number of cases of CC.  This 
trend was mirror by the findings from RLH, though there was a lag period, likely 
related to the RLH HPB unit establishing itself for referrals, with the same number of 
cases presenting in 2008, followed by an increase in cases for RLH the subsequent 
year. 
  
Figure 16: Number of cases of Cholangiocarcinoma presenting to HH and RLH, 
1990-2010 
 
 
 
To gain a more representative spread of data a 3-year time period was used, to reduce 
error introduced by cases falling either side of the beginning and end of the calendar 
year.   For HH data, 1990 was the year of introduction of the computerised system 
used to search for cases, so data was assessed from 1991 onwards to ensure 
completeness of annual data collection.  For RLH data cases were included from 
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2001, as the HPB unit was opened in 1999, thus ensuring data collection was 2 years 
post-opening to enable referral patterns to settle.  The annual incidence per 100,000 
population was calculated using the catchment area population figures for each 
institution, as shown in Figure 17 and Table 13.  
 
Figure 17: Incidence of CC per 100,000 Population  
 
 
Table 13: Incidence of CC per 100,000 Population 
 Year HH RLH HH + RLH 
1991-1993 0.118  0.118 
1994-1996 0.221  0.221 
1997-1999 0.162  0.162 
2000-2002 0.177 0.045 0.124 
2003-2005 0.604 0.091 0.348 
2006-2008 0.811 0.333 0.572 
2009-2010  0.682 0.631 
 
The sex distribution of the study cohorts was similar, with a male to female ratio of 
1.18:1 for HH, and 1.14:1 for RLH. 
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Cholangiocarcinoma was uncommon below the age of 34, with a steady increase in 
the number of cases presenting with CC thereafter.  The median age at diagnosis was 
64 years (range 23-85 years).  There was a peak in the age of presentation of CC at 
70-74 years, as demonstrated in Figure 18. 
Figure 18: Age of presentation of cholangiocarcinoma 
 
 
 
Figure 19: Proportion of cases by anatomical subtype 
 
All cases of CC were classified by anatomical subtype as per TNM anatomical 
classification where possible (Nakeeb et al. 1996), in cases where it was not possible 
RLH HH 
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to determine the anatomical subtype of the tumour due to extensive spread they have 
been classified as ‘other’.  There was a significant difference in the proportion of 
anatomical subtypes of CC presenting to each institution, with PHCC being most 
frequent at HH, with 69 cases (44.5%), compared to ECC being the most frequent at 
RLH, with 54 cases (60%).   See Figure 19.  
 
Figure 20: Hammersmith Hospital: Annual Incidence of CC by Anatomical 
Subtype 
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Over the 20-year study period the incidence of all anatomical subtypes of CC 
increased.  For the HH cohort the incidence of PHCC preceded that of ICC and ECC, 
however for the RLH cohort the incidence of ECC was significantly higher (Figure 
20).  
Figure 21: Annual Incidence of CC for HH and RLH Combined Comparing 
Anatomical Subtypes 
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When data for HH and RLH were combined it revealed an increase in all subtypes 
until 2003-2005 for ICC, and 2006-2008 for PHCC, when their incidence gradually 
declines.  However, the incidence ECC continued to increase.  Most epidemiological 
studies of CC group PHCC and ECC as one subtype, and compare it to ICC, as shown 
in Figure 21, to enable comparison with other published studies.  The broad trend 
shows an increase in both ICC and PHCC/ECC over the study period, however the 
incidence of ICC decreased from 2003-2010. 
 
Table 14: Incidence of CC per 100,000 Population 
 ICC PHCC ECC PHCC+ECC 
1991-1993 0.015 0.044 0.029 0.074 
1994-1996 0.059 0.118 0.029 0.147 
1997-1999 0.044 0.074 0.044 0.118 
2000-2002 0.009 0.071 0.036 0.107 
2003-2005 0.162 0.108 0.063 0.171 
2006-2008 0.153 0.237 0.170 0.407 
2009-2010 0.070 0.160 0.331 0.491 
 
Of the 155 cases assessed at HH, 95 (61.3%) were deemed potential operable at MDT 
discussion and underwent surgical exploration plus or minus complete resection 
resection.  Sixty-seven of the 90 cases assessed at RLH (74.4%) were deemed 
potentially operable.  The majority of cases of ECC were potentially operable, 
compared to approximately two-thirds of cases of PHCC, and half the cases of ICC.  
Figure 22 shows the proportion of potentially operable cases by anatomical subtype.   
 
Sixty cases at HH, and 23 cases at RLH were deemed inoperable at presentation.  
Inoperable cases were discussed at the MDT, and referred to the oncologist for 
medical therapy depending on performance status.  Medical therapy included 
systemic chemotherapy plus or minus external beam radiotherapy.   
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Figure 22: Proportion of potentially operable cases by anatomical subtype for 
each hospital 
 
 
Disease survival data was available for all HH patients, and for 43 patients at RLH.  
The 43 patients at RLH with survival data were all operatively managed.  Survival 
analysis was performed using Kaplan Meier survival analysis (Prism).   
 
The median overall survival for all patients at HH was 13 months.  When medical and 
surgically treated cases were assessed separately they demonstrated significantly 
different survival, as shown in Figure 23 and Figure 24.  Median survival for the 
medically managed cohort was 7 months, compared to 22 months for the surgically 
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managed group.  Survival was significantly different between the two groups, (p 
<0.0001), with a hazard ratio of 4.092, 95% confidence interval 2.611 to 6.413.  
 
Figure 23: Hammersmith Hospital: Overall survival (all cases) 
 
 
 
Figure 24: Hammersmith Hospital: Overall Survival: Medical vs Operative 
(resection) treatment 
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For the RLH cohort survival data was available for 43 of the surgically managed 
cases.   At the time of analysis 20 cases had died, with a range of 0-36 months; 20 
patients were still alive, with a range of 4-35 months; and 3 patients were lost to 
follow-up, with a range of 2-14 months.  Median overall survival was 26 months 
(Figure 25).  
 
Figure 25: Royal London Hospital: Overall survival (Resection cases) 
 
 
Survival for surgically managed patients (resection group) was similar for both 
institutions, with no statistical difference in survival, with a median survival of 22 
months for HH, and 26 months for RLH, Figure 26. 
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Figure 26: Overall survival of resected cases between institutions 
 
 
For operatively treated cases where complete surgical resection was not possible, 
residual tissue was treated by radiofrequency ablation and or marked with surgical 
clips for post-operative radiotherapy.  At HH there were 30 R0 resections performed, 
21 R1, and 41 R2 resections.   At RLH there were 15 R0 resections, 20 R1 resections, 
and 4 R2 resections.  Surprisingly survival did not relate to resection status as shown 
in Figure 27 and Figure 28.  
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Figure 27: Hammersmith Hospital: Survival by resection status 
 
 
Figure 28: Royal London Hospital: Survival by Resection Status 
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3.3 Discussion 
Cholangiocarcinoma is a relatively rare malignancy, and over the past three decades 
the incidence of ICC has been reported as increasing worldwide.  However, the 
incidence of ECC has been reported as static (once assessed separately to gallbladder 
carcinoma, as explained in the Introduction Chapter I). 
 
We have assessed 241 cases of CC from 1990-2010 from two institutions.  We have 
analysed the age of presentation, incidence, anatomical subtypes, operability, and 
survival.  The peak age of presentation for CC was 70-74 years in the study group, 
with a very slight male preponderance (1.18:1), consistent with current literature for 
the epidemiology of CC (Lepage et al. 2011, Lazaridis and Gores 2005).   
 
During the study period there was a significant increase in the number of cases of CC 
assessed at each HPB unit.  However the distribution of cases anatomical subtype was 
significantly different by institution.  The majority of cases assessed by HH were 
PHCC (44%), whereas at RLH the majority of cases were ECC (60%).  This may 
represent differing patterns of referral form the catchment hospitals for each unit, or 
due to the different referral population, for example, RLH referral population includes 
East London, which has a high proportion of ethnic minorities, which may affect the 
incidence of different anatomical subtypes. 
 
The incidence for all anatomical subtypes was shown to increase over the study 
period, however there was a decline in the incidence of ICC and PHCC in the final 
two years. Patel et al. assessed data for incidence and mortality rates for ICC from the 
SEER program (Surveillance, Epidemiology, and End Results) in the United States 
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between 1973-1997 (Patel 2001).   They found that the incidence of ICC increased 
from 0.13 per 100,000 population in 1973 to 0.67 per 100,000 in 1997.  The incidence 
rates were mirrored by an increase in the age-adjusted mortality rate from 0.07 per 
100,000 to 0.69 per 100,000 over the same period. Khan et al. analysed age-
standardised mortality rates (ASMR) per 100,000 population for CC in England and 
Wales, Scotland, USA, Japan, Australia, France and Italy from 1979-1997.  They 
found a worldwide increase in the ASMR of ICC, from 0.27 in 1979-1981 increasing 
to 0.83 in 1995-1997 for England and Wales (Khan et al. 2002b).  For our study 
cohort the incidence of ICC increased from 0.015 per 100,000 population in 1991-
1993, to 0.153 in 2006-2008, before it dropped to 0.07 in 2009-2010.  The trend is 
similar to that reported by Patel et al. and Khan et al., however the actual incidence 
rates are considerably lower.  It is possible that the incidence rates are lower in our 
study as not all cases of ICC may be referred to the HPB centre for assessment. 
 
The incidence of PHCC in our study increased from 0.044 per 100,000 population in 
1991-1993, to 0.237 in 2006-2008, before dropping to 0.16 in 2009-2010.  For ECC 
the incidence steadily increased, from 0.029 in 1991-1993, to 0.33 in 2009-2010.  In 
epidemiological studies ECC and PHCC are assessed together, and when we 
calculated the combined incidence of PHCC and ECC the rates were 0.074 per 
100,000 in 1991-1993, increasing to 0.491 in 2009-2010.  In a later study Khan et al. 
assessed age-standardised incidence rates (ASIR) for CC for England and Wales and 
the United States using the National Cancer Registry (England and Wales) and the 
SEER program database (US) (Khan et al. 2012).  They reclassified all cases of 
PHCC that had been incorrectly coded by previous editions of the International 
Disease Classification of Oncology.  Reclassifying PHCC with ECC revealed that the 
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incidence of ICC was still increasing, although gradually, from 1990-2008, and the 
incidence of PHCC and ECC was static over the same time period, if not gradually 
decreasing.  The incidence of ICC increased from 0.43 to 1.84 per 100,000 males 
from 1990-2008 for males, and incidence of ECC decreased from 0.78 to 0.51 per 
100,000 females.  Our data shows an ongoing increase in the incidence of ECC unlike 
that reported by Khan et al.  The study by Khan et al. acknowledged that the 
classification for CC is further floored in their study, despite reclassifying where 
possible for PHCC tumour (Khan et al. 2012).  This is because if CC is not reported 
topographically and is simply reported as ‘cholangiocarcinoma’, then the National 
Cancer Registry classifies this as ICC, when in fact it could be PHCC or ECC.  The 
advantage of our study is that all cases were cross-checked for anatomical location 
using radiology, clinical letters and MDT discussion where appropriate to prevent any 
misclassification, and therefore may represent a more accurate anatomical distribution 
of incidence. 
 
We assessed the overall survival for CC, and found that operative treatment 
significantly improved median survival from 7 months in the medically managed 
group to 22 months in the surgically managed group.  However, we were surprised to 
find that resection status did not significantly affect survival, as reported by some 
other groups (Rocha et al. 2010, Yusoff et al. 2012).  The finding of resection status 
not affecting survival was found in the studies from both institutions.  This is an 
important finding, as patients with R2 resection (macroscopic tumour at resection 
margin) still derived survival benefit from resection. 
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This study represents a comprehensive review of consecutive CC patients presenting 
to two large HPB institutions.  The age, sex and survival of patients is similar to that 
reported in other studies, and validates the use of this patient cohort in our further 
studies.  Interestingly our study has identified an increase in incidence of ECC over 
the study period, a finding not reported in other epidemiological studies.  This may 
represent the referral practice of hospitals referring to this tertiary referral unit, or it 
may in fact represent a true increase in incidence of ECC identified due to the 
meticulous classification of cases in this study, which is not possible in large-scale 
epidemiological studies using pre-entered categorised data. 
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CHAPTER IV 
4 Array Comparative Genomic Hybridization 
 
 
 
 
 
 
 
 
 
The material presented in this chapter has been published in a scientific paper, and as two poster 
presentations at an international conference: 
 
Array comparative genomic hybridization identifies novel potential therapeutic targets for 
cholangiocarcinoma.  
McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, Spalding DRC.  
HPB Journal. 2011; 13(5): 309-19. 
 
Copy number gain at chromosome 8q21-24.3 correlates with poor survival in cholangiocarcinoma. 
McKay SC, Unger K, Hess J, Pericleous S, Stamp G, Chin Aleong J, Thomas G, Spalding DRC, Hutchins 
RR. 
The 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 
2011, Hepatology.  
 
Differing copy number alteration profiles identified by array CGH in Thai Intrahepatic 
Cholangiocarcinoma related to prognosis.  
McKay SC, Unger K, Sriraksa R, Zeller C, Pericleous S, Limpaiboon T, Hutchins R, Spalding DRC, Brown 
B, Thomas G.  
The 61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 
2010. Hepatology 2010, 52: 4 (S):945A  
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4.1 Introduction 
The incidence of cholangiocarcinoma varies widely internationally, with high rates of 
ICC in South East Asia, and considerably lowers rates in the West (Khan et al. 2002b, 
Khan et al. 2008, Patel 2001).  However, the incidence of ICC has significantly 
increased over the previous three decades, an observation first identified in the UK 
(Khan et al. 2002b).  Despite this discovery, our understanding of the pathogenesis of 
CC, especially in the UK is lacking.  There have been no published reports of copy 
number alterations (CNA) in CC within a UK population (except for the data from 
this thesis (McKay et al. 2011)).  Furthermore, there has been only one array-CGH 
study of CNA in CC, which unfortunately did not publish the detailed regions of CNA 
(Miller et al. 2009).  All other studies of CNA in CC have used metaphase-CGH, 
identifying large regions of alteration, making identification of key genes difficult and 
labour intensive (Shiraishi et al. 1999, Shiraishi et al. 2001a, Shiraishi et al. 2001b, 
Homayounfar et al. 2009, Koo et al. 2001, Lee et al. 2004, Uhm et al. 2005, Wong et 
al. 2002, Rijken et al. 1999, Kim et al. 2004, Ma et al. 2007, Ghosh et al. 2005).  
More importantly, there have been no copy number alterations published that 
correlate with survival, suggesting that the key alterations for further investigation 
have not yet been identified. 
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4.1.1 Copy Number Variation and Alteration 
Originally it was thought that greater than 99.9% of the human genome was the same 
in all individuals.  However, it is now understood that the human genome incorporates 
a large proportion of chromosomal structural variability, possibly involving up to 
12% of the human genome (Redon et al. 2006).  This chromosome structural 
variability is known as copy number variation (CNV) in reference to germline 
changes, and as copy number alteration (CNA) in reference to acquired somatic 
changes.  Copy number alteration and variation are defined as a DNA fragment copy 
number change of 1Kb to 3Mb length (Feuk, Carson and Scherer 2006), 
encompassing duplications, amplifications, and deletions.  DNA copy number 
changes play a key role in human evolution and disease.  For the majority of genes we 
inherit one copy from each parent, resulting in two copies of each gene.  However 
with copy number changes there are different numbers of genes present, either less 
than two copies in the case of deletion, or more than two copies in the case of 
amplification.   
 
Copy number variations can be normal non-disease related alterations, for example, 
CNV of AMY1, a salivary amylase gene.  AMY1 copy number varies widely among 
the European-American normal population, from 2 to 15 copies, without any apparent 
influence on phenotype or disease (Perry et al. 2007).  However, phenotypes can be 
influenced by CNV, an early example being the duplication of BAR gene in 
Drosophila melanogaster.  BAR gene duplication causes a reduction in size of the eye 
in Drosophila, resulting in the ‘Bar phenotype’ in this species (Bridges 1936).  Copy 
number variation can also lead to disease susceptibility, for example low copy number 
of CCL3L1 gene was found to be associated with increased susceptibility to vertical 
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transmission of HIV-1 in a global study of 4,308 individuals (Gonzalez et al. 2005).   
 
Much interest has been placed on CNA in malignancy, as de novo CNA has been 
found to lead to cancer development and progression. Copy number alteration 
involves copy number gain, amplification and deletion, and can cause gain-of-
function of oncogenes, or loss-of-function of tumour suppressor genes, leading to 
increased or decreased gene transcription and translation.  Genomic rearrangement 
resulting in the fusion of two genes or regulatory sequences can also generate gain- or 
loss-of-function alterations.  Genomic rearrangement can occur through the breakage-
fusion-bridge cycle. 
 
4.1.1.1 Mechanisms of Copy Number Alteration Formation 
4.1.1.1.1 Breakage-Fusion-Bridge Cycle 
The breakage-fusion-bridge cycle (BFB cycle) is where chromosomes break, often at 
a fragile site (see below), and the two broken ends of the chromatids fuse creating a 
dicentric chromosome (Figure 29).  During anaphase the centromeres separate to 
opposite poles, and an anaphase bridge is created by the fused chromatids.  Increased 
tension as the centromeres are drawn apart causes the anaphase bridge to break at a 
weak point, and the chromatids enter the separate daughter nuclei (McClintock 1941, 
Ramanna 1985). The BFB cycle continues in subsequent cell cycles, as sister 
chromatids fuse following DNA replication, increasing copy number amplification 
and deletions.  The BFB cycle continues until chromosomes are stabilised by the 
addition of a telomere, or the cell undergoes apoptosis.  BFB cycles have been shown 
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to be a key mechanism of gene amplification and genomic instability in human cancer 
cells (Lo et al. 2002). 
 
Figure 29: The Breakage Fusion Bridge Cycle 
1. Two pairs of chromosomes within cell; 2. The chromatids break at a fragile site; 3. The end of the 
chromatid doesn’t rejoin; 4. The chromatids fuse at their broken ‘sticky-ends’ creating dicentric 
chromosome. 5. Centromere separate to daughter cells creating anaphase bridge; 6. Chromatids break 
at a weak point; 7a. Cell contains a chromosome with a duplicated region with additional DNA; 7b. 
Cell contains a chromosome with a deleted region. 
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Acquirement of CNA usually occurs through the BFB cycle, there are other 
mechanisms for the creation of CNA: non-allelic homologous recombination; non-
homologous end-joining; and fork stalling and template switching.    
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4.1.1.1.2 Non-allelic homologous recombination (NAHR) 
This occurs with DNA sequences with high levels of similarity, but not identical 
sequences i.e. non-allelic (Chen et al. 2010).  Common similar non-allelic regions 
include region specific low-copy number repeats and repetitive sequences.  Regions 
are aligned, and cross over occurs, with fusion of the two non-allelic sequences 
(Figure 30).  Either gain or loss of DNA can occur, with duplication, deletion or 
inversion.  Typically NAHR occurs during meiosis or mitosis and is a major 
mechanism of CNA.  The majority of recombination rearrangement associated with 
disease occurs through NAHR (Lee, Carvalho and Lupski 2007). 
 
Figure 30: Non-Allelic Homologous Recombination 
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4.1.1.1.3 Non-homologous end-joining (NHEJ) 
This mechanism is used to repair double-stranded DNA breakages typically caused by 
ionising radiation and reactive oxygen species.  The broken ends do not require 
sequence similarity, and fusion occurs as a result of imprecise DNA repair, involving 
either the broken ends of the same chromosome, or the broken ends of different 
chromosomes (Figure 31).   
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Figure 31: Non-Homologous End-Joining 
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4.1.1.1.4 Fork stalling and template switching (FoSTeS) 
This is a more complex mechanism of creating CNA.  Here the DNA replication fork 
stalls at a region of genomic instability, causing disengagement of the lagging strand.  
This results in replication switching to a different near-by template, and continuing 
until disengagement again occurs, and switching back.  Stalling of the replication folk 
and template switching can occur several times during replication, leading to complex 
alterations with multiple deletions, insertions and inversions, with segments of normal 
DNA sequence and copy number within duplicated regions (Lee et al. 2007). 
 
4.1.1.1.5 Fragile sites 
Bignell et al analysed somatic genomic rearrangements in two breast cancer cell lines, 
and found breakage fusion junctions formed by both NAHR and NHEJ (Bignell et al. 
2007).  In NAHR and NHEJ alterations frequently occur at regions where DNA is 
susceptible to breakage, called fragile sites.  Fragile sites are defined as ‘site-specific 
gaps or breaks seen on metaphase chromosomes after partial inhibition of DNA 
synthesis’ (Glover and Stein 1987).  Fragile sites are defined according to the class of 
drugs that affects the replication process, and further classified into ‘common’ and 
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‘rare’ fragile sites (Glover et al. 1984, Debacker and Kooy 2007). Most common 
fragile sites are induced by aphidicolin, whereas most rare fragile sites are induced by 
folate.  Common fragile sites are present in all individuals, and are made up of AT-
rich sequences.  Rare fragile sites are present in up to 5% of the population, and 
consist of CGG-repeats (Debacker and Kooy 2007), which are susceptible to 
hypermethylation and gene silencing.  Common fragile sites are frequently associated 
with cancer, as a point of a double strand DNA breakage.  Eighty-nine common 
fragile sites have been identified (Debacker and Kooy 2007).  The AT-repeats within 
common fragile sites cause increased flexibility of the DNA strand, and enable the 
DNA strand to form hairpin structures, delaying replication and increasing their 
susceptibility to breakage (Arlt, Casper and Glover 2003).  This is demonstrated by 
the inactivation of FHIT tumour suppressor gene at chromosome 3p14.2.  Common 
fragile site FRA3B is located within the FHIT gene, and multiple rearrangements, 
normally large deletions, have been identified localised to FRA3B, which inactivate 
FHIT.  Tumour cell growth is inhibited in vitro and in vivo when FHIT is over-
expressed, and FHIT knock-out mice develop more spontaneous and induced tumours 
(Arlt et al. 2003, Siprashvili et al. 1997, Fong et al. 2000). FHIT inactivation has been 
implicated in several malignancies, including gastric, oesophageal, and colonic 
carcinoma (Ohta et al. 1996).  
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4.1.2 Copy Number Alteration and Cancer 
The development and progression of cancer is driven by genomic mutations, 
including single nucleotide substitutions, translocations and copy number alteration.  
In this thesis the term genomic is used to describe changes in the somatic genome i.e. 
acquired during cancer development and progression.  The number and type of 
genomic rearrangements in cancer genomes varies widely between tissue types, but 
within each type of cancer the alterations are often common. Analysis of tumour 
genomes often identifies many altered region, not all of which are causally implicated 
in cancer, some gene alterations are ‘driver’ mutations, and some ‘passenger’ 
mutations.  Driver mutations directly contribute to tumourigenesis, conferring growth 
or invasive characteristics, whereas passenger mutations are non-contributory to 
tumourigenesis, and are a sign of DNA instability within the tumour genome 
(Stratton, Campbell and Futreal 2009).  Identifying which are driver mutations is key 
to understanding tumourigenesis, and offers potential targets for treatment.  Genomic 
alterations lead to alterations in gene and protein expression, and subsequent 
alteration of cell signaling, cell growth, the cell cycle and apoptosis, leading to the 
development and progression of cancer. The Sanger Institute has created a Cancer 
Gene Census (http://www.sanger.ac.uk/genetics/CGP/Census/), listing genes with 
mutations that have been causally implicated in cancer (Futreal et al. 2004).  At 
present (1st January 2012) there are 467 genes listed, with 16 implicated through 
amplification, and 31 through somatic deletion mutations, as listed in Table 15 and 
Table 16. 
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Table 15: Cancer Gene Census: Amplified Cancer Genes  
Symbol Tumour name (somatic mutations) 
AKT2 Ovarian, pancreatic 
ALK ALCL, NSCLC, Neuroblastoma 
CCNE1 serous ovarian 
EGFR Glioma, NSCLC 
ERBB2 Breast, ovarian, other tumour types, NSCLC, gastric 
JUN Sarcoma 
LMO1 T-ALL, neuroblastoma 
MDM2 Sarcoma, glioma, colorectal, other 
MDM4 GBM, bladder, retinoblastoma 
MITF Melanoma 
MYC Burkitt lymphoma, amplified in other cancers, B-CLL 
MYCL1 Small cell lung 
MYCN Neuroblastoma 
NKX2-1 NSCLC 
REL Hodgkin Lymphoma 
SOX2 NSCLC, oesophageal squamous carcinoma 
 
 
Table 16: Cancer Gene Census: Cancer Genes with Somatic Deletion Mutations 
Symbol Tumour Types (Somatic Mutations) Cancer Syndrome 
APC Colorectal, pancreatic, desmoid, hepatoblastoma, glioma, other CNS 
Adenomatous polyposis coli; 
Turcot syndrome 
ARID1A Clear cell ovarian carcinoma, RCC  
ATM T-PLL Ataxia-telangiectasia 
BRCA1 Ovarian Hereditary breast/ovarian cancer 
BRCA2 Breast, ovarian, pancreatic Hereditary breast/ovarian cancer 
CDKN2A Melanoma, multiple other tumour types 
Familial malignant melanoma 
CDKN2C Glioma, MM  
CDKN2a(p14) Melanoma, multiple other tumour types 
Familial malignant melanoma 
FBXO11 DLBCL  
FBXW7 Colorectal, endometrial, T-ALL  
IKZF1 ALL, DLBCL  
KDM6A Renal, oesophageal SCC, MM  
MADH4 Colorectal, pancreatic, small intestine Juvenile polyposis 
MAP2K4 Pancreatic, breast, colorectal  
MEN1 Parathyroid tumors, Pancreatic neuroendocrine tumors 
Multiple Endocrine Neoplasia 
Type 1 
MLH1 
Colorectal, endometrial, ovarian, CNS Hereditary non-polyposis 
colorectal cancer, Turcot 
syndrome 
MSH2 Colorectal, endometrial, ovarian Hereditary non-polyposis colorectal cancer 
NF1 Neurofibroma, glioma Neurofibromatosis type 1 
NF2 Meningioma, acoustic neuroma, renal Neurofibromatosis type 2 
PAX5 NHL, ALL, B-ALL  
PBRM1 Clear cell renal carcinoma, breast  
PRDM1 DLBCL  
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PTEN Glioma, prostate, endometrial Cowden Syndrome, Bannayan-Riley-Ruvalcaba syndrome 
RB1 Retinoblastoma, sarcoma, breast, small cell lung 
Familial retinoblastoma 
SMARCB1 Malignant rhabdoid Rhabdoid predisposition syndrome 
STK11 NSCLC, pancreatic Peutz-Jeghers syndrome 
SUFU Medulloblastoma Medulloblastoma predisposition 
TNFAIP3 
Marginal zone B-cell lymphomas, 
Hodgkin's lymphoma, primary 
mediastinal B cell lymphoma 
 
VHL Renal, hemangioma, pheochromocytoma 
von Hippel-Lindau syndrome 
WT1 Wilms, desmoplastic small round cell tumor 
Denys-Drash syndrome, Frasier 
syndrome, Familial Wilms tumor 
WTX Wilms tumour  
 
 
Copy number alteration is common among cancer genomes.  Beroukhim et al 
assessed copy number alteration in 3,131 cancer samples including 26 different 
cancer types, compared to 1,140 normal tissue samples (Beroukhim et al. 2010).  In 
the cancer samples, an average of 17% of the genome was amplified, and 16% 
deleted, compared to 0.35% amplified and less than 0.1% deleted in the normal 
samples.  They identified frequent regions of CNA, with c-myc amplification and 
CDKN2A deletion occurring in 14% of samples. 
 
A mutation or deletion of a tumour suppressor gene leads to a loss or decrease of gene 
transcription, and subsequent loss of function the translated protein.  For example, in 
pancreatic adenocarcinoma p16INK4A gene is deleted in numerous studies.  Aguirre et 
al demonstrated copy number deletion of the region containing p16INK4A at 9p21 using 
array comparative genomic hybridisation, and confirmed absence of p16INK4A gene 
expression using qRT-PCR (Aguirre et al. 2004).  p16INK4A is a tumour suppressor 
gene that inhibits transition through the cell cycle, and its deletion enables cancer 
cells to replicate unchecked (Okamoto et al. 1994). 
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A mutation or amplification of an oncogene leads to increased gene transcription, and 
subsequent increase of the translated protein.  An example is ErbB-2 gene 
amplification in breast cancer, leading to ErbB-2 protein over expression was 
demonstrated using array comparative genomic hybridsation by Albertson (Albertson 
2003).  
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4.1.3 Comparative Genomic Hybridisation 
Comparative genomic hybridisation (CGH) is a method of scanning the whole 
genome for DNA copy number alterations.  This technique identifies regions of DNA 
gain and loss, and is especially useful in studying tumours (Kallioniemi 2008).  
 
In CGH tumour and normal DNA are differentially labeled with fluorescent dyes: 
tumour DNA Cy3; reference DNA Cy5.  The labeled DNA is then co-hybridized to 
metaphase spreads of chromosomes.  Hybridisation of repetitive sequences is blocked 
using human Cot-1 DNA.  Reference and tumour DNA hybridise in a competitive 
manner with their complementary sequences on the metaphase chromosomes.  The 
fluorescence of reference DNA and tumour DNA binding to each chromosome are 
measured and quantified.  The relative amounts of hybridised reference and tumour 
DNA reflect the copy number of genomic regions.  A fluorescence ratio in favour of 
Cy3 (tumour) reflects a copy number gain, whilst a ratio in favour of Cy5 (reference 
DNA) reflects tumour copy number loss.  The location of the copy number alteration 
is mapped to the physical location on the chromosome (Kallioniemi et al. 1992).  
 
The use of metaphase spreads in conventional CGH is technically challenging, and 
allows identification of copy number alterations at a relatively low resolution of 5-10 
Mb (Inazawa, Inoue and Imoto 2004).  Vast advances have been achieved in CGH 
methodology over the last decade, moving from conventional metaphase-CGH to 
array-CGH, which uses DNA microarrays instead of human metaphase chromosome 
spreads (Pinkel and Albertson 2005).  DNA Fragments such as large-insert clone 
BACs (bacterial artificial chromosomes) or oligonucleotides, representing the human 
genome are immobilised onto glass slides, to which the fluorescently-labeled DNA 
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hybridizes, as shown in Figure 32 (Pinkel and Albertson 2005, Fiegler et al. 2003, 
Lipshutz et al. 1999, Albertson and Pinkel 2003).  The advantage of array-CGH is a 
vastly improved resolution of 1Mb to 50kb. Furthermore it is faster and does not 
require cytogenetic expertise.  
 
Amplification of oncogenes and deletion of tumour suppressor genes is a hallmark of 
cancer, and is a key mechanism of tumourigenesis.  Array-CGH pinpoints regions of 
alteration within the tumour genome, highlighting potential key oncogenes and 
tumour suppressor genes. Identifying driver genes within regions of genomic 
alteration can be a challenge.  One method involves analysing the shape of the 
amplicon, or region of highest frequency of alteration within the amplified region.  
This is because with ongoing selection pressure the amplicons shorten, with the area 
of highest amplitude containing the driver gene (Albertson et al. 2000).   
 
Array-CGH is also useful for discovering treatment targets, identifying copy number 
gain of key target genes for cancer treatment.  For example, in breast cancer ErbB-2 
protein over expression is caused by ErbB-2 gene amplification in >90% cases, which 
can be identified using array-CGH.  Improved survival is well established in breast 
cancer patients using ErbB-2 targeted therapy (trastuzumab) (Lohrisch and Piccart 
2001b, Lohrisch and Piccart 2001a).   
Chapter IV: Array Comparative Genomic Hybridisation 
 
4-173 
Figure 32: Array Comparative Genomic Hybridisaton 
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Array-CGH can also be used to identify genomic alterations with prognostic 
significance.  For example, in a study of 224 cases of diffuse large B-cell lymphoma 
copy number gain of the region 3p11-p12 was associated with significantly worse 
survival (Bea et al. 2005).  Altered regions with prognostic significance can be 
utilised as clinical tests to better inform patients, and can also highlight a key genomic 
region for carcinogenesis for further study. 
 
 
To date there have been eleven reports of CGH investigating CC, and three reports 
using cholangiocarcinoma cell lines (Rijken et al. 1999, Shiraishi et al. 1999, 
Shiraishi et al. 2001b, Shiraishi et al. 2001a, Koo et al. 2001, Lee et al. 2004, Uhm et 
al. 2005, Homayounfar et al. , Kim et al. 2001, Ma et al. 2007, Ghosh et al. 2005, 
Wong et al. 2002).  However, all of the reports of CC tissue samples have used 
metaphase-CGH, giving broad regions of copy number alteration, making further 
study of the altered regions time-consuming and difficult, except for the study by 
Miller et al which used array-CGH but did not detail the regions of alteration.  
Furthermore, no CGH study of CC has identified any regions of CNA associated with 
prognostic significance. 
 
This aim of this study is to undertake a detailed study of CNA in CC in a UK 
population to identify molecular targets for targeted treatments, and to identify 
prognostic signatures for patient risk stratification.  We will also compare copy 
number alterations identified in the UK study with a Thai cohort, where there is a 
clear aetiological factor (liver fluke infection) contributing to the molecular 
pathogenesis of CC.  In the UK there is no clear frequent aetiological factor, and we 
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hypothesis that UK CC will exhibit significantly different CNA profiles, suggesting 
that medical treatment, and the use of targeted agents should be tailored differently to 
studies performed in a South East Asian population. 
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4.2 Methods 
4.2.1 1Mb BAC array-CGH Study 
Detailed methods are written within Methods Chapter II.   In summary, tissue samples 
were obtained from three UK HPB Centres: Hammersmith Hospital (Imperial College 
Healthcare NHS Trust); Barts and The London Hospital (Barts Heath NHS Trust); 
and The Royal Marsden Hospital (The Royal Marsden).  Clinico-pathological data 
was collected as described in the Clinical Database Chapter III.  Ethical approval for 
the study was obtained through the Imperial College Healthcare NHS Trust Tissue 
Bank authorised by the Wales MREC (Application number R08/010 and R11004), 
and the London Research Ethics Committee (Ethics Reference Number 
09/H0718/41).   
 
DNA was extracted from formalin-fixed paraffin embedded archival tissue samples.  
Tissue samples were macroscopically dissected to remove normal tissue.  A modified 
extraction protocol using NaSCN incubation and the Qiagen QIAmp DNA Microkit 
were used to breakdown covalent cross-links within the DNA caused by tissue 
fixation.  The quality of extracted DNA was assessed using a size-multiplex PCR, and 
purity was assessed using the NanoDrop spectrophotometer. 
 
DNA was fluorescently labeled with Cy3-dCTP (tumour samples), and Cy5-dCTP 
(reference DNA) using the CyScribe kit (Amersham).  Tumour and normal reference 
DNA (Promega) were sex-mismatched as an internal hybridisation control, and 
hydridised to 1Mb BAC arrays containing the Sanger 1Mb BAC array clone set, with 
each BAC clone spotted in triplicate covering the whole genome. 
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After scanning for fluorescence intensities raw data was normalised using R package 
MANOR, and segmented using the CBS algorithm (Venkatraman and Olshen 2007, 
Neuvial et al. 2006).  CGHcall and CGHregions were used to identify regions of copy 
number alteration (van de Wiel and van Wieringen 2007).  Clinical data was used to 
assess alterations with clinical or prognostic significance. 
 
4.2.2 180K Oligonucleotide array-CGH Study 
Detailed methods are written within the Methods Chapter II.  In summary, samples 
were obtained through collaboration with R Sriraksa (RS), Professor B Brown, and 
Professor T Limpaiboon.  All CC samples and clinical data were kindly supplied by 
the Liver Fluke and Cholangiocarcinoma Research Centre, Khon Kaen University 
(Khon Kaen, Thailand), and approved by the Khon Kaen University Ethics 
Committee for Human Research (HE510651).  Clinico-pathological data for all cases 
were collected, including age at initial diagnosis, gender, gross types, histological 
grades and the overall survival time (excluding patients who died within 4 weeks after 
surgery). 
 
DNA was extracted from the samples by RS.  Briefly, the samples were from fresh 
frozen tissue blocks, and DNA was extracted using the DNeasy Tissue Kit (Qiagen) 
according to the manufacturer’s protocols.  DNA was labeled using random primer 
labeling (Enzo Life Sciences CGH Labeling Kit): tumour DNA Cy3-dCTP; sex-
mismatched reference DNA Cy5-dCTP (Promega).  Labeled samples were hybridised 
to 180K Agilent Oligonucleotide array-CGH slides for 24 hours.  Microarray slides 
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were scanned at 3 µm (Agilent), fluorescence intensities extracted using the Feature 
Extraction Software (Agilent) and subsequently analysed within the statistical 
environment R using the CBS algorithm for segmentation of profiles and the CGHcall 
package for calling of copy number gains and losses.  Clinical data was used to assess 
copy number alterations with prognostic significance. 
 
To assess copy number alterations in tumour-associated stroma compared to invasive 
tumour cells laser capture micro dissection was performed for 2 UK FFPE samples 
through collaboration with Biotheranostics (USA).  Whole genome amplification was 
performed using the GenomePlex Single Cell Whole Genome Amplification Kit 
(Sigma Aldrich) according to manufacturers protocol due to low DNA yield.   DNA 
labeling in this experiment was performed with the Genomic DNA ULS Labeling Kit 
(Agilent). 
 
4.2.3 Assessment of Copy Number Alterations between DNA from 
Formalin-Fixed Paraffin-Embedded Samples and Fresh Frozen 
Samples 
Archival formalin-fixed paraffin embedded (FFPE) tissue samples were used in this 
study as cholangiocarcinoma is a relatively rare tumour and prospective collection of 
fresh frozen tissue would take a considerable time period.   
 
Pathologists have used formalin as a tissue fixative since the late 1800s.  Formalin 
creates covalent cross-links with primary amino groups on proteins and nucleic acids, 
stabilising the tissue and preventing tissue degradation (Fox et al. 1985, O'Leary et al. 
2009).  Formalin fixation is commonly used as it produces minimal shrinkage and 
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distortion of the tissue, and is excellent for morphological analysis of tissue.  
However, FFPE tissue yields considerably degraded nucleic acid (DNA/RNA), which 
introduces an element of ‘noise’ with a variety of platforms including array-CGH, and 
can complicate analysis, reducing sensitivity.  Van Beers et al demonstrated that 
DNA extracted using a modified protocol with NaSCN incubation (as followed in our 
experiments) broke down DNA cross-links, and improved the extraction of higher 
quality DNA (van Beers et al. 2006). 
 
We assessed the effect of formalin-fixation and paraffin-embedding (FFPE) compared 
to fresh frozen tissue storage, to ensure that FFPE tissue did not introduce significant 
levels of ‘noise’ and variability in calling of CNA.  To do this we compared copy 
number profiles in matched FFPE and fresh frozen samples.  We used the 
cholangiocarcinoms cell line HUCC to reduce inter-sample variability.  Using 1Mb 
BAC array-CGH we compared CNA profiles FFPE and fresh frozen cell pellets from 
the same passage.  DNA was extracted from a fresh frozen cell pellet and from a 
10µm section from a FFPE cell pellet.  Samples were labeled and hybridised to 1Mb 
BAC array-CGH slides, and analysed as described previously.  A diagram explaining 
how to assess copy number plots is shown in Figure 42.  As shown in Figure 33, 
overall the profiles were similar.  However, regions of loss are called more frequently 
in the fresh frozen sample.  Furthermore there was a region of opposite calling that 
occurred at chromosome 1p, where in the fresh frozen sample the region showed a 
copy number loss, and the FFPE sample showed a copy number gain. 
 
To further assess copy number calling between fresh frozen and FFPE samples two 
tumour tissue samples were analysed, one ICC sample and one PHCC sample, both 
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which were pre-operatively downstaged with gemcitabine and cisplatin.  The copy 
number plots are shown in Figure 34 and Figure 35. 
 
The first paired tumour samples shown in Figure 34 shows many common copy 
number alterations, for example gain at 1p, 8q, 10p, 18p/q, and loss at 1p, 3p, 6q, 11p, 
14p/q and 21p.  However, there are regions of copy number gain identified in the 
fresh frozen sample that are not identified in the FFPE sample, for example gain at 3q, 
and loss at 7q and 9p/q.  Likewise there are regions of alteration in the FFPE sample 
not identified in the fresh frozen sample, for example gain at 7p and 12p, and loss at 
4p/q.  Furthermore there are some regions that reveal opposing calls between FFPE 
and fresh frozen samples, for example 1p reveals a gain in one, and a loss in the other. 
Figure 35 shows the copy number plot of a second paired tumour sample.  This plot 
shows very few alterations – and there is no correlation between the FFPE and fresh 
frozen samples. 
 
In summary, Figure 33 shows a copy number plot of a paired FFPE and fresh frozen 
cell line DNA, which shows good correlation of copy number calling, however the 
fresh frozen sample enabled more sensitive calling of copy number alterations.  
Figure 34 shows a tumour sample with moderate correlation between FFPE and fresh 
frozen tissue, and Figure 35 shows a tumour sample with no correlation between 
FFPE and fresh frozen tissue in a tumour sample that overall has very few alterations.   
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Figure 33: 1Mb BAC array-CGH Copy Number Plots Showing the log2-profile and Call Probabilities of Segments between FFPE and 
Fresh Frozen Cell Line Sample (fresh frozen sample in top profile, FFPE sample in bottom profile).  
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability. 
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Figure 34: 1Mb BAC array-CGH Copy Number Plots Showing the log2-profile and Call Probabilities of Segments between FFPE and 
Fresh Frozen Tissue Sample (fresh frozen sample in top profile, FFPE sample in bottom profile) 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability. 
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Figure 35: 1Mb BAC array-CGH Copy Number Plots Showing the log2-profile and Call Probabilities of Segments between FFPE and 
Fresh Frozen Tissue Sample (fresh frozen sample in top profile, FFPE sample in bottom profile) 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability. 
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The cell line experiments used pooled cells from the same passage and showed 
minimal variability between tissue storage/fixation techniques, demonstrating the 
FFPE tissue works well with the 1Mb BAC array-CGH platform, with slightly 
reduced sensitivity for accurately calling alterations due to additional noise.  However 
the tumour tissue samples did not demonstrate such close correlation.  This is most 
likely due to tumour heterogeneity.  Whereas the cell pellet samples were from the 
same cell population, the tumor samples were derived from different tissue blocks 
within the same tumour.  Tumour heterogeneity is a recognised phenomenon, with 
cells within the same tumour appearing morphologically different, and exhibiting 
different molecular alterations (Unger et al. 2004).  Cholangiocarcinoma is a very 
heterogeneous tumour, often associated with a prolific stromal reaction with isolated 
islands of tumour cells.  This is demonstrated in the H&E sections of CC shown in 
Figure 36.  This tumour heterogeneity can explain the disparity in profiles between 
FFPE and fresh frozen tissue. 
 
The 1Mb BAC array-CGH experiments demonstrated the increased sensitivity of 
DNA extracted from fresh frozen tissue compared to formalin-fixed paraffin-
embedded tissue for the calling of copy number alterations.  Although the copy 
number profiles were broadly similar with the 1Mb BAC-array platform, we wanted 
to investigate if the new more sensitive 180K oligonucleotide array-CGH platform 
would improve copy number calling in FFPE tissue samples for future experiments.  
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Figure 36: H&E sections of 2 cholangiocarcinoma samples demonstrating islands 
of heterogeneous tumour within a stromal matrix 
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Figure 37: 180K Oligonucleoitide array-CGH Copy Number Plots Showing the log2-profile and Call Probabilities of Segments between 
FFPE and Fresh Frozen SkChA1 Cell Line Sample (fresh frozen sample in top profile, FFPE sample in bottom profile) 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability. 
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Figure 38: 180K Oligonucleoitide array-CGH Copy Number Plots Showing the log2-profile and Call Probabilities of Segments for 
Chromosome 1 between FFPE and Fresh Frozen SkChA1 Cell Line Sample (fresh frozen sample in left profile, FFPE sample in right 
profile) 
P-arm of chromosome 1 along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability. 
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Figure 39: 180K Oligonucleoitide array-CGH Copy Number Plots Showing the log2-profile and Call Probabilities of Segments between 
FFPE and Fresh Frozen CC Tissue Sample (fresh frozen sample in top profile, FFPE sample in bottom profile) 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability. 
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Using 180K oligonucleotide array-CGH FFPE and fresh frozen samples were 
compared.  DNA was extracted from a fresh frozen SkChA1 cell pellet and a FFPE 
SkChA1 cell pellet, and from a paired CC tissue sample.  Samples were labeled and 
hybridised to 180K oligonucleotide array-CGH slides, and analysed as described 
previously. 
 
Figure 37 and Figure 39 shows the copy number plots for matched fresh frozen and 
FFPE cell line and CC tissue samples.  Figure 38 shows a ‘close-up’ view of the 
alterations on chromosome 1 for the cell line experiment.   
 
Overall the profiles for both the cell line and tissue sample correlate exceptionally 
well, except for a higher degree of ‘noise’ for the FFPE sample.  The 180K 
oligonucleotide array demonstrated a significant improvement to the profiles seen in 
the 1Mb BAC array-CGH comparison.  Figure 37 demonstrates this well, with very 
consistent regions of loss at 1p, however, some variation between FFPE and fresh 
frozen profiles in the region of gain at 1q.  This is due to the degraded DNA in the 
FFPE sample introducing ‘noise’ into the data, reducing the sensitivity of calling.  A 
further example of disparity between FFPE and fresh frozen is shown by the gain of a 
region on chromosome 18 in the cell line in the fresh frozen sample – the same region 
was not altered in the FFPE sample. 
 
Unlike the 1Mb BAC array-CGH CC tissue sample analysis, the correlation between 
FF and FFPE is significantly improved with the 180K oligonucleotide array, shown in 
Figure 39.  Although the 180K oligonucleotide platform does offer more sensitive and 
detailed calling, however the significant improvement in the tissue sample profile 
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correlation is most likely related to reduced sample heterogeneity in the sample used 
for 180K oligonucleotide array-CGH analysis. 
 
 
4.2.4 DNA Quality Assessment (1Mb BAC array-CGH) 
Size-multiplex PCR (see Methods Chapter II) was used to assess DNA quality, as 
described by Van Beers et al.  DNA with up to 200 base pair (bp) length was deemed 
of adequate quality for array-CGH (van Beers et al. 2006).  
 
DNA was extracted from 121 UK cases.  The quality of extracted DNA was assessed 
using size-multiplex PCR.  The size-multiplex PCR results are shown in Table 17, 
where DNA was extracted from FFPE samples using the modified protocol to 
breakdown DNA cross-links.  One hundred and eleven samples had DNA of greater 
than or equal to 200 bp length, and therefore passed the QA for array-CGH.  Figure 
40 shows a representative agarose gel electrophoresis of the size-multiplex PCR 
products. 
 
Table 17: Size-multiplex PCR of UK samples 
DNA fragment length on multiplex PCR Number of cases 
<100 bp 3 
100 bp 7 
200 bp 32 
300 bp 15 
400 bp 64 
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Figure 40: Agarose Gel Electrophoresis of Size-Multiplex PCR Products  
(LD = 1Kb ladder; 1-12 = samples.  Samples 1-2, 4-6, 8-12 contain DNA of 400 bp; 
sample 3 of 100 bp, and sample 2 of 200 bp). 
 
4.2.5 Reference DNA was Good Quality and Did Not Exhibit Any 
Significant Copy Number Alterations  
Normal reference DNA was purchased from Promega.  The Promega DNA was 
supplied as pooled DNA from 10 healthy subjects, and was purchased as separate 
aliquots of male or female DNA.  The integrity of the reference DNA was assessed by 
agarose gel electrophoresis using a 1Kb DNA ladder (Invitrogen).  As shown in 
Figure 41 the DNA was good quality, with no significant degradation, and was at 
least 12.2 Kb length. 
 
 
Figure 41: Agarose Gel Electrophoresis of Male and Female Reference DNA 
(1 = Male DNA; 2 = Female DNA; 3 = 1Kb DNA ladder) 
 
 
400 bp 
300 bp 
200 bp 
100 bp 
LD LD  1        2        3       4      5        6       7       8       9      10     11      12 
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If the reference DNA exhibited significant CNV it would alter the ‘calling’ of tumour-
associated CNA.  To ensure significant CNV was not present within the reference 
DNA, male and female reference DNA were assessed with 1Mb BAC array-CGH.  
Male DNA was labeled with Cy3-dCTP and female DNA labeled with Cy5-dCTP.   
 
Figure 42 is a copy number plot showing the log2-profiles and call probabilities of 
altered segments comparing male and female reference DNA.  The copy number plot 
shows each chromosome along the x-axis, with the X chromosome labeled as 23, and 
the Y chromosome labeled as 24.  The p-arm of the chromosome is to the left of the 
chromosome number, and the q-arm is to the right.  The raw data for each BAC clone 
is represented by a black dot.  The breakpoint segmentation of gains and losses are 
represented by the blue line.  A region of copy number gain is represented by a green 
bar.  A region of copy number loss is represented by a red bar.  In this individual 
cases analysis regions of copy number gain or loss are deemed significant if they 
reach 50% probability, i.e. 0.5 line along the y-axis.   
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Figure 42: 1Mb BAC array-CGH Copy Number Plot of log2-profiles and call probabilities of altered segments by chromosome with 
male DNA Cy3, female DNA Cy5  
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability, on this plot only the X and Y chromosomes (23 and 24) reveal 
significant alterations due to sex-mismatching. 
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The only significant alterations demonstrated are due to sex-mismatching, an internal 
hydridisation control: loss at chromosome 23 (X) and gain at chromosome 24 (Y).  
This is because female DNA contains two X chromosomes, whereas male DNA 
contains only one X and 1 Y chromosome.  Therefore when compared the male 
sample shows copy number loss at chromosome 23 sample as it has only one copy of 
the X chromosome, compared to two copies in the female, and it shows copy number 
gain at chromosome 24, as males unlike females have a Y chromosome. 
 
This experiment demonstrates the use of sex-mismatching as an internal hydridisation 
control, which is used in all array-CGH experiments in this thesis, and also 
demonstrates that the reference DNA does not exhibit any significant CNV that would 
bias the calling of tumour-associated CNA in subsequent array-CGH experiments.  
 
4.2.6 Comparing Macroscopic and Microscopic tissue dissection: does 
tumour-associated stroma make a significant difference? 
The 1Mb BAC-array study was performed using macroscopically dissected FFPE 
tissue, and the 180K oligonucleotide-array study was performed using fresh frozen 
tissue tumour blocks.  Each tissue sample contained tumour epithelial cells and a 
variable degree of tumour-associated stroma.  Tumour-associated stroma is 
considered a ‘driver’ of tumour progression, producing growth factors that ‘feed’ the 
tumour.  Normal non-tumour associated cells were largely removed by macroscopic 
dissection.  To investigate if the stromal element of the tumour (containing tumour-
associated fibroblasts) exhibited any significant CNA that would affect the tumour 
CNA profile for our study, laser-capture micro dissection was employed to separate 
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tumour epithelial cells from the tumour-associated stroma in this validation 
experiment.   
 
Tumour epithelial cells and tumour-associated stroma were separated by laser-capture 
micro dissection (LCM) performed through collaboration with Biotheranostics using 
standard LCM techniques.  DNA was extracted from these two components of the 
tumour using the standard FFPE extraction protocol.  Whole genome amplification 
was employed due to a low DNA yield obtained, and the samples were labeled using 
the ULS labeling kit and arrayed using the 180K Oligonucleotide array.  Two tumour 
epithelial cell samples and two matched tumour-associated stromal samples were 
assessed.  As an alteration to the standard hybridisation protocol the samples were 
hybridised for 48hrs to improve the foreground/background ratio, as the ULS labeling 
kit does not involve an amplification step in the labeling, and thus has a low total 
fluorescence.  
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Figure 43: Sample A: Copy Number Plots Showing the log2-profile and Call Probabilities of Segments between Tumour Epithelium and 
Tumour-Associated Stroma (tumour epithelium sample in top profile, stromal sample in bottom profile) 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability. 
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Figure 44: Sample B: Copy Number Plots Showing the log2-profile and Call Probabilities of Segments between Tumour Epithelium and 
Tumour-Associated Stroma (tumour epithelium sample in top profile, stromal sample in bottom profile) 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red; breakpoints in blue; individual 
BAC clone calls as black dots.  Copy number alterations are significant if they reach 0.5 probability. 
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The copy number plots showing the log2-profile and call probabilities of segments 
between tumour epithelium and tumour-associated stroma are shown in Figure 43 and 
Figure 44.  In sample A, other than the alteration demonstrated at chromosome 23 and 
24 for sex-mismatching, only three significant copy number alterations are 
demonstrated in the tumour-associated stroma sample: copy number loss at 9q; 17p 
and 19p/q.  Sample B demonstrates no significant copy number alterations in the 
tumour-associated stromal sample other than for sex-mismatching.  The copy number 
alterations seen in the stroma in sample A are also present in the tumour epithelium 
sample, and may represent contamination of the sample with tumour-epithelium.  
Also noted is the very high level of noise in both samples A and B, which is not seen 
in 180K oligonucleotide array of other FFPE samples (e.g. Figure 37), which is likely 
caused by laser capture micro dissection and whole genome amplification.  Therefore 
the method of macrodissection of FFPE tissue was validated, without laser capture to 
remove the stromal element, which then required whole genome amplification. 
 
4.2.7 1Mb BAC array-CGH Quality Assessment of Hybridisation and 
Fluorescence Scanning 
Formalin-fixed paraffin embedded DNA samples can produce a significant degree of 
background noise on analysis of fluorescence intensities.  Normalisation algorithms 
(as described in the Methods Chapter II) were applied to reduce the level of noise in 
the analysis.  The level of noise was assessed by pre-screening the data using 
CAPweb, and data normalised using the R-package MANOR as previously described, 
and viewed using VAMP software (Neuvial et al. 2006, La Rosa et al. 2006, Liva et 
al. 2006).   
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In samples where the percentage of usable clones was less than 85%, the sample was 
excluded from further analysis, as it did not reach the 85% surviving clones threshold. 
‘Usable clones’ are those clones passing the quality assurance filtering steps such as 
replication deviation and background-to-foreground ratio.  This 85% threshold is 
based on extensive BAC array-CGH experience with FFPE tissue from Integrative 
Biology Group, Helmholtz Zentrum München, Germany.  The quality assessment plot 
for one case following normalisation is shown in Figure 45.  It demonstrates that 99% 
of the clones were usable, i.e. above the threshold of 85% usable clones for the 
inclusion in the study.  The clones are represented on the graph labeled ‘pan-genomic-
representation’, where each clone is represented by a dot: yellow clones have no 
significant CNA, green clones represent a CN loss, and red clones represent a CN 
gain on the pre-screening of the data.   
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Figure 45: CAPweb Quality Assessment of ‘usable’ clones: Passed, as 99% 
usable clones 
Individual BAC clones are represented by each dot in the Pan-Genomic Representation, with red dots 
representing a copy number gain, yellow dots are normal, and green dots representing copy number 
loss; Array Image is a representation of the array slide to identify smears or washing errors. 
 
 
Seventy-one cases demonstrated greater than 85% usable clones and were included in 
the final analysis.  The most frequent cause of a significant proportion of unusable 
clones observed on some of the hybridisations was due to smears or dust on the array 
during the washing and drying stage resulting in high background fluorescence, as 
shown in Figure 46, where the array ‘failed’ the quality assessment as only 81% of 
BAC clones were usable, and the array image demonstrates a smear on the right side 
of the image where fluorescence intensities could not be measured.  This case was 
excluded from further analysis.  This is also demonstrated in Figure 47 with 2 scanned 
BAC slides.  On the scans each spot represents a BAC clone, and on the first scan 
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there is a high proportion of usable clones and the case passed the quality assurance 
criteria, however on the second scan a smear can be clearly seen due to dust during 
the washing and drying stages, therefore the sample had to be excluded due to a high 
proportion of unusable clones. 
 
 
Figure 46: CAPweb Quality Assessment of ‘usable’ clones: Failed, as 81.89% 
usable clones 
Individual BAC clones are represented by each dot in the Pan-Genomic Representation, with red dots 
representing a copy number gain, yellow dots are normal, and green dots representing copy number 
loss; Array Image is a representation of the array slide to identify smears or washing errors. 
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Figure 47: Florescence scan of 1Mb BAC array slides: the first case ‘passed’ with 
a high level of usable BAC clones; the second case ‘failed’ with a high level of 
unusable BAC clone 
Each BAC clones is represented by a florescent spot 
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4.3 1Mb BAC array-CGH Results 
Seventy-one cases were included in the final analysis following all quality assessment 
steps. 
4.3.1 Clinical data for study group 
The sex distribution of the study group was consistent with the sex-related incidence 
of CC, with 40 men and 31 women included in the study group, giving a ratio of 1.3-
to-1.  The mean age at presentation was 63 years, with a range 25-80 years.   The 
anatomical locations of the cases are listed in Table 18, with the highest proportion of 
cases being ECC. 
 
Table 18: Anatomical Location of Cases 
Anatomical Location Number of Cases Percentage 
ICC 14 19.7% 
PHCC 23 32.4% 
ECC 31 43.6% 
ICC/PHCC* 2 2.9% 
GBCC** 1 1.4% 
*Unable to distinguish between ICC and PHCC 
**Originally classified as ECC, but re-classified to GBCC on review of case 
 
Fifty-six cases were operatively managed, and 15 cases received medical management 
alone.   For the cases treated operatively there were 28 R0, 18 R1, and 10 R2 
resections.  The histopathology for each case was reviewed, and H&E sections of 
three example cases are shown in Figure 48.  Histopathology assessment of each case 
revealed 8 cases of papillary adenocarcinoma.   Twenty-seven cases were lymph node 
positive at resection, 24 cases demonstrated lympho-vascular invasion, and 38 
demonstrated perineural invasion.  
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Figure 48: H&E sections of a representative case of CC used in the study at two 
magnifications 
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Assessment of survival revealed 36 cases had died at the time of analysis, with a 
range of 2-48 months from diagnosis.  Twenty-three cases were still alive, with a 
range of 4-90 months, and 7 cases were lost-to-follow-up, with a range of 1-14 
months of recorded follow-up.  Overall the median survival was 28 months for all 
cases (Figure 49).  For operable cases the median survival was 31 months, compared 
to 10 months for inoperable cases (Figure 50). 
 
Figure 49: Kaplan-Meier Survival Plot for UK Cases in BAC array-CGH Study 
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Figure 50: Kaplan-Meier Survival Plot for Operable and Inoperable Cases 
 
 
4.3.2 Copy Number Alterations 
All chromosomes exhibited copy number alterations, and overall there were 98 altered 
chromosomal regions.  The classification of calls used in the assessment of copy 
number alterations is listed in Table 10.  There were 79 regions of copy number gain, 
ranging in frequency from 1.4 to 92.9% cases.  There were 39 regions of 
amplification, ranging in frequency from 1.4 to 25.7%.  Fifty-six regions 
demonstrated copy number loss, ranging from 1.4 to 54.3% cases.  The regions of 
copy number gain, amplification and loss are listed in Table 20 and Table 21.  A 
summary plot of all of all cases demonstrating the significant copy number alterations 
is shown in Figure 51.   
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Table 19: CGHcall classification (‘calling’)  
Call Classification Number of DNA Copies 
Loss < 2 Copies 
Normal 2 Copies 
Gain 3-4 Copies 
Amplification > 4 copies 
 
 
Table 20: Regions of copy number gain 
Chromosome Location Number of Clones 
Copy number 
gain 
(% cases) 
Copy Number 
amplification  
(% cases) 
1p36.33-34.1 44 78.6 0 
1p34.1-32.3 13 25.7 0 
1p13.2-12 14 40 0 
1q21.1 2 45.7 4.3 
1q21.1-21.3 8 61.4 7.1 
1q21.3-22 3 60 10 
1q23.1-25.3 27 38.6 1.4 
1q31.1-32.1 14 2.9 0 
1q32.1 8 70 12.9 
1q32.2-44 40 34.3 0 
2p35.2 4 28.6 0 
2q37.1-37.3 13 60 0 
3p25.3-25.1 8 64.3 0 
3p22.2 2 22.9 0 
3p22.1-14.3 20 44.3 0 
4p16.3-16.1 10 38.6 0 
5p15.33-15.2 14 20 1.4 
5q23.3-34 43 11.4 0 
5q34-35.3 14 35.7 2.9 
6p25.3-21.1 51 27.1 0 
6q25.2-25.3 2 4.3 0 
6q25.3-27 15 20 0 
7p22.3-22.1 10 38.6 4.3 
7p22.1-q11.21 60 7.1 0 
7q11.21-11.22 9 32.9 0 
7q11.23 4 42.9 24.3 
7q22.1 6 61.4 10 
7q32.1-32.2 3 11.4 1.4 
7q36.1-36.3 16 40 10 
8p23.3 4 21.4 0 
8p23.2-q12.2 69 1.4 0 
8q12.2-22.2 36 5.7 0 
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8q22.2-24.12 23 8.6 0 
8q24.12-24.3 21 27.1 0 
8q24.3 4 44.3 0 
9q21.33-22.33 20 22.9 0 
9q22.33-33.2 32 2.9 0 
9q33.2-33.3 4 34.3 0 
9q33.3-34.12 8 68.6 7.1 
9q34.12-34.3 8 68.6 17.1 
10p15.3-q11.22 50 1.4 0 
10q21.3-26.3 76 10 0 
11p15.5 6 8.6 15.7 
11q12.2-13.4 18 78.6 11.4 
11q13.4-14.1 8 37.1 2.9 
11q23.1-25 30 57.1 0 
12p13.33-13.1 16 37.1 0 
12p12.3-q13.11 34 2.9 0 
12q13.11-13.13 10 74.3 10 
12q13.13-13.3 4 60 2.9 
12q22 4 14.3 0 
12q24.11-24.23 12 68.6 2.9 
12q24.23-24.33 18 70 2.9 
13q34 2 12.9 4.3 
13q34 4 12.9 12.9 
14q32.11-32.33 17 28.6 0 
15q11.2-26.3 83 7.1 0 
16p13.3 2 71.4 8.6 
16p13.3-12.1 29 65.7 1.4 
16p11.2 3 61.4 8.6 
16p11.2-q21 18 40 0 
16q21 9 10 0 
16q21-24.3 29 67.1 2.9 
17p13.3-q21.33 66 92.9 2.9 
17q22 6 30 1.4 
17q22-25.1 22 85.7 1.4 
17q25.1-25.3 9 68.6 21.4 
18q23 4 5.7 25.7 
19p13.3-13.11 17 81.4 7.1 
19p12-q11 8 35.7 0 
19q12-13.43 34 82.9 7.1 
20p11.21-11.1 24 15.7 0 
20q11.23-11.21 13 81.4 1.4 
20q12-13.11 5 68.6 1.4 
20q13.12-13.33 31 82.9 1.4 
21q11.2-21.3 19 1.4 0 
21q22.11-22.3 10 47.1 0 
21q22.3 4 54.3 4.3 
22q11.1-13.33 30 91.4 5.7 
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Table 21: Regions of copy number loss 
Chromosome Location Number of Clones Copy Number loss (% cases) 
1p36.33-34.1 44 2.9 
1p34.1-32.3 13 4.3 
1p32.3-p13.3 59 18.6 
1p13.2-12 14 2.9 
1q31.1-32.1 14 54.3 
2p25.3-q36.3 255 1.4 
3p26.3-26.1 14 5.7 
3p25.1-22.3 26 22.9 
3p22.2 2 2.9 
3p14.3-p13 15 2.9 
3p13-q13.13 37 21.4 
4p16.1-q35.2 175 14.3 
5p15.2-q23.2 117 8.6 
5q23.3-34 43 1.4 
5q34-35.3 14 1.4 
6p21.4-q25.2 106 25.7 
6q25.2-25.3 2 18.6 
6q25.3-27 15 5.7 
7q11.23-21.3 29 4.3 
7q22.1-32.1 28 2.9 
8q12.2-22.2 36 18.6 
8q22.2-24.12 23 18.6 
8q24.12-24.3 21 1.4 
8q24.3 4 1.4 
9p24.3-q21.33 63 7.1 
9q21.33-22.33 20 4.3 
9q22.33-33.2 32 2.9 
9q33.2-33.3 4 4.3 
9q33.3-34.12 8 1.4 
9q34.12-34.3 8 1.4 
10p15.3-q11.22 50 2.9 
10q11.22-21.3 19 21.4 
11p15.5 6 1.4 
11p15.4-q12.1 59 1.4 
11q12.2-13.4 18 1.4 
11q13.4-14.1 8 1.4 
11q14.1-22.3 37 4.3 
11q23.1-25 30 1.4 
12q14.1-21.33 40 4.3 
12q24.11-24.23 12 1.4 
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12q24.23-24.33 18 1.4 
13q12.11-33.3 98 2.9 
13q34 2 2.9 
13q34 4 1.4 
14q11.2-31.3 77 1.4 
14q32.11-32.33 17 1.4 
16q21 9 2.9 
17p13.3-q21.33 66 2.9 
17q22 6 32.9 
17q22-25.1 22 1.4 
17q25.1-25.3 9 2.9 
18p11.32-q23 86 2.9 
20q11.23-11.21 13 1.4 
20q13.12-13.33 31 1.4 
21q11.2-21.3 19 21.4 
21q22.3 4 1.4 
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Figure 51: Summary Plot of Copy Number Alterations for All UK Cases  
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red. In this summary plot only 
significant copy number alterations are represented. 
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4.3.2.1 Phenotype analysis 
Unsupervised hierarchical cluster analysis was performed, and the cases clustered into 
4 groups (Figure 52), however the clusters did not relate to any identified phenotypes 
(anatomical subtype, differentiation, lymph node status, perineural invasion etc.).   
 
Figure 52: Unsupervised Hierarchical Cluster Analysis 
Individual cases represented horizontally, labeled on left y-axis; chromosome location of alteration 
from chromosome 1-22 from left to right along x-axis; copy number gain in green, copy number loss in 
red, no significant copy number alteration in black; clustering of cases represented by separators on 
right y-axis. 
 
Supervised analysis was performed using the following categories: survival; 
perineural invasion; lymph node status; sex; anatomical location; tumour 
differentiation; operable compared to inoperable cases; papillary subtype; and 
lympho-vascular invasion.  Using CGHregions to assess multiple samples, altered 
regions were considered significant if the p-value was less than or equal to 0.05, and 
false discovery rate was less than or equal to 20%.  Differential profiles were 
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identified for all categories except for lympho-vascular invasion and papillary 
subtype.  
4.3.2.2 Copy Number Alterations Associated with Survival 
Sixty-five cases were included in the survival analysis (those with adequate follow-up 
data).  Five regions were identified as altered in relation to survival with statistically 
significant outcomes, as listed below: 
 
• Copy number gain 8q24.21-24.3 
• Copy number gain 8q12.2-22.2  
• Copy number loss 6q25.3-27 
• Copy number gain 8q22.2-24.12 
• Copy number loss 11q14.1-22.3 
 
4.3.2.2.1 Copy number gain 8q24.21-24.3 
A copy number gain at chromosome 8q24.21-24.3 was identified in 15 cases and was 
significantly related to survival.  Copy number gain of this 21.9Mb chromosomal 
region was associated with poorer survival compared to cases without the copy 
number gain as shown in Figure 53.  The median survival was 14.4 months for cases 
with the copy number gain, compared to 28.3 months without the copy number gain, 
with a p-value of 0.016.  
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Figure 53: Kaplan-Meier Survival Plot for Copy Number Alteration at 8q24.21-
24.3 
 
Variables including perineural invasion; lymph node status; sex; anatomical location; 
tumour differentiation; operable compared to inoperable cases; papillary subtype; and 
lympho-vascular invasion were assessed for impact on survival using univariate cox-
proportional hazard analysis.  The only variable found to have a significant impact on 
survival was operable status with a p-value of 0.0024, and was thus included in 
multivariate analysis with copy number alteration at 8q24.21-24.3 to assess if the 
copy number alteration was an independent predictor of survival.  The survival plot 
for copy number alteration and operability is shown in figure 54.  It demonstrates that 
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copy number gain at 8q24.21-24.3 is an independent predictor of poor survival, as 
cases with the copy number gain demonstrated poor survival whether operable or not.  
Poorest survival was seen with copy number gain and inoperable tumours, and best 
survival was seen with no copy number gain and operable tumours.  Operable cases 
with the copy number gain had a worse survival than without CN gain, however it 
was only marginally better than inoperable cases without CN gain. 
 
Figure 54: Kaplan-Meier Survival Plot for Copy Number Alteration at 8q24.21-
24.3 separated by operable and inoperable tumours 
 
 
The region contained 74 genes and 8 miRNA.  Analysis of the genes within the region 
was performed using the web-based platform ‘Database for Annotation, Visualization 
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and Integrated Discovery’ (DAVID).  DAVID Analysis identified genes involved in 
key cellular pathways through Gene Ontology (GO) Term analysis and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway analysis.   
 
GO term analysis revealed enrichment of genes for the terms ‘regulation of 
transcription’ involving 24 genes, and ‘DNA binding’ involving 31 genes.  The genes 
involved in the ‘regulation of transcription’ and ‘DNA binding’ are listed in Table 22 
and Table 23. 
 
Table 22: GO Term: Regulation of Transcription: 24 Genes 
 
Gene Symbol Gene Name 
ATAD2 ATPase family, AAA domain containing 2 
KHDRBS3 KH domain containing, RNA binding, signal transduction associated 3 
POU5F1B POU class 5 homeobox 1B 
TAF2 TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
150kDa 
EIF2C2 eukaryotic translation initiation factor 2C, 2 
FOXH1 forkhead box H1 
HSF1 heat shock transcription factor 1 
PUF60 poly-U binding splicing factor 60KDa 
TIGD5 tigger transposable element derived 5 
MAFA v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian) 
MYC (c-myc) v-myc myelocytomatosis viral oncogene homolog (avian) 
ZFAT zinc finger and AT hook domain containing 
ZNF16 zinc finger protein 16 
ZNF250 zinc finger protein 250 
ZNF251 zinc finger protein 251 
ZNF34 zinc finger protein 34 
ZNF517 zinc finger protein 517 
ZNF572 zinc finger protein 572 
ZNF623 zinc finger protein 623 
ZNF696 zinc finger protein 696 
ZNF7 zinc finger protein 7 
ZNF707 zinc finger protein 707 
ZHX1 zinc fingers and homeoboxes 1 
ZHX2 zinc fingers and homeoboxes 2 
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Table 23: GO Term: DNA Binding: Genes 
Gene Symbol Gene Name 
ATAD2 ATPase family, AAA domain containing 2 
GLI4 GLI family zinc finger 4 
POU5F1B POU class 5 homeobox 1B 
RECQL4 RecQ protein-like 4 
TAF2 TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 150kDa 
CHRAC1 chromatin accessibility complex 1 
DSCC1 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) 
FOXH1 forkhead box H1 
HSF1 heat shock transcription factor 1 
JRK jerky homolog (mouse) 
PUF60 poly-U binding splicing factor 60KDa 
SCXA, SCXB scleraxis homolog A (mouse); scleraxis homolog B (mouse) 
SCRT1 scratch homolog 1, zinc finger protein (Drosophila) 
TIGD5 tigger transposable element derived 5 
TOP1MT topoisomerase (DNA) I, mitochondrial 
MAFA v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian) 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 
ZFAT zinc finger and AT hook domain containing 
ZNF16 zinc finger protein 16 
ZNF250 zinc finger protein 250 
ZNF251 zinc finger protein 251 
ZNF34 zinc finger protein 34 
ZFP41 zinc finger protein 41 homolog (mouse) 
ZNF517 zinc finger protein 517 
ZNF572 zinc finger protein 572 
ZNF623 zinc finger protein 623 
ZNF696 zinc finger protein 696 
ZNF7 zinc finger protein 7 
ZNF707 zinc finger protein 707 
ZHX1 zinc fingers and homeoboxes 1 
ZHX2 zinc fingers and homeoboxes 2 
 
KEGG pathway analysis identified c-myc and PTK2 as key genes within the altered 
region. 
 
The c-myc gene, which stands for v-myc myelocytomatosis viral oncogene homolog 
(avian) (also known as MYC, MRTL, or bHLHe39) is located at 8q24.21.  It is a 
known oncogene, important in the pathogenesis of several malignant tumours.  KEGG 
pathway analysis demonstrated its importance in several key signaling and cancer 
related pathways, as listed in Table 24.   
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Table 24: KEGG Pathways related to c-myc 
 
As described in the introduction, the MAPK signaling, ErbB signaling, JAK-STAT 
signaling and alterations in the cell cycle are key to the molecular pathogenesis of CC.  
The role of c-myc in these pathways is highlighted in red in the KEGG pathway 
diagrams on the following pages (Figure 55, Figure 56, Figure 57, Figure 58). 
 
KEGG Pathways 
MAPK signaling pathway ErbB signaling pathway 
Cell cycle Wnt signaling pathway 
TGF-beta signaling pathway Jak-STAT signaling pathway 
Pathways in cancer Colorectal cancer 
Endometrial cancer Thyroid cancer 
Bladder cancer Chronic myeloid leukemia 
Acute myeloid leukemia Small cell lung cancer 
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Figure 55: KEGG Pathway: MAPK Signaling (key genes highlighted in red from region 8q24.12-24.3) 
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Figure 56: KEGG Pathway: ErbB2 Signaling (key genes highlighted in red from region 8q24.12-24.3 
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Figure 57: KEGG Pathway: Cell Cycle (key genes highlighted in red from region 8q24.12-24.3) 
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Figure 58: KEGG Pathway: JAK-STAT Signaling (key genes highlighted in red from region 8q24.12-24.3) 
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The PTK2 gene, which stands for Protein tyrosine kinase 2 (also known as FAK, 
FADK, FAK1, FRNK, PPP1R71, p125FAK or pp125FAK) is located at 8q24.3.  It is a 
known oncogene, important in the pathogenesis of several malignant tumours.  KEGG 
pathway analysis demonstrated its importance in several key signaling and cancer 
related pathways, as listed in Table 25.   
 
Table 25: KEGG Pathways related to PTK2 
 
As described in the introduction, the VEGF signaling pathway is key to the molecular 
pathogenesis of CC, and the role of PTK2 in this pathway is highlighted in red in the 
KEGG pathway diagram in Figure 59. 
 
4.3.2.2.2 Copy number gain 8q12.2-22.2 
Copy number gain of the chromosomal region 8q12.2-22.2 was associated with poor 
survival (Figure 60).  Copy number gain of this region was found to be highly 
statistically significant for worse survival, with a p-value of 3.47 x 10-7. The median 
survival was 4.6 months for cases with the copy number gain, compared to 28.2 
months without the copy number gain.  However, there were only 4 cases with a 
gained region associated with poorer survival, compared to 66 cases without a gain of 
the region.  There were not enough cases in each arm to perform multivariate analysis.
KEGG Pathways 
ErbB signaling pathway Chemokine signaling pathway 
Axon guidance VEGF signaling pathway 
Focal adhesion Leukocyte transendothelial migration 
Regulation of actin cytoskeleton Pathways in cancer 
Small cell lung cancer  
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Figure 59: KEGG Pathway: VEGF Signaling (key genes highlighted in red from region 8q24.12-24.3) 
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This 36Mb region contains 162 genes and 1 miRNA.  Functional annotation analysis 
using DAVID identified GO Term enrichment for ‘cell cycle phase’ and ‘cell cycle 
process’ involving 7 and 8 genes respectively.  The gene RAD54B was identified 
using Online Mendelian Inheritance in Man (OMIM) disease search terms as a gene 
of interests related to the phenotypes colon adencarcinoma and non-Hodgkins 
lymphoma.  The gene RAD54B is located at 8q22.1. 
 
Figure 60: Kaplan-Meier Survival Plot for Copy Number Alteration at 8q12.2-
22.2 (x-axis time in months; y-axis percentage survival) 
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4.3.2.2.3 Copy number loss 6q25.3-27 
Copy number loss of the chromosomal region 6q25.3-27 was associated with poor 
survival (Figure 61).  Copy number loss of this region was found to be statistically 
significant for worse survival, with a p-value of 0.0369.  The median survival was 8.7 
months for cases with the copy number loss, compared to 28.2 months without the 
copy number loss.  However, there were only 4 cases with a loss in this region 
associated with poorer survival, compared to 66 cases without a loss.  This 15Mb 
region contains 68 genes and 1 miRNA. There were not enough cases in each arm to 
perform multivariate analysis. 
Figure 61: Kaplan-Meier Survival Plot for Copy Number Alteration at 6q25.3-27 
(x-axis time in months; y-axis percentage survival) 
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The genes PARK2 and IGF2R were identified using Online Mendelian Inheritance in 
Man (OMIM) disease search terms as a gene of interest.  The PARK2 gene located at 
6q26 is a known tumour suppressor gene, and associated with OMIM phenotypes: 
adenocarcinoma lung, somatic; and adenocarcinoma ovarian, somatic. The IGR2R 
gene (insulin-like growth factor 2 receptor) is located at 6q25.3, and is associated 
with the OMIM phenotype Hepatocellular carcinoma.  KEGG pathway analysis 
identified MAS1 oncogene as a gene of interest, located at 6q25.3. 
 
4.3.2.2.4 Copy number gain 8q22.2-24.12 
Copy number gain of the chromosomal region 8q22.2-24.12 was associated with poor 
survival (Figure 61).  Copy number gain of this region was found to be statistically 
significant for worse survival, with a p-value of 0.039.  The median survival was 9.3 
months for cases with the copy number gain, compared to 28.2 months without the 
copy number gain.  However, there were only 6 cases with a gain in this region 
associated with poorer survival, compared to 64 cases without a gain.  This 23Mb 
region contains 57 genes and 2 miRNAs.  However analysis of the genes in DAVID 
did not highlight any significant gene enrichment of disease pathways for further 
investigation. There were not enough cases in each arm to perform multivariate 
analysis. 
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Figure 62: Kaplan-Meier Survival Plot for Copy Number Alteration at 8q22.2-
24.12 (x-axis time in months; y-axis percentage survival) 
 
 
4.3.2.2.5 Copy number loss 11q14.1-22.3 
Copy number loss of the chromosomal region 11q14.1-22.3 was associated with 
improved survival (Figure 63).  Copy number loss of this region was found to be 
statistically significant for a better survival, with a p-value of 0.052 i.e. copy number 
loss of 11q14.1-22.3 was protective for survival.  All 3 cases with the copy number 
loss were alive at time of analysis compared to 27.8 months median survival without 
the copy number loss.  However, there were only 3 cases with a loss in this region 
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associated with improved survival, compared to 67 cases without a loss.  This 37Mb 
region contains 126 genes and 3 miRNAs.  The gene ATM was identified using 
Online Mendelian Inheritance in Man (OMIM) disease search terms as a gene of 
interest.  The ATM gene located at 11q22.3 and associated with OMIM phenotypes: 
breast cancer, susceptibility to; lymphoma, B-cell non-Hodgkin, somatic; lymphoma, 
mantle cell; T-cell prolymphocytic leukaemia, sporadic.  Analysis of GO Terms 
identified enrichment for the ‘regulation of apoptosis’ involving 11 genes.  KEGG 
pathway analysis identified the apoptosis pathway as being enriched, as shown in 
Figure 64. There were not enough cases in each arm to perform multivariate analysis. 
Figure 63: Kaplan-Meier Survival Plot for Copy Number Alteration at 11q14.1-
22.3 (x-axis time in months; y-axis percentage survival) 
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Figure 64: KEGG Pathway: Apoptosis (key genes highlighted in red from region 11q14.1-22.3) 
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4.3.2.3 Copy Number Alterations Associated with Perineural Invasion 
Different CNA profiles were identified between cases with and without perineural 
invasion, as shown in Figure 65.  In these summary frequency plots all alterations 
shown are significant (unlike the individual case plot shown earlier where cases had 
to reach 0.5 probability to be significant), and each plot is a summary of all significant 
alterations, with regions of gain in green, and region of loss in red.  One region was 
specific for perineural invasion: cases with perineural invasion demonstrated a higher 
proportion of a loss at 1q31.2-32.1, a region encompassing 14 clones.  Loss at this 
region was identified in 66% cases with perineural invasion, but in only 23% cases 
without perineural invasion (p 0.0184, FDR 0.0478). This region included 25 genes, 
and 4 miRNAs (Table 26).   
 
Table 26: Genes and miRNAs in region 1q31.2-32.1 
Gene Symbol Description Gene Symbol Description 
ERVMER61-1 Endogenous retrovirus group MER61, member 1 CFHR2 Complement factor H-related 2 
FAM5C Family with sequence similarity 5, member C CFHR4 Complement factor H-related 4 
RGS18 Regulator of G-protein signaling 18 CFHR5 Complement factor H-related 5 
RGS21 Regulator of G-protein signaling 21 F13B Coagulation factor XIII, B polypeptide 
RGS1 Regulator of G-protein signaling 1 ZBTB41 Zinc finger and BTB domain containing 41 
RGS13 Regulator of G-protein signaling 13 DENND1B DENN/MADD domain containing 1B 
RGS2 Regulator of G-protein signaling 2, 24kDa LHX9 LIM homeobox 9 
UCHL5 Ubiquitin carboxyl-terminal hydrolase L5 NEK7 
NIMA (never in mitosis gene a)-
related kinase 7 
TROVE2 TROVE domain family, member 2 ATP6V1G3 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G3 
GLRX2 Glutaredoxin 2 PTPRC Protein tyrosine phosphatase, receptor type, C 
B3GALT2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 MIR1278 microRNA 1278 
KCNT2 K+channel, subfamily T, member 2 MIR181B1 microRNA 181b-1 
CFH Complement factor H MIR181A1 microRNA 181a-1 
CFHR3 Complement factor H-related 3 MIR4426 microRNA 4426 
CFHR1 Complement factor H-related 1   
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Figure 65: Summary Frequency Plots of Copy Number Alterations With and Without Perineural Invasion 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red. In this summary plot only 
significant copy number alterations are represented. 
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Gene Ontology (GO) term analysis of the genes in the region 1q31.2-32.1 revealed 
gene enrichment for ‘negative regulation of signal transduction’ and ‘cell 
communication’ (PTPRC, RGS1, RGS13, RGS18, RGS2, and RGS21) (p = 0.000023 
and 0.000041 respectively).  MicroRNAs miR181a1 and miR181b1 were also within 
the altered region, and have been linked to several other malignancies.   
 
4.3.2.4 Copy Number Alterations Associated with Lymph Node Status 
For lymph node status there were two significantly different regions of copy number 
loss between lymph node negative (N0) and lymph node positive (N1) cases (Table 
27).  The region at 6q contained 4 genes, listed in Table 28, however the region at 21q 
contained no functional genes.  A higher proportion of N0 cases exhibit a loss of the 
region 6q21.3 (6 cases, compared to 1).   
 
Table 27: Significantly altered regions comparing lymph node positive and 
negative cases 
 
Chromosome 
Location 
Number of 
genes 
No. BAC 
clones 
p-
value FDR N0 Loss N1 Loss Difference 
6q21.3 4  2 0.0418 0.1049 6/21 (29%) 1/27 (4%) 25% 
21q21.1-21.3 0 19 0.0192 0.0852 7/21 (33%) 1/27 (4%) 30% 
 
Table 28: Genes in region 6q21.3 
Gene symbol Description 
TIAM2 T-cell lymphoma invasion and metastasis 2  
TFB1M Transcription factor B1, mitochondrial  
CLDN20 Claudin 20  
NOX3 NADPH oxidase 3  
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Figure 66: Summary Frequency Plots of Copy Number Alterations With and Without Lymph Node Involvement (N0 = lymph node 
negative, N1 = lymph node positive) 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red. In this summary plot only 
significant copy number alterations are represented. 
Chapter IV: Array Comparative Genomic Hybridisation 
 
 
4-235 
4.3.2.5 Copy Number Alterations Associated with Male and Female Sex 
There were 15 regions which were significantly differentially altered between males 
and females, as listed in Table 29.  The two most statistically significant regions were 
1q42.13-42.2 (p 0.002, FDR 0.033), and 12p13.33-13.1 (p 0.002 FDR 0.033).  Both 
regions were more frequently gained in females.  The region 1q42.13-42.2 showed 
GO Term gene enrichment for ‘cell surface receptor linked signal transduction’ (59 
genes), and ‘G-protein coupled receptor protein signaling pathways’ (50 genes).   
 
Table 29: Significantly Altered Regions Comparing Male and Female Sex 
Chromosome 
Location Number of genes 
Number 
of BAC 
clones 
p-value FDR Female Gain 
Male 
Gain Difference 
1p36.33-34.1 517 genes; 12 miRNAs 44 0.019 0.084 
27/29 
(93%) 
27/40 
(68%) 26% 
1p13.3-12 98 genes; 3 miRNAs 14 0.038 0.112 
16/29 
(55%) 
11/40 
(28%) 28% 
1q21.1 4 genes 2 0.039 0.112 19/29 (66%) 
15/40 
(38%) 28% 
1q21.1 1 gene 8 0.047 0.112 24/29 (83%) 
17/40 
(58%) 25% 
1q42.13-42.2 218 genes; 6 miRNAs 40 0.002 0.033 
16/29 
(55%) 
7/40 
(18%) 38% 
6p25.3-22.1 461 genes; 5 miRNAs 51 0.014 0.074 
13/29 
(45%) 
6/40 
(15%) 30% 
7q11.21-
11.22 13 genes 9 0.048 0.112 
14/29 
(48%) 
9/40 
(23%) 26% 
7q11.23 37 genes; 1 miRNA 4 0.028 0.108 
24/29 
(83%) 
22/40 
(55%) 28% 
12p13.33-
13.1 
165 genes; 2 
miRNAs 16 0.002 0.033 
17/29 
(59%) 
8/40 
(20%) 39% 
12q24.11-
24.22 
67 genes; 2 
miRNAs 12 0.013 0.074 
26/29 
(90%) 
24/40 
(60%) 30% 
12q24.23-
24.33 96 genes 18 0.012 0.074 
26/29 
(90%) 
24/40 
(60%) 30% 
16p13.3 18 genes 2 0.033 0.112 27/29 (93%) 
28/40 
(70%) 23% 
16p13.3-12.1 233 genes; 13 miRNAs 29 0.049 0.112 
24/29 
(83%) 
23/40 
(58%) 25% 
16p11.2 53 genes; 1 miRNAs 3 0.036 0.112 
25/29 
(86%) 
24/40 
(60%) 26% 
21q22.11-
22.3 
56 genes; 1 
miRNAs 10 0.008 0.074 
20/29 
(69%) 
13/40 
(33%) 36% 
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Figure 67: Summary Frequency Plots Copy Number Alterations for Male and Female Sex  
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red. In this summary plot only 
significant copy number alterations are represented. 
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4.3.2.6 Copy Number Alterations Associated with Anatomical Subtype 
There were no significant copy number alterations identified between ICC and PHCC.  
However, ECC exhibited a significantly different alteration profile to ICC and PHCC, 
with 12 regions of copy number gain expressed differentially, as listed in Table 30.  
The most statistically significantly altered region was copy number gain at 14q32.11-
32.33 (p 0.0004, FDR 0.008), which was more frequent in ECC.  This region contains 
the genes TCL1A and TCL1B, which are recognised oncogene in T-cell lymphocytic 
leukaemia (Laine et al. 2000, Pekarsky, Hallas and Croce 2001). 
 
Table 30: Significantly Altered Regions Comparing ECC to ICC and PHCC 
Chromosome 
Location 
Number of 
genes 
Number 
of BAC 
clones 
p-value FDR ICC/PHCC Gain ECC Gain Difference 
1q21.1-21.3 181 genes; 2 miRNAs 8 0.035 0.124 
22/39 
(56%) 
25/30 
(83%) 27% 
2p25.3 5 genes 4 0.021 0.098 6/39 (15%) 13/30 (43%) 28% 
3p23.2-14.3 214 genes; 10 miRNAs 20 0.009 0.064 
11/39 
(28%) 
19/30 
(63%) 35% 
6q25.3-27 55 genes; 1 miRNAs 15 0.010 0.064 3/39 (8%) 
11/30 
(37%) 29% 
8p23.3 1 gene 4 0.039 0.124 4/39 (10%) 10/30 (33%) 23% 
9q21.1-22.33 68 genes; 8 miRNAs 20 0.009 0.064 4/39 (10%) 
12/30 
(40%) 30% 
11p15.5 63 genes; 3 miRNAs 6 0.040 0.124 5/39 (13%) 
11/30 
(37%) 24% 
12q24.11-
24.23 
68 genes; 2 
miRNAs 12 0.036 0.124 
24/39 
(62%) 
26/30 
(87%) 25% 
13q34 20 genes 4 0.047 0.154 6/39 (15%) 12/30 (40%) 25% 
14q32.11-
32.33 
194 genes; 
53 miRNAs 17 0.0004 0.008 4/39 (10%) 
16/30 
(53%) 43% 
18q23 8 genes 4 0.018 0.085 7/39 (18%) 14/30 (47%) 29% 
20q12-13.11 8 genes 5 0.010 0.064 22/39 (56%) 
26/30 
(87%) 30% 
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Figure 68: Summary Frequency Plots Copy Number Alterations Between ECC (ECC yes) vs PHCC and ICC (ECC no) 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red. In this summary plot only 
significant copy number alterations are represented. 
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4.3.2.7 Copy Number Alterations Associated with Tumour Differentiation 
Tumour differentiation was divided into 5 categories, as listed in Table 31.  Three 
regions showed different frequencies of copy number gain at 1p36.33-34.1, 12q24.11-
24.23, and 12q24.23-24.33 between differentiation categories. 
 
Table 31: Tumour Differentiation Categories 
Differentiation Categories 
Well 
Well-to-Moderate 
Moderate 
Moderate-to-Poor 
Poor 
 
Table 32: Significantly Altered Regions Comparing Tumour Differentiation 
Chromosome 
Location 
Number 
of genes 
Number 
of BAC 
clones 
p-
value FDR 
Well 
Gain 
Well-
mod 
Gain 
Mod 
Gain 
Mod-
Poor 
Gain 
Poor 
Gain 
1p36.33-
34.1 
517 
genes; 12 
miRNA 44 0.041 
0.15
4 
4/7 
(57%) 
3/3 
(100%) 
22/25 
(88%) 
1/4 
(25%) 
14/16 
(88%) 
12q24.11-
24.23 
69 genes; 
2 
miRNA 12 0.041 
0.15
4 
3/7 
(43%) 
2/3 
(66%) 
22/25 
(88%) 
1/4 
(25%) 
13/16 
(81%) 
12q24.23-
24.33 97 genes 18 0.041 
0.15
4 
3/7 
(43%) 
2/3 
(66%) 
22/25 
(88%) 
1/4 
(25%) 
14/16 
(88%) 
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Figure 69: Summary Frequency Plots of Copy Number Alterations Associated with Tumour Differentiation Status 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red. In this summary plot only 
significant copy number alterations are represented. 
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4.3.2.8 Copy Number Alterations Associated with Operability 
There were fifty-five operatively managed cases, and 14 medically managed cases 
included in this analysis.  There were 12 regions of differential copy number gain: 11 
regions were more frequently gained in operable cases, and one region was more 
frequently gained in inoperable cases.  Region 8q24.3 was most significantly different 
between groups, with 53% of operable cases having a gain of this region, compared to 
only 7% of inoperable cases.  This small 4Mb region contains 63 genes and 4 
miRNAs.  Interestingly it is a within the region associated with survival (8q24.21-
24.3), however it does not contain the c-myc gene.  GO term analysis revealed 
enrichment of genes for ‘regulation of transcription’ and ‘DNA binding’. 
 
Chromosome 
Location 
Number of 
genes 
Number of 
BAC 
clones 
p-
value FDR 
Inoperable 
Gain 
Operable 
Gain Difference 
2p25.3 5 genes 4 0.014 0.065 0/14 (0%) 19/55 (35%) 35% 
3p25.3-25.1 39 genes; 1 miRNA 8 0.038 0.087 5/14 (36%) 
3/55 
(71%) 35% 
7q36.1-36.3 69 genes; 3 miRNA 16 0.006 0.046 2/14 (14%) 
32/55 
(58%) 44% 
8q24.3 56 genes; 3 miRNA 4 0.003 0.046 1/14 (7%) 
29/55 
(53%) 46% 
9q21.33-
23.33 
69 genes; 8 
miRNA 20 0.035 0.087 0/14 (0%) 
16/55 
(29%) 29% 
9q33.2-33.3 35 genes; 2 miRNA 4 0.025 0.082 9/14 (64%) 
15/55 
(27%) 37% 
11p15.5 63 genes; 3 miRNA 6 0.029 0.082 0/14 (0%) 
16/55 
(29%) 29% 
11q23.1-25 193 genes; 5 miRNA 30 0.006 0.046 3/14 (21%) 
37/55 
(67%) 46% 
13q43 20 genes 4 0.016 0.070 0/14 (0%) 18/55 (33%) 33% 
16p11.2-q21 86 genes; 1 miRNA 18 0.046 0.099 2/14 (14%) 
26/55 
(47%) 33% 
21q22.11-
22.3 
56 genes; 1 
miRNA 10 0.011 0.063 2/14 (14%) 
31/55 
(56%) 42% 
21q22.3 64 genes 4 0.029 0.082 4/14 (29%) 36/55 (65%) 37% 
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Figure 70: Summary Frequency Plots of Copy Number Alterations of Operable and Inoperable Cases 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in green; copy number loss in red. In this summary plot only 
significant copy number alterations are represented. 
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4.3.2.9 Copy Number Alterations Associated with Known Molecular Targets 
Candidate genes were identified from the Ensembl database 
(http://www.ensembl.org) and a literature search of known amplified oncogenes in 
human cancers with established and promising agents for molecular targeting 
(Santarius et al. 2010).  Altered regions were then assessed for the presence and 
frequency of alteration associated with the genes of interest.  Several genes of interest 
were identified within the altered regions (Table 33).  The BAC clones covering the 
genes ERBB2, MEK2, PDGFB, MTOR and RAF1 were gained in over 50% cases. 
Regions covering the genes PDGFA, VEGFR 3, EGFR and MEK1 were also gained, 
but at a lower frequency.  Gains of these key regions did not correlated with survival, 
however it should be noted that none of the cases were treated with targeted agents. 
 
Table 33: Gene Targets Indentified Within Altered Regions 
Target Chromosome Location Frequency of Gain Frequency of 
Amplification 
ERBB2 (NEU, HER-2, 
CD340) 
17q11.2-q12 92.9% 2.9% 
MEK2 (MAP2K2) 19p13.3 81.4% 7.1% 
PDGFB (SSV) 22q13.1 91.4% 5.7% 
MTOR (RAFT1, 
RAPT1, FLJ44809) 
1p36.22 78.6% 0% 
RAF1 (c-Raf) 3p25.1 64.3% 0% 
PDGFA (PDGF1) 7p22.3 38.6% 4.3% 
VEGFR 3 (FLT4, PCL) 5q34-q35 35.7% 2.9% 
EGFR (ERBB1) 7p12 7.1% 0% 
MEK1 (MAP2K1, 
MAPKK1) 
15q22.1-q22.33 7.1% 0% 
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4.3.2.9.1 ErbB-2  
The most frequent gain with an associated gene of interest was the gain of 17q11.2-
q12, and within this region is the ErbB-2 gene.  There was a copy number gain in 68 
cases, of which 4 showed amplification on CGH, 1 case was normal, and 2 cases 
revealed a deletion.   
 
To investigate if this DNA gain correlated with an increase in protein expression of 
ErbB-2, immunohistochemistry was performed for ErbB-2 protein over-expression.  
A random selection of 21 cases was included in this analysis. The ToGA Trial criteria 
for ErbB-2 scoring in gastric adenocarcinoma as shown in Table 12 was used 
(detailed in the Methods Chapter II) (Ruschoff et al. 2010).  All cases were scored by 
GS (Consultant Histopathologist) and SM.   
 
Table 34: IHC scoring of ErbB-2 over expression (adapted from (Ruschoff et al. 
2010)) 
 
Staining 
Intensity 
Score 
Staining Pattern ErbB2 Over 
expression 
Status 
0 No reactivity or membranous reactivity in < 10% of tumour cells Negative 
1+ Faint/ barely visible membranous reactivity in ≥ 10% of tumour 
cells; cells are reactive only in part of their membrane 
Negative 
2+ Weak to moderate complete, basolateral, or lateral membranous reactivity in ≥10% of tumour cells Equivocal 
3+ Strong complete, basolateral or lateral membranous reactivity in ≥ 
10% of tumour cells 
Positive 
  
 
The H&E and ErbB-2 stained sections revealed the CC samples to be very 
heterogeneous as previously described.  In some samples there was a prolific stromal 
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reaction, with islands of tumour cells (see Figure 36) with varying degrees of ErbB-2 
staining, from negative through to strong to levels of staining (Figure 70).  In total 21 
cases were assessed, and the results are shown in Table 35. 
 
Table 35: ErbB-2 IHC 
Staining Intensity Score Number of Cases 
0 6 
1+ 4 
2+ 9 
3+ 2 
 
 
Nine cases were selected for analysis of ErbB-2 amplification using the Ventana 
BDISH (Brightfield Dual-Colour In Situ Hybridisation), using the gastric cancer 
criteria. The BDISH ratio should be <2.0 and is positive for amplification when > 2.2.  
CEP is Chromosome Enumeration Probe, used as a standard to assess for polysomy.  
Of the 4 cases that revealed amplification by CGH, 2 underwent IHC, and one 
underwent in situ hybridization.  One case was 1+, and one 3+ for ErbB-2 protein, 
and the 3+ case underwent in situ hybridization and revealed a high level 
amplification (>50 copies). 
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Figure 71: ErbB-2 Immunohistochemistry. 
ErbB2 staining is represented by the brown stain and staining intensity classification 0 to 3+ as 
described in text  
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Table 36: ErbB-2 Paired IHC and in situ Hydridisation Results 
Sample ErbB-2 IHC BDISH Ratio CEP 17 Conclusion 
A 2+ (focal) 1.15 1.35 No amplification 
B 2+ 1.24 2.6 Ch 17 polysomy 
C 1+, 2+, 3+ (increased 
expression on in situ 
epithelium) 
4.5 in situ 
1.6 invasive 
1.17 Focal amplification, mainly 
on in situ disease, not present 
in invasive component 
D 2+ (heterogenous) 2.7 1.3 Low-level amplification 
E 3+ >50 1.2 High-level amplification 
F 0 1.1 1.26 No amplification 
G 1+/0 0.95 1.3 No amplification 
H 0/1+ 1.1 1.18 No amplification 
I 2+ (focal) 1.35 1.25 No amplification 
 
 
4.3.2.9.2 EGFR Protein Expression 
A copy number gain in the region 7p12 was gained with a low frequency of 7.1% 
cases.  The EGFR gene is located within this region.   To investigate if this DNA gain 
correlated with an increase in gene function we performed immunohistochemistry 
was for EGFR protein over-expression.  
 
Sixteen cases were selected for analysis, a combination of cases with and without the 
altered region of interest. Three cases had strong (3+) staining, 9 cases had moderate 
(2+) staining, and 3 cases had weak staining (1+), and 1 case was negative for EGFR 
staining. 
 
Chapter IV: Array Comparative Genomic Hybridisation 
 
 
4-248 
4.4 180K Oligonucleotide array-CGH Results 
4.4.1 Clinical Data for Thai Study Cohort 
There were 24 ICC cases included in the study cohort.  There were 16 men and 8 
women, giving a sex ratio of 2-to-1.  The mean age at presentation was 59 years, with 
a range 39-76 years.   All cases were well differentiated, mass-forming tumours. 
Patients with survival less than 4 weeks were excluded from the study by our 
collaborator RS to reduce bias from post-operative complications.  The median 
overall survival was 4.5 months, with a range of 1.2 to 46.9 months, as shown in 
Figure 72.   
 
Figure 72: Kaplan-Meier Survival Plot for Thai Cases in 180K Oligonucleotide 
array-CGH Study 
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4.4.2 Copy Number Alterations for Thai Study Cohort 
All chromosomes exhibited copy number alterations, and overall there were 1,578 
altered chromosomal regions, a significantly higher number of regions than seen with 
the 1Mb BAC-array due to the increased sensitivity of the 180K oligonucleotide 
array-CGH, enabling altered regions to be characterised in more detail.  The 
classification of calls used in the assessment of copy number alterations was as in the 
1Mb BAC array-CGH study.  A frequency plot of all significant copy number 
alterations for all Thai cases is shown in Figure 73.  The Thai study cohort was a 
selected group, with the same pathological phenotypes, therefore assessment for 
pathological phenotypic alterations was not performed.  However, survival data was 
available for all cases, and analysis for regions with relation to survival was 
performed. 
 
 
4.4.2.1 Copy Number Alterations Associated with Survival 
There were 27 altered regions associated with copy number gain and survival, and 47 
altered regions associated with copy number loss and survival.  Altered regions were 
classed as statistically significant if the p-value was less than or equal to 0.05, and the 
false discovery rate was less than or equal to 20%.  However, the altered regions had 
a low number of cases in the study arm.  Regions of copy number gain with three or 
more cases in the study arm were assessed further, and the regions are listed in Table 
37. 
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Figure 73: Summary Plot of Copy Number Alterations for All Cases 
Chromosomes by number along x-axis; percentage probability of alteration along y-axis; copy number gain in black; copy number loss in grey. In this summary plot only 
significant copy number alterations are represented. 
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Table 37: Regions of Copy Number Gain Associated with Survival 
Chromosome 
Location 
Number of Cases 
with CN Gain 
Number of Cases 
with No CN Gain 
p-value FDR 
7p11.2 5 19 0.0018 12.2% 
18q11.2 3 21 0.0005 4.7% 
19q13.12 3 21 0.0025 14.4% 
19q13.12 3 21 0.0025 14.4% 
19q13.2 3 21 0.0025 14.4% 
19q13.2 3 21 0.0025 14.4% 
 
Five cases demonstrated a copy number gain of region 7p11.2, which was protective 
for survival.  Cases with a copy number gain in this region had a median survival of 
29 months, compared to 3 months in the cases without copy number gain in this 
region, as shown in Figure 74.  This 0.5Mb region is located in between the genes 
EGFR and LANCL2, however it does not code any genes, as shown in Figure 75. 
 
Figure 74: Kaplan-Meier Survival Plot for Copy Number Gain of Region 7p11.2 
(x-axis time in days; y-axis percentage survival) 
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Figure 75: 7p11.22 
Location of altered region along chromosome 7 demonstrated by red rectangle, and genes up- and down-stream of region identified in orange in ‘Region in detail’ 
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Copy number gain of the regions 18q11.2, 19q13.12, and 19q13.2 were associated 
with worse survival.  Gain of the region 18q11.2 was associated with a median 
survival of 2 months, compared to 9 months without the gain.  Gain of the region 
19q13.12 and 19q13.2 were associated with a median survival of 1 month, compared 
to 9 months without the gain. GO Term analysis revealed enrichment for genes 
involved in  ‘cell proliferation’ and ‘regulation of transcription’ within these regions.  
Within these altered regions were the following genes with biological significance: 
CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1 (biliary 
glycoprotein)), CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, 
CEACAM8, and CEACAM21. 
 
For regions of copy number loss there were very low numbers in the study arm 
cohort, with only one or two cases.  Regions of copy number loss with two cases in 
the study arm were assessed further, and the regions are listed in Table 38. 
Table 38: Regions of Copy Number Loss Associated with Survival 
Chromosome 
Location 
Number of Cases 
with Loss 
Number of Cases 
with No Loss 
p-value FDR 
10q26.3 2 22 0.0006 2.1% 
10q26.3 2 22 0.0006 2.1% 
10q26.3 2 22 0.0006 2.1% 
11p15.5 2 22 0.0006 2.1% 
11p15.5 2 22 0.0006 2.1% 
13q34 2 22 0.0006 2.1% 
16q24.2 2 22 0.0006 2.1% 
22q11.1-11.21 2 22 0.0006 2.1% 
22q11.21 2 22 0.0006 2.1% 
22q11.21 2 22 0.0006 2.1% 
22q11.21 2 22 0.0006 2.1% 
22q13.32 2 22 0.0006 2.1% 
22q13.32 2 22 0.0006 2.1% 
22q13.31 2 22 0.0023 7.7% 
22q13.31 2 22 0.0023 7.7% 
22q13.32 2 22 0.0023 7.7% 
Chapter IV: Array Comparative Genomic Hybridisation 
 
 
4-254 
 
The Kaplan-Meier survival plot for cases with copy number loss (with 2 cases in 
study arm) is shown in Figure 76.  Copy number loss of the regions listed in Table 38 
was associated with a worse prognosis, with a median survival of 2 months associated 
with copy number loss, compared to 7 months without copy number loss.  The region 
11p15.5 contains an gene of interest: the gene DUSP8 which plays a role in 
inactivating the MAPK- signaling pathway (Keyse 2008).  The region 22q11.1-11.21 
contains a gene of interest, the anti-apoptotic gene Bcl2L13, also known as Bcl-
Rambo. 
 
Figure 76: Kaplan-Meier Survival Plot for Region of Loss Associated with Poor 
Survival (same profile for regions on Chromosome 10, 11, 13, 16, and 22) (x-axis 
time in days; y-axis percentage survival) 
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4.4.2.2 Copy Number Alterations Associated with Known Molecular Targets 
As with the 1Mb BAC array-CGH UK study, altered regions were interrogated for the 
presence of copy number gain for regions encoding genes with known molecular 
targeted agents in clinical practice.  There were 4 genes with molecular targeting 
agents within chromosomal copy number gain in the Thai study, as listed in Table 39. 
 
Table 39: Gene Targets Indentified Within Altered Regions 
Target Chromosome Location Frequency of Gain 
MEK2 (MAP2K2) 19p13.3 29.2% 
PDGFB (SSV) 22q13.1 4.2% 
MTOR (RAFT1, RAPT1, FLJ44809) 1p36.22 16.7% 
VEGFR 3 (FLT4, PCL) 5q34-q35 4.2% 
 
There were no copy number gains in the regions encoding ErbB2, Raf1, PDGFB, 
EGFR, or MEK1. 
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4.5 Comparing UK and Thai Copy Number Alterations 
Copy number alteration profiles were compared for UK and Thai cohorts.  Different 
platforms were used for each study: 1Mb BAC array-CGH for the UK study; 180K 
oligonucleotide array-CGH for the Thai study.  This was due to a significant 
reduction in the price of the 180K oligonucleotide array during the study period, 
improving its affordability for the study.   
 
In the UK cohort 79 regions of copy number gain, 39 regions of copy number 
amplification, and 56 regions of copy number loss were identified.  In the Thai study 
989 regions of copy number gain, and 938 regions of copy number loss were 
identified.  Summary plots are shown in Figure 51 and Figure 73, and Figure 77 
shows a comparison of the two groups separated by chromosome. 
 
Comparing the copy number profiles for the UK and Thai cohorts there are several 
regions of similarity, for example copy number gain at 2q, and copy number loss at 
4p/q, 9p/q and 13p/9.  However, there are significant differences between the profiles.  
The UK cohort overall exhibits a significantly higher proportion of altered DNA, with 
a significantly higher degree of copy number gain, for examples at 16p/q, 17p/q, 
19pp/q, 20p/qand 22p/q.  
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Figure 77: Comparison of Copy Number Alterations between Thai and UK Studies by Chromosome (Thai on left, UK on right) 
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4.6 Discussion 
This work presents a comprehensive analysis of copy number alterations in 
cholangiocarcinoma in UK and Thai cohorts.  Using array-CGH, a more sensitive 
technique than metaphase-CGH, DNA alterations in this tumour have been identified.  
Previous studies of CNA in CC have been performed using metaphase-CGH (except 
for one array-CGH study that did not publish the altered regions in detail (Miller et al. 
2009)).  In this study we compared Thai and UK DNA copy number alterations, 
comparing a population with a clear recognised aetiological factor, and a population 
with an unclear aetiology. No previous study has been performed assessing CNA in 
CC in a UK population.  Furthermore, and most importantly, this is the first CC study 
using CGH to identify CNAs related to survival. 
 
There were five copy number alterations identified associated with survival in the UK 
cohort, and 64 alterations in the Thai cohort.  However, the alterations identified in 
the Thai cohort were in the majority associated with only one or two cases in the 
study arm, limiting the clinical impact and significance.  The most clinically 
significant alteration was in the UK cohort, copy number gain of 8q24.21-24.3.  This 
alteration was identified in 15 cases associated with a poorer prognosis, compared to 
50 cases without the alteration, and was an independent predictor of survival.  GO 
term analysis identified enrichment for genes associated with ‘regulation of 
transcription’ and ‘DNA binding’, but most interestingly the genes c-myc and PTK2 
were highlighted as genes of interest within this region. 
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c-myc is a recognised oncogene associated with several key-signalling pathways. c-
myc is associated with an increase risk of developing familial breast cancer, and in 
colorectal carcinoma activation of c-myc and K-ras have been identified as key events 
in its carcinogenesis (Wirtenberger et al. 2005, Smith et al. 1995).  Interestingly c-myc 
amplification has been identified in colon adenocarcinoma samples, however low 
level amplification of c-myc was found to be associated with improved survival, as 
opposed to worse survival associated with copy number gain in our study (Augenlicht 
et al. 1997).  In CC cell line experiments c-myc was found to be over-expressed, and 
inhibiting c-myc significantly reduced tumour cell invasion (Li et al. 2011).  In a 
small study Takahashi et al. examined 10 ICC using FISH and found one case of 
amplification of c-myc, however there was no survival analysis performed (Takahashi 
et al. 2007).  Tokumoto et al. examined 24 ICC for c-myc over-expression using IHC 
and found over-expression in 41.7% of cases, and Voravud et al. examined 63 Thai 
and UK ICC and found c-myc to be frequently over-expressed, in 47/63 cases (75%) 
(Voravud et al. 1989, Tokumoto et al. 2005).  Conversely Terada et al. examined 20 
CC using IHC and found no evidence of c-myc over-expression (Terada and 
Nakanuma 1996).  Therefore it can be concluded that c-myc over-expression is 
variable in CC, and in this study c-myc copy number gain was significantly associated 
with a poorer prognosis, and following validation in future studies it may represent a 
useful prognostic marker for CC. 
 
The PTK2 gene, also frequently known as FAK, has been implicated as an oncogene 
in several malignancies, and resides within the region 8q24.21-24.3.  PTK2 is a focal 
adhesion kinase that concentrates in the junctions between growing cells, and is 
implicated in intracellular signal transduction within the extracellular matrix (Andre 
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and Becker-Andre 1993).  Mouse models have been used to demonstrate the key role 
of PTK2 as an ‘angiogenic switch’ for endothelial cell interaction, leading to 
increased vascular permeability. PTK2 inhibition prevented VEGF-mediated 
signalling and reduced vascular permeability (Chen et al. 2012c).  Cai et al. examined 
PTK2 over-expression in oesophageal carcinoma using quantitative-PCR, and found 
mRNA over-expression in 80.17% of 121 samples, and levels correlated with depth of 
invasion and lymph node metastasis (Cai et al. 2012).  Also, higher PTK2 mRNA 
expression in non-small cell lung cancer was associated with poorer survival, in 
combination with decreased nm23-H1 expression (Hsu et al. 2007).  Therefore cases 
with a copy number gain of PTK2 may exhibit poorer survival due to increased 
VEGF-signaling and a more invasive tumour phenotype. 
 
Four other regions were altered with relation to survival in the UK cohort: 8q12.22-
22.2; 6q25.3-27; 11q14.1-22.3; and 8q22.2-24.12.  However, only a small number of 
cases were in the study arm associated with the copy number alteration, so these 
regions have been considered as regions of interest for potential further study, that 
would require validation within a larger data set.  Several genes of interest were 
identified, including: RAD54B; PARK2; IGF2R; and ATM.   
 
The RAD54B gene plays a role in chromosome recombination, and mutations of 
RAD54B have been identified in Non-Hodgkin lymphoma and colon carcinoma 
(Hiramoto et al. 1999).  The PARK2 gene has been identified as a tumour suppressor 
gene in several studies, with deletion in several cancer populations.  Copy number 
loss of PARK2 was identified in 24.4% colon adenocarcinomas, 24.5% glioblastomas 
(Veeriah et al. 2010), and partial deletions or point mutations have been identified in 
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ovarian and lung cancer samples (Cesari et al. 2003).  Loss of heterozygosity of 
IGF2R gene and point mutations have been identified 70% of hepatocellular 
carcinomas in a study of by Souza et al (Souza et al. 1996).  The ATM gene is 
involved in DNA repair, and deletion of ATM is a common alteration in B-cell 
chronic lymphocytic leukaemia, associated with poorer survival and lymph node 
involvement (Schaffner et al. 1999).  
 
Our Thai study identified a large number of alterations related to survival, however 
the majority were related to only one or two cases.  The most clinically significant 
region was copy number gain of 7p11.2, which was protective for survival.  The 5 
cases with the copy number gain had a median survival of 29 months, compared to 3 
months without the copy number gain.  Interestingly this small 0.5Mb region didn’t 
contain any genes, however it was in between EGFR and LANCL2, and copy number 
gain may have an effect on EGFR transcription, which may influence survival.  It has 
been shown that copy number alteration in the region of a gene, though not actually of 
the gene itself can influence gene expression (Henrichsen et al. 2009).  It has been 
found that genes within 50-250Kb from copy number breakpoints have significantly 
higher expression than more distant transcripts.  It has been proposed that these gene 
dosage effects caused by alterations in down stream regions may be caused by 
alteration in cis-acting regulators, or changes in chromatin structure or control in the 
nucleus.  This region was interrogated for motifs and regulatory sequences in our 
study, and was positive for both.  This mechanism of increased gene dosage due to 
copy number change of downstream regulatory elements of genes has not been 
described in CC, and is especially interesting in view of it’s location and likely 
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interaction with EGFR.  Further analysis of this region is necessary, and will form the 
basis of further studies from this thesis. 
 
Genes of interest within the other regions which were gained in the Thai cohort with 
relation to poorer survival included the genes: CEACAM1; CEACAM3; CEACAM4; 
CEACAM5; CEACAM6; CEACAM7; CEACAM7; CEACAM8; and CEACAM 21.  
The CEACAM family of genes are known as CarcinoEmbryonic Antigen-related Cell 
Adhesion Molecules.  The most widely known member of the family is CEA a serum 
tumour marker used in colorectal carcinoma, the expression of which was discussed 
in the introduction.  CEACAM6 over-expression in colorectal carcinoma has been 
identified as an independent predictor of poor survival, when assessed in 243 cases 
(Jantscheff et al. 2003). In pancreatic carcinoma cell line experiments, CEACAM6 
over-expression was found to increase gemcitabine chemoresistance, which was 
reduced with CEACAM6 gene silencing (Duxbury et al. 2004).  This is especially 
interesting, as patients with copy number gain of the region encoding CEACAM6 in 
this study had poorer survival, which may be as a consequence of CEACAM6 over-
expressions contributing to gemcitabine chemoresistance (the main chemotherapeutic 
agent used to treat CC).  CEACAM7 was found to be over-expressed in gastric 
carcinoma, and was associated with CEA over-expression in 345 gastric carcinoma 
cases (Zhou et al. 2011).  These findings highlight the CEACAM family as genes of 
interest for future study. 
 
Two genes were highlighted with potential biological significance in the regions of 
loss in the Thai cohort associated with survival: DUSP8 and BCL-2L13.  The DUSP8 
gene, which unlike other members of the DUSP family has not been extensively 
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studied in malignancy, however it is known that it plays a role in inactivating 
mitogen-activated protein kinase (Martell et al. 1995, Keyse 2008).  Therefore loss of 
DUSP8 may enable increased MAPK-signaling, leading to increased cellular 
proliferation and evasion of apoptosis, explaining the poorer survival of this study 
group.  Copy number loss of the region 22q11.1-11.21 in Thai CC was associated 
with worse survival.  This region contains the gene BCL-2L13, also known as BCL-
Rambo.  This gene has apoptotic function, and when over-expressed in experimental 
studies it independently induced apoptosis (Kataoka et al. 2001), therefore copy 
number loss of this gene may lead to decreased apoptosis, and hence a more 
proliferative tumour, accounting for the worse survival with deletion of this region.  
However, studies of childhood acute lymphocytic leukaemia have found that over-
expression of BCL-2L13 correlated with worse survival, the opposite effect theorised 
from this study, therefore this requires further investigation (Yang et al. 2010, 
Holleman et al. 2006). 
 
 
In addition to copy number alterations associated with prognosis, in the UK cohort 
alterations were identified related to perineural invasion, lymph node status, male and 
female sex, anatomical subtype of tumour, tumour differentiation, and operable vs 
inoperable tumours. 
 
Copy number alteration of only one region was associated with perineural invasion: 
copy number loss at 1q31.2-32.1.  Two miRNAs coded within this region are of 
particular interest for further study: miR181A1 and miR181B1.   In oral squamous 
cell carcinoma miR181A1 has been found to be frequently down regulated, and 
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stimulated over expression of miR181A1 decreased K-ras protein expression levels 
(Shin et al. 2011).  Due to miR181A1’s effect on K-ras, it has been proposed as a 
tumour suppressor in oral SCC.  Down regulated levels of miR181B1 have also been 
associated with malignancy, and in a study of chronic lymphocytic leukaemia (CLL) 
decreased miR181B1 levels were associated with progressive disease (Visone et al. 
2011).  It was also found that miR181B was a target for Mcl-1, and decreased 
miR181B1 levels were inversely associated with increased Mcl-1 and Bcl-2 levels.  In 
a further study of CLL down regulation of both miR181A1 and miR181B1 were 
identified, and were inversely associated with increased Bcl-2 and TCL-1 levels (Zhu 
et al. 2011).  
 
Lymph node negative cases exhibited a higher frequency of copy number loss at 
6q21.3, therefore this region is intact in a higher proportion of lymph node positive 
cases.  Genes of interest in this region included TIAM2, TFB1M, CLDN20 and 
NOX3.  The TIAM2 (T-cell lymphoma Invasion and Metastasis 2) gene is over 
expressed in 86% HCC samples, and also in breast and pancreatic adenocarcinoma 
(Chen et al. 2012a).  Cell line experiments with the HepG2 hepatocellular carcinoma 
cell line demonstrated the role of TIAM2 in promoting proliferation and invasiveness 
by promoting epithelial-to-mesenchymal transition.  TIAM2 expression may be 
maintained in lymph node positive cases, accounting for their increased metastatic 
potential. 
 
As detailed in the Introduction Chapter I it is believed that the intrahepatic and 
extrahepatic biliary tree develop from two different hepatic buds (Roskams and 
Desmet 2008), and thus it is hypothesized that ICC and ECC will exhibit different 
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molecular profiles due to their different embryological origins.  Perihilar CC is often 
categorized with ECC, as the hilum is considered more comparable to the extrahepatic 
biliary tree than the intrahepatic biliary tree.  Surprisingly the molecular profiles of 
ICC and PHCC did not show any significant differences.  However, the profile of 
ECC was different to the ICC and PHCC combined profiles.  There were 12 regions 
of differing copy number alteration between the two groups, and the most statistically 
significant region was 14q32.11-32.33.  This region was gained more frequently in 
ECC, and contained two genes of interest: TCL1A and TCL1B.  The genes TCL1A and 
TCL1B have been found to enhance cell proliferation and survival via AKT activation 
in T-cell lymphocytic leukaemia (Laine et al. 2000, Pekarsky et al. 2001).  Both genes 
are frequently involved in activating inversions or translocations in leukaemia.   
 
 
We have demonstrated that the CNA profiles in a UK and Thai population are 
significantly different.  Thailand harbours this highest worldwide incidence of ICC, 
with an incidence of 96 cases per 100,000 men in northeast Thailand (Khan et al. 
2002b), compared to an incidence of 1.33 per 100,000 men in England and Wales 
(Khan et al. 2002a).  In South East Asia liver flukes are recognised carcinogenic 
stimuli, associated with the high of incidence of CC (Bouvard, Lancet Oncol 2009).  
However, in the UK there is no frequently recognised aetiological factor associated 
with CC, although there are several infrequent recognised risk factors.  The UK cases 
showed significantly a higher proportion of CNA.  This could be related to Thai CC 
having a clear aetiological agent (liver flukes), and UK CC not having a clear 
aetiological agent.  Therefore UK CC likely develops through multiple ‘hits’ from 
different carcinogenic stimuli creating a more complex molecular profile.  This has 
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key implications, as copy number gain of key molecular targets was significantly 
different between the two populations, and with the increased use of targeted therapy 
in treating cancer interpreting data should therefore ideally be performed on an 
individual basis, but at the very least on a population basis with similar aetiological 
factors. 
 
The presence of copy number gain in the regions of nine molecular targets were 
identified at varying frequencies.  Studies to date of CC have shown widely variable 
expression profiles for many molecular targets in CC.  The region encoding ErbB2 at 
17q12 showed copy number gain in 92.7% UK cases of CC, and 0% of Thai cases in 
our study.  Other CGH studies using metaphase-CGH, identified CN gain in the 
region containing ErbB2 in 0-50% cases shown in Figure 77 and Table 40.  The 
figure and table demonstrate how frequently the region containing the listed genes 
demonstrated a copy number gain in each study, potentially representing gene 
amplification.  
 
High levels of concordance (97%) have been shown between ErbB2 gain identified 
by array-CGH and protein over-expression in a previous breast cancer study (Yeh et 
al. 2009).   However, when ErbB-2 protein over-expression was assessed in 21 cases 
in our UK study, and we identified 2 cases had strong (3+) staining, 9 cases had 
moderate (2+) staining, and 4 cases had weak staining (1+), and 6 cases were negative 
for ErbB-2 staining, despite 92.7% cases showing CN gain.  
 
ErbB-2 protein over expression has been variable among other CC studies, and the 
percentage of cases of CC with ErbB-2 over expression are summarised in Figure 78. 
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Figure 78: Frequency of Copy Number Gain of DNA Containing Genes With 
Known Molecular Targets in Other CGH Studies 
 
 
 
Table 40: Frequency of Copy Number Gain of DNA Containing Genes With 
Known Molecular Targets in Other CGH Studies 
  
Present 
study: UK 
Present 
Study: 
Thai 
Homayounfar 
et al.  
Rijken et 
al. 
Koo et 
al. 
Lee et 
al.  
Uhm et 
al.  
Shiraishi et 
al. 
(Cancer) 
ERRB2 92.9% 0% 14% 50% 0% 45% 21% 36% 
MEK2 81.4% 29.2% 5% 0% 0% 15% 0% 4% 
PDGFB 91.4% 4.2% 5% 25% 0% 9% 5% 26% 
MTOR 78.6% 16.7% 23% 0% 0% 0% 0% 12% 
VEGFR 
3 
35.7% 4.2% 23% 0% 0% 3% 11% 0% 
PDGFA 38.6% 0% 27% 0% 27% 15% 16% 36% 
RAF1 64.3% 0% 0% 0% 0% 0% 5% 8% 
EGFR 7.1% 0% 32% 0% 27% 15% 16% 32% 
MEK1 7.1% 0% 5% 25% 0% 30% 16% 14% 
 
 
Case numbers were variable from each study, from 6 to 236 cases.  Also, different 
criteria were used for defining positive cases, with some being very stringent, and 
some more lax criteria.  For an overview, if you combine all the cases from each 
study, there are 1,291 cases of CC, of which 429 showed ErbB-2 over-expression, i.e. 
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33.2% of all cases (Shafizadeh et al. 2010, Chiba et al. 2007, Altimari et al. 2003, 
Ukita, Kato and Terada 2002, Harder et al. 2009, Yoshikawa et al. 2008, Voravud et 
al. 1989, Choi, Kim and Choi 2009, Kim et al. 2007, Collier et al. 1992, Brunt and 
Swanson 1992, Chow et al. 1995, Ashida et al. 1998, Ito et al. 2001, Aishima et al. 
2002, Endo et al. 2002, Nakazawa et al. 2005, Settakorn et al. 2005). 
 
 
Figure 79: ErbB-2 protein expression in cholangiocarcinoma (using 
immunohistochemistry) 
 
 
A frequent mechanism for ErbB-2 protein over-expression in malignancy is by gene 
amplification (several DNA copies of the gene, leading to increased protein product).  
In our study 9 cases were assess using in situ hybridisation for ErbB-2 amplification, 
and 3/9 cases revealed amplification to varying degrees: high-level amplification 
associated with 3+ protein expression, focal amplification associated with 
heterogeneous expression, and low-level amplification associated with 2+ expression.  
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Amplification was assessed in six of the IHC studies listed above: of the IHC positive 
cases, gene amplification ranged from 2% to 100% of cases (Altimari et al. 2003, 
Ukita et al. 2002, Harder et al. 2009, Kim et al. 2007, Nakazawa et al. 
2005).Pignochino; Kawamoto; Kim; Nakazawa; Altimari; Utika).  However, in one 
study 4 cases harboured gene amplification, but were classified as negative for protein 
over-expression (Ukita 2002), suggesting a silencing of gene expression. 
 
A human CC cell line (HUCCT1) and 2 rat cell lines (C611B and BDEneu) were used 
to test targeted therapy in CC (Zhang et al. 2010).  The cell lines were treated with 
AG879 (ErbB2 inhibitor), AG1517 (EGFR inhibitor), and lapatinib (EGFR/ErbB2 
tyrosine kinase inhibitor approved for metastatic breast carcinoma).  The HUCCT1 
cell line showed over-expression of ErbB2, but not through amplification.  ErbB1 and 
ErbB2 were over-expressed in all cell line to varying degrees, and the level of growth 
inhibition of each cell line correlated with the degree of tyrosine kinase receptor 
expression.  Lapatinib, the mixed EGFR/ErbB2 inhibitor, was the most potent of the 3 
inhibitors tested on growth inhibition.  However, when the cell lines were inoculated 
into rats, and enabled to grow for 8 days, lapatinib surprisingly had no effect on cell 
growth.  In these later stage tumours there was reduced expression of ErbB2 and an 
increase in desmoplastic stroma.  It has been suggested that ErbB2 over-expression is 
an early event in CC, and tumours may become lapatinib resistant due to stroma 
‘driving’ the tumour. 
 
Array-CGH identified copy number gain in the region of ErbB-2 in 92.7% cases. 
However, in situ hybridisation (ISH) for ErbB-2 identified gene amplification in only 
one third of cases assessed (3/9).  ErbB-2 protein staining was found in 15/21 cases, 
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however strong staining (3+) classed as positive by the gastric criteria was only found 
in 2/9 cases, with 9/21 equivocal cases (2+).  The IHC and ISH data have shown CC 
to exhibit heterogeneous staining/amplification for ErbB2 across and within tumour 
samples, with focal areas showing strong staining with amplification, and other areas 
within the same tissue showing weaker staining and no amplification. In five cases 
only (the non amplified anywhere by ISH) the results are discordant. However given 
that in the positive cases the ISH signal was patchy, one possible explanation is a 
heterogeneous distribution of amplification. The material used for array-CGH and 
IHC/ISH was from a different part of the tissue block compared with the sections 
used for ISH. Array-CGH does not identify if the signal is heterogeneous lay 
distributed (i.e. some amplified and some non amplified nor whether there are areas 
that are more highly amplified than others).  Heterogeneous distribution is therefore 
the only possible explanation. This tumour heterogeneity explains in part why CC is 
such a treatment resistant tumour, as different tumour cell populations exhibit 
different molecular changes/growth characteristics within the same tumour, which 
will be affected by medical treatment to different degrees.   
 
Muenphon et al investigated levels of amplification of 21q22.3 in Thai ICC 
(Muenphon et al. 2006).  They identified copy number gain in 7.5-32.5% of allelic 
markers at 21q22.3, with amplification copy number ranging from 1.35-4.24.  They 
found that if patients with ICC had amplification of the gene TFF within the region 
21q22.3 they had a poorer prognosis.  In our study we identified copy number gain at 
21q22.3 in 54.3% cases, amplification in 4.3%, and copy number loss in 1.4%, 
however copy number gain was not associated with survival in our cohort. 
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To date there have been eleven reports of CGH investigating CC, and three reports 
using cholangiocarcinoma cell lines (Rijken et al. 1999, Shiraishi et al. 1999, 
Shiraishi et al. 2001b, Shiraishi et al. 2001a, Koo et al. 2001, Lee et al. 2004, Uhm et 
al. 2005, Homayounfar et al. , Kim et al. 2001, Ma et al. 2007, Ghosh et al. 2005, 
Wong et al. 2002).  
 
Rijken et al. (Rijken et al. 1999) examined eight cases of ECC from USA using 
metaphase-CGH, and also performed karyotype analysis of 7 of the tumours.  Copy 
number (CN) gain was more common than copy number loss (2.2:1), with an average 
of 10.6 CN alterations per tumour.   Chromosome arm 8q was most frequently gained, 
in six cases, and in 4 cases the chromosome whole arm (both p and q) was gained.  
This frequent gain of 8q was also found to be significantly altered with relation to 
prognosis in our study. 
 
Shiraishi et al. (Shiraishi et al. 1999, Shiraishi et al. 2001a, Shiraishi et al. 2001b) 
published three studies of metaphase-CGH in biliary tract cancer, with each 
subsequent study containing cases from the previous report; therefore the most recent 
study will be discussed (Shiraishi et al. 2001a).  Fifty Japanese cases of biliary tract 
cancer were included in the study: 8 ICC; 9 PHCC; 16 ECC; and 17 GBCC.  
Metaphase CGH was used.   Copy number loss at chromosome 9p, confirmed by 
FISH, was frequent, especially in early stage tumours.   Early stage tumours also 
frequently exhibited loss of 5q, 8p, 18q and gain of 1q, 8q, and 20q.  Gains at 7p12-
p14, 7p21-pter, and 7q31 were more frequent in tumours with distant metastases.  The 
gain of 8q and 7p12-p14 are interesting, as the 8q gain was identified in our UK study 
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as related to survival, and CN gain of 7p12-14 was identified in our Thai and UK 
studies.  In our Thai study the CN gain in at 7p12 was related to survival. 
 
Koo et al. compared 11 ICC with 24 HCC from Korea using metaphase-CGH (Koo et 
al. 2001).  Gains frequently found in ICC included 5p, 7p, 8q, 13q, 20q, and losses 
(similar in both ICC and HCC) at 16q, 17p and 18q.  The gain at 20q in ICC, and 1q 
in HCC was the most striking difference in the study, and characteristic of each 
tumour (p < 0.05). 
 
Wong et al. studied 13 cases CC (10 ICC, 3 PHCC) in a study from Hong Kong using 
metaphase-CGH (Wong et al. 2002).  They identified frequent CN gains at 1q, 8q, 3q, 
15q, 17q, 5, 11q, and 20.  Frequency CN losses were identified at 4q, 6q, 3p, 9p, 17p, 
18q, 8p and 14q.  Region 3p13-p21 was identified as a minimal region with frequent 
deletion (40% cases): this region contains the gene RASSF1A, and a high incidence of 
RASSF1A promoter methylation was identified, correlating with a decrease in 
RASSF1A expression.  The group proposed RASSF1A was key tumour suppressor 
gene in CC. 
 
Lee et al. performed metaphase-CGH of 33 Korean ICC samples (Lee et al. 2004). 
There was an average of 9 CN alterations observed per tumour, with all chromosomes 
altered in the study.  Frequent CN gains were observed at 20q, 17, and 11q11-q13.  
Gains at 11q11-q13, 17 and 18p were more common in moderately to poorly 
differentiate tumours, and gain of 3q25-qter was more frequent in moderately 
differentiated tumours. 
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Uhm et al. studied 19 ICC cases from Korea (Uhm et al. 2005). Copy number gains at 
8q22~qter and 5p14~pter were frequent.  Gains at 5p, 15q24-qter, 18q and 19q were 
more frequently detected in poorly differentiated tumours compared to moderately 
differentiated tumours. 
 
Homayounfar et al. studied 78 German primary liver cancers, including: 22 ICC; 49 
HCC; and 7 mixed HCC/ICC, with metaphase-CGH (Homayounfar et al. 2009).  ICC 
was found to have more CN alterations than HCC and mixed HCC/ICC tumours.  
Combined losses at 6q and 3p were highly characteristic of ICC.  In this German 
study, CN losses were more frequent than CN gains, unlike previous studies. Frequent 
losses were observed at 6q, 3p, 9p, 14q, and 13q, and CN gains at 1q, 7q, 7p, and 8q. 
 
Miller et al. performed the most recent study of CC CN alteration, being the first 
study to use array-CGH, rather than metaphase-CGH (Miller et al. 2009).  They also 
reported gene expression data using the Affymetrix platform HG-U133A GeneChip.  
Thirty-four biliary tract cancers from USA were included in the study: 13 ICC, 12 
ECC, and 9 GBCC.  Unfortunately the CN alterations were not reported in detail, as 
the report focused more on gene expression.  Copy number loss at 1p was found in 
75% ICC, and 50% ECC.  Frequently gained regions included: 1q; 3q; 5p; 7p; 7q; 8q; 
and 20q.  Frequent regions of loss included: 3p; 6q; 8p; 9p; and 14q.  
 
It is interesting that all of the previous studies have identified copy number gain of 8q 
in CC.  However no previous study has identified it as a region of importance, as no 
survival analysis has been performed.  Our study was the first to identify prognostic 
copy number alterations using array-CGH in CC, and have thus identified copy 
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number gain at 8q at an important alteration, and highlighted c-myc with potential 
biological significance.  
 
In summary, this study has produced a comprehensive assessment of copy number 
alterations in CC in a UK population.  We have identified the copy number gain of 
regions containing several key molecular targets, which if targeted may improve 
response to medical management in CC.  We have identified a copy number alteration 
that significantly correlates with survival, containing the c-myc oncogene.  Significant 
regions of copy number alteration have been identified for different phenotypes in the 
study cohort, highlighting genes of particular interest for further study.  Region 
7p11.2 is of particular interest for further study in the Thai cohort, due to the gene 
dosing effects related to survival of this small region downstream of EFGR. 
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CHAPTER V 
5 miRNA Alterations 
 
 
 
 
 
 
 
 
 
 
 
 
 
The material presented in this chapter has been published as two abstracts with two poster 
presentations at an international conference: 
 
A four microRNA signature correlates with improved survival in cholangiocarcinoma. 
McKay SC, Unger K, Pericleous S, Stamp G, Chin Aleong J, Hutchins RR, Thomas G, Spalding DRC. 
The 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011, 
Hepatology.  
 
MicroRNA profiling reveals key microRNAs and molecular pathways involved in biliary tract cancer. 
McKay SC, Unger K, Pericleous S, Stamp G, Chin Aleong J, Spalding DRC, Hutchins RR, Thomas G. 
The 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011, 
Hepatology.  
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5.1 Introduction 
In 1993 Lee et al identified a small non-coding RNA in Caenorhabditis elgans, with 
complementary sequence to the Lin-14 gene (Lee, Feinbaum and Ambros 1993).  The 
Lin-14 protein is key to larval development.  They identified that this small non-
coding RNA, later termed microRNA (miRNA), caused post-transcriptional 
modulation of the Lin-14 gene by RNA-RNA interaction, thus influencing larval 
development. 
 
MicroRNAs are small non-coding RNAs approximately 22 nucleotides in length.  
They are regulators of gene expression.  MicroRNAs play a key role in the 
suppression of gene expression depending on the degree of complementarity of their 
nucleotide sequence to the 3’-untranslated region (3’-UTR) of mRNA.  MicroRNA is 
initially transcribed as a large single-stranded primary-miRNA (pri-miRNA) by RNA 
polymerase II.  Pri-miRNA is processed into pre-miRNA: a folded stem-loop 
structure of approximately 70 nucleotides.  Processing of pri-miRNA is performed by 
DROSHA an RNA polymerase III, and DGCR8 an RNA binding protein.  DGCR8 
recognises and binds to pri-miRNA, and DROSHA complexes with DGCR8 and 
cleaves pri-miRNA, resulting in pre-miRNA (Lee et al. 2003).  Pre-miRNA is 
exported out of the nucleus by the transporter Exportin-5 (Yi et al. 2003).  In the 
cytoplasm the enzyme DICER excises the pre-miRNA hairpin creating miRNA, 
approximately 22 nucleotides in length (Grishok et al. 2001).  MicroRNA is 
incorporated into the miRNA-induced silencing complex (miRISC) including: 
DICER; miRNA; and several binding proteins.  The miRISC complex identifies its 
target mRNA, and in the presence of imperfect complemetarity with the 3’-UTR 
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represses translation of the gene (Doench and Sharp 2004, Rana 2007, Lee et al. 
2002).  As miRNAs are small, and their 5’-end binds with incomplete 
conmplementarity to the 3’-UTR of genes, each miRNA can bind and alter the 
translation of several genes.  It has been estimated that a single miRNA can bind to up 
to 200 different genes (Esquela-Kerscher and Slack 2006).  In silico techniques can be 
used to predict which genes will have complimentarity to which miRNAs. 
 
5.1.1 MicroRNA and cancer 
Through evolution many miRNAs have been conserved, suggesting they play an 
essential role in development and in adult life.  They regulate important cellular 
processes such as proliferation, differentiation and apoptosis, and are therefore 
oncogenic when dysregulated (Bartels and Tsongalis 2009).  Calin et al investigated 
the location of 186 miRNAs, and found 52.8% were located in fragile sites, or 
minimal regions of loss of heterozygosity, amplification or common breakpoints, i.e. 
regions associated with cancer, suggesting that miRNA alteration plays a key role in 
cancer development and progression (Calin et al. 2004).   
 
Calin et al were the first to demonstrate the link of miRNA as tumour suppressors, 
identifying deletion and down regulation of two miRNAs, miR15 and miR16 in 68% 
of patients with chronic lymphocytic leukaemia (CLL) (Calin et al. 2002).  Both 
miRNAs were in the region 13q14, frequently deleted in CLL.  In colorectal 
carcinoma, miR143 and miR145 were shown to be significantly down regulated 
compared to normal colonic tissue by Michael et al, and down regulated levels of 
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these two miRNAs were also detected in pre-cancerous adenomatous polyps (Michael 
et al. 2003).    
 
The lethal-7 (Let-7) family of miRNAs were first identified in C. Elegans (Pasquinelli 
et al. 2000), and have subsequently been identified as oncomirs regulating Ras 
oncogene expression.  Ras proteins are a family of GTPase signaling proteins that 
regulate cell growth and differentiation.  Let-7a miRNA has been shown to regulate 
Ras expression, in experiments using the HepG2 cell line, derived from human 
hepatocellular carcinoma.  HepG2 cells normally do not express Let-7a, however 
Johnson et al transfected them with Let-7a miRNA.  The transfected HepG2 cells 
demonstrated a 70% decrease in Ras protein expression following transfection 
(Johnson et al. 2005).  Furthermore, transfection of gastric cancer cells with Let-7f 
miRNA inhibited invasion, cell migration, and metastasis in cell culture and xenograft 
models (Liang et al. 2011).  Let-7a and Let-7f levels were investigated in lung 
adenocarcinoma, and down regulated levels of Let-7 correlated with poorer survival 
(p = 0.0003) (Takamizawa et al. 2004). 
 
In CLL, a unique signature of 13 miRNAs has been shown to discriminate tumours 
according to prognosis (Calin et al. 2004).  In lung and breast cancer upregulated 
miR-155 and down regulated Let-7a-2 both correlate with poor prognosis (Johnson et 
al. 2005), (Iorio et al. 2005), and in hepatocellular cancer miRNA223 is down 
regulated (Wong et al. 2008).  This correlates with higher expression of strathmin 1 
(STMN1) which is associated with higher histological grade, shorter survival time 
and resistance to chemotherapy in a number of tumour types, including breast (Ghosh 
et al. 2007, Alli et al. 2007).  
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Circulating miRNA species, isolated from serum, are also proving to be a valuable 
tool.  Recently, serum miRNA levels of miR-375 and miR-141 have been shown to 
correlate with prognosis in prostate cancer (Brase et al. 2010).  In addition, miR-17-
5p, miR-21, miR-106a, miR-106b and let-7a levels in plasma have been shown to 
correlate with the presence of gastric cancer (Tsujiura et al. 2010) and it has been 
suggested that circulating levels of miR-106a and miR-17 could be used as a 
surrogate marker for circulating tumour cells in patients with gastric cancer (Zhou et 
al. 2010).   
 
MicroRNAs are potentially ideal biomarkers as they are present within biofluids and 
withstand fixation and paraffin embedding in routine histological material (Zhang et 
al. 2008, Doleshal et al. 2008, Xi et al. 2007).   
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5.2 Methods 
Detailed methods are written within the Methods Chapter (Chapter II).   In summary, 
tissue samples were obtained from three UK HPB Centres: Hammersmith Hospital 
(Imperial College Healthcare NHS Trust); Barts and The London Hospital (Barts 
Heath NHS Trust); and The Royal Marsden Hospital (The Royal Marsden).  Clinico-
pathological data was collected as described in the Clinical Database Chapter III.  
Ethical approval for the study was obtained through the Imperial College Healthcare 
NHS Trust Tissue Bank authorised by the Wales MREC (Application number 
R08/010 and R11004), and the London Research Ethics Committee (Ethics Reference 
Number 09/H0718/41).   
 
MicroRNA was extracted from formalin-fixed paraffin embedded archival tissue 
samples.  Tissue samples were macroscopically dissected to remove normal tissue.  
The RNeasy FFPE kit (Qiagen) for Total RNA extraction was used.  The total RNA 
sample was assessed for the presence of miRNA using qRT-PCR for the ‘house-
keeping’ microRNA RNU24, using the TaqMan® Small RNA Assays Protocol.  If 
RNU24 expression was identified, the sample was deemed of sufficient quality to 
undergo array analysis.  The quality of extracted miRNA was assessed for purity 
using the NanoDrop spectrophotometer. 
 
The Human miRNA V3 Microarray kit (8 x 15K, G4470C, Agilent) was used.  Each 
array contained probes for 866 human and 89 human viral microRNAs represented 
from the Sanger miRBase (release 12.0).  Tumour samples were labeled with Cy3-
pCp, and the labeling protocol included the ‘Spike-In’ Solution in the protocol to act 
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as an internal control for assay processing.  Samples were hybridized for 20hrs at 
55°C. 
 
The arrays were scanned for fluorescence intensities using a 5 µm resolution scanner 
(Agilent).  The raw intensities were extracted using Agilent Feature Extraction 
Software and data was analysed within the R statistical environment.  KEGG gene 
pathways and GO enrichment were assessed for genes predicted to be regulated by 
microRNAs with a miRDB prediction score >80. 
 
5.2.1 Assessment of miRNA from Formalin-Fixed Paraffin-Embedded 
Samples and Fresh Frozen Samples for miRNA Array Analysis 
Archival formalin-fixed paraffin-embedded (FFPE) samples were used to assess 
miRNA alterations in CC.  To validate the use of FFPE miRNA with the Human 
miRNA V3 Microarray FFPE derived miRNA was compared to miRNA extracted 
from fresh frozen samples, the gold standard.  To reduce inter-sample variability cell 
line samples were used from the same passage of cells.  The HUCC-T1 cell line was 
used.   
 
As shown in Figure 80 and Figure 81 the correlation between FFPE and fresh frozen 
samples was excellent, with 98.09% correlation, thus FFPE samples were used 
without concern for reducing sensitivity due to tissue fixation and storage methods. 
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Figure 80: HUCC-T1 Fresh Frozen and FFPE Samples Human miRNA V3 
Microarray Normalised Log2- intensities 
 
 
Figure 81: Correlation Plot of HUCC-T1 Fresh Frozen and FFPE Samples Log2- 
intensities of pairs plotted against each other 
 
 
 
Chapter V: miRNA Array 
 
 
5-285 
5.2.2 miRNA Quality Assessment: qRT-PCR 
To ensure microRNA was present in each sample before the microRNA array was 
performed each sample underwent qRT-PCR for ‘house-keeping’ microRNA RNU24.  
If RNU24 expression was identified, the sample was deemed of sufficient quality to 
undergo array analysis.  The TaqMan® MicroRNA Assay was used as per the 
TaqMan® Small RNA Assays Protocol. 
 
All cases demonstrated amplification of RNU24 during qRT-PCR, and thus were 
eligible to undergo labeling and miRNA array hybridization, as shown in Figure 82. 
 
Figure 82: qRT-PCR plot demonstrating amplification of RNU24 in all samples 
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5.3 Results 
MicroRNA was extracted from 44 archival formalin-fixed paraffin-embedded 
samples.   
 
Two studies were performed: 
(1.3.1) Comparing miRNA expression between normal and malignant cholangiocytes; 
(1.3.2) Assessing miRNA expression for prognostic signatures. 
 
5.3.1 Comparing miRNA expression between normal and malignant 
cholangiocytes  
Thirty-four biliary tract carcinoma (BTC) samples were included in the study, 
including 11 PHCC, 22 ECC, and 1 gallbladder carcinoma (GBCC).  The GBCC was 
included in the study as it was originally coded as PHCC at the time of the 
experiment, but it was later reclassified to gallbladder carcinoma after review.  All 
cases underwent macroscopically complete resections for treatment of BTC.  Normal 
non-malignant cholangiocytes were used as controls obtained from non-laser capture 
microscopic dissection of 10 normal gallbladder samples.  
 
All samples revealed RNU24 expression by qRT-PCR and were labeled and 
hybridised to as previously described.  A fluorescence scan of a sample miRNA array 
is shown in Figure 83. 
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Figure 83: Florescence scan of Human miRNA V3 Microarray slide 
 

Chapter V: miRNA Array 
 
 
5-289 
Differential miRNA expression was identified between malignant and non-malignant 
samples. Listed in Table 41 and 3 are the TopTable results for significantly altered 
miRNAs, with p-values less than 0.05, sorted by logFC.  ‘TopTable’ is a program 
incorporated into R package, which summarises the results, and enables hypothesis 
and statistical testing to produce p-values adjusted for multiple testing.  The ‘logFC’ 
is an estimate of the log2-fold-change corresponding to the effect i.e. up regulation or 
down regulation compared to normal cholangiocytes.  ‘AveExpr’ is the mean log-2 
expression for the miRNA over all arrays.  't’ is a moderated t-statistic assessed for 
each probe. ‘adj.P.Val’ is the adjusted p-value, adjusted by the Benjamini-Hochberg 
method to control for the false-discovery rate.  ‘B’ is the log-odds that the gene is 
differentially expressed e.g. a B-statistic of 0 gives a 50-50 chance of the miRNA 
being differentially expressed (Smyth 2004). 
 
Thirty-seven miRNAs showed significantly different expression compared to normal 
cholangiocytes.  Nineteen miRNAs were significantly down regulated, and 18 
miRNAs were significantly unregulated.  A heatmap with 20 out of the 37 
significantly altered miRNA with the highest variance is shown in Figure 84. 
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Table 41: Down regulated miRNAs: CC vs normal cholangiocytes 
miRNA ID logFC AveExpr t P.Value adj.P.Val B 
hsa-miR-451 -1.679 9.237 -5.431 2.30E-06 0.00003 4.472 
hsa-miR-29c -1.115 8.535 -9.228 7.51E-12 6.799E-10 16.892 
hsa-miR-145 -0.980 8.707 -6.600 4.42E-08 7.274E-07 8.345 
hsa-miR-192 -0.916 8.189 -4.986 1.01E-05 0.00010 3.027 
hsa-miR-195 -0.861 8.174 -11.387 1.05E-14 1.906E-12 23.343 
hsa-let-7a -0.767 10.944 -3.673 0.0006 0.00249 -0.977 
hsa-let-7g -0.724 8.926 -4.846 1.60E-05 0.00014 2.581 
hsa-miR-26b -0.715 8.273 -8.008 3.94E-10 1.428E-08 12.991 
hsa-miR-23b -0.656 8.730 -4.591 3.68E-05 0.00029 1.774 
hsa-miR-29b -0.650 8.320 -7.515 2.03E-09 4.591E-08 11.378 
hsa-let-7f -0.647 9.813 -3.923 0.0003 0.00131 -0.255 
hsa-miR-720 -0.640 13.034 -2.596 0.0128 0.02571 -3.756 
hsa-miR-99a -0.637 8.300 -5.835 5.90E-07 0.00001 5.802 
hsa-miR-125b -0.617 9.363 -4.071 0.0002 0.00096 0.182 
hsa-miR-27b -0.543 8.363 -4.874 1.46E-05 0.00014 2.669 
hsa-miR-126 -0.536 8.344 -5.333 3.19E-06 0.00004 4.152 
hsa-miR-19b -0.532 8.186 -6.437 7.69E-08 1.160E-06 7.801 
hsa-miR-16 -0.527 9.143 -3.780 0.0005 0.00188 -0.670 
hsa-miR-199a-3p -0.522 9.191 -3.022 0.0042 0.01112 -2.731 
 
 
Table 42: Upregulated miRNAs: CC vs Normal Cholangiocytes 
miRNA ID logFC AveExpr t P.Value adj.P.Val B 
hsa-miR-134 0.519 8.433 3.631 0.0007 0.00271 -1.096 
hsa-miR-671-5p 0.520 8.499 2.831 0.0070 0.01660 -3.204 
hsa-miR-574-5p 0.531 8.826 3.804 0.0004 0.00179 -0.603 
hsa-miR-939 0.545 9.232 3.130 0.0031 0.00863 -2.453 
hsa-miR-940 0.558 8.671 4.417 6.44E-05 0.00043 1.233 
hsa-miR-1275 0.572 8.945 4.300 9.35E-05 0.00057 0.873 
hsa-miR-630 0.590 8.780 2.591 0.0129 0.02571 -3.767 
hsa-miR-188-5p 0.591 8.716 3.351 0.0017 0.00537 -1.869 
hsa-miR-572 0.606 9.068 4.038 0.0002 0.00101 0.085 
hsa-miR-1224-5p 0.608 8.908 3.584 0.0008 0.00304 -1.230 
hsa-miR-1202 0.658 10.170 2.853 0.0066 0.01587 -3.150 
hsa-miR-1915 0.701 11.156 3.205 0.0025 0.00722 -2.257 
hsa-miR-638 0.721 11.938 2.813 0.0073 0.01698 -3.248 
hsa-miR-1308_v15.0 0.810 10.887 3.243 0.0023 0.00682 -2.158 
hsa-miR-575 0.831 9.237 4.472 5.40E-05 0.00038 1.403 
hsa-miR-1207-5p 0.832 10.711 4.296 9.45E-05 0.00057 0.863 
hsa-miR-1225-5p 0.832 10.844 3.901 0.0003 0.00136 -0.319 
hsa-miR-1268 0.838 9.826 4.211 0.0001 0.00069 0.605 
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Figure 84: Heatmap showing 20 miRNAs with highest variance between 
malignant and non-malignant cholangiocytes. 
Individual cases represented vertically, labeled on x-axis; miRNAs on y-axis 
 
 
The miRDB database (http://mirdb.org) was used to identify predicted gene targets 
for miRNAs of interest (Wang 2008, Wang and El Naqa 2008).  The miRDB database 
4.0 uses miRNA information from ‘miRBase V18’.  Predicted genes were excluded 
that had a prediction score of less than 80, predicted using the bioinformatics tool 
MirTarget2.  Five miRNAs had no genes with prediction scores of greater than 80, 
and were excluded from further analysis (hsa-miR-1224-5p; hsa-miR-126; hsa-
miR1308_v15.0; hsa-miR-572; hsa-miR-638).  Nine-hundred and fifty-three genes 
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were identified as gene targets with a prediction score > 80.  The list of 953 genes was 
analysed using ‘DAVID’ for enrichment of Gene Ontology (GO) terms, KEGG gene 
pathways, and Swiss-Prt (SP) and Protein Information Resource (PIR) terms. 
 
Twenty-three genes were enriched for the SP_PIR term ‘proto-oncogene’, and these 
were assessed further for down regulation of related miRNAs.  For the 23 genes 
highlighted by the SP_PIR search 13 of the significantly altered miRNAs were down 
regulated in association with the proto-oncogenes.  Fifteen genes were enriched for 
SP_PIR term ‘tumour suppressor’, and one miRNA was upregulated with a prediction 
score greater than 80 for the associated gene, see Table 43 and Table 44.   
 
Table 43: Genes for SP_PIR term ‘Proto-oncogene’ associated with down 
regulated miRNAs 
Gene Symbol Gene Name Down regulated miRNA Prediction Score 
AFF1 AF4/FMR2 family, member 1 hsa-miR-19b 97 
AFF4 AF4/FMR2 family, member 4 hsa-miR-27b hsa-let-7f 
92 
84 
FLI1 Friend leukemia virus integration 1 hsa-miR-145 96 
MEIS1 Meis homeobox 1 hsa-miR-23b 92 
CBFB core-binding factor, beta subunit hsa-miR-27b 84 
CCNL1 cyclin L1 hsa-miR-19b 80 
HMGA2 high mobility group AT-hook 2 hsa-let-7g hsa-let-7a 
95 
95 
PLAG1 pleiomorphic adenoma gene 1 
hsa-let-7f 
hsa-let-7a 
hsa-miR-16 
hsa-miR-195 
99 
99 
94 
94 
RRAS2 
related RAS viral (r-ras) oncogene 
homolog 2; similar to related RAS viral 
(r-ras) oncogene homolog 2 
hsa-miR-23b 84 
TOP1 topoisomerase (DNA) I hsa-miR-23b 97 
TPM3 tropomyosin 3 hsa-miR-145 93 
MYCL1 
v-myc myelocytomatosis viral oncogene 
homolog 1, lung carcinoma derived 
(avian) 
hsa-miR-19b 84 
ZNF521 zinc finger protein 521 hsa-miR-19b 83 
 
Table 44: Genes for SP_PIR Term: ‘Tumour Suppressor’ associated with 
upregulated miRNAs 
Gene Symbol Gene Name Upregulated miRNA Prediction Score 
LIN9 lin-9 homolog (C. elegans) hsa-miR-671 95 
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Gene enrichment for SP_PIR terms also highlighted genes involved in ‘Wnt 
signaling’, ‘angiogenesis’, and ‘cell division’.  KEGG pathway analysis of predicted 
gene targets identified several key pathways, including: ‘p53 signaling pathway’; 
‘TGF-beta signaling pathway’; and ‘Wnt signaling pathway’.  See Tables 45, 46, and 
47.   
 
Table 45: KEGG Pathway: p53 signaling 
Gene Symbol Gene Name 
FAS Fas (TNF receptor superfamily, member 6) 
APAF1 apoptotic peptidase activating factor 1 
CCNE1 cyclin E1 
CCNG1 cyclin G1 
CDK6 cyclin-dependent kinase 6 
IGF1 insulin-like growth factor 1 (somatomedin C) 
PTEN phosphatase and tensin homolog; phosphatase and tensin homolog pseudogene 1 
RCHY1 ring finger and CHY zinc finger domain containing 1 
 
Table 46: KEGG Pathway: TGF-beta Signaling 
Gene Symbol Gene Name 
E2F5 E2F transcription factor 5, p130-binding 
SKP1 S-phase kinase-associated protein 1 
SMAD7 SMAD family member 7 
SMURF1 SMAD specific E3 ubiquitin protein ligase 1 
ACVR2A activin A receptor, type IIA 
ACVR2B activin A receptor, type IIB 
BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) 
GDF6 growth differentiation factor 6 
INHBB inhibin, beta B 
 
 
Table 47: KEGG Pathway: Wnt Signaling 
Gene Symbol Gene Name 
SKP1 S-phase kinase-associated protein 1 
BTRC beta-transducin repeat containing 
CSNK2A1 casein kinase 2, alpha 1 polypeptide pseudogene; casein kinase 2, alpha 1 polypeptide 
CTNNBIP1 catenin, beta interacting protein 1 
FZD5 frizzled homolog 5 (Drosophila) 
LRP6 low density lipoprotein receptor-related protein 6 
PPP2R5D protein phosphatase 2, regulatory subunit B', delta isoform 
PPP2R5E protein phosphatase 2, regulatory subunit B', epsilon isoform 
PPP3CA protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform 
PPP3R1 protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform 
PPP3R2 protein phosphatase 3 (formerly 2B), regulatory subunit B, beta isoform 
TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 
NT3A wingless-type MMTV integration site family, member 3A 
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5.3.2 Assessing miRNA expression for prognostic signatures 
A subset of 30 of the 34 BTC samples assess in the above study were used to identify 
prognostic signatures.  Thirty samples were included in the analysis: 10 PHCC; 19 
ECC; and 1 GBCC.  The median age of the cohort was 63 years (range 30-75).  All 
cases were operatively treated with macroscopically complete resections (29 R0 
resections, 1 R1), and none died within the 30-day post-operative period.  There was 
one case of papillary CC, 19 lymph node positive cases, 8 cases with lympho-vascular 
invasion, and 19 cases with perineural invasion.  At time of analysis 13 patients had 
died, and 17 patients were alive.  The median overall survival for the group was 26.4 
months (Figure 84). 
 
Figure 85: Kaplan-Meier Plot: Overall Survival for miRNA Study 
 
 
Data analysis of miRNA expression revealed that a miRNA expression signature 
consisting of 4 miRNAs correlated with overall survival. The 4 miRNAs were 
"protective" i.e. higher expression lowered the risk and improved survival and lower 
expression increased the risk and led to poorer survival.  The expression data for all 4 
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miRNAs were used to calculate a risk-factor for each patient that allowed to assign 
the patients to a low-risk (high expression of the signature) and a high-risk (low 
expression of the signature) group, respectively. The 4 miRNAs were: hsa-miR-
765, hsa-miR-1471, hsa-miR-345, and hsa-miR-663.  The two groups showed a 
median survival of 15.7 months vs 35.6 months: p = 0.00016, hazard ratio 1.71 (95% 
confidence interval 1.26-2.34) (Figure 85).  Variables including resection status, 
papillary subtype, lymph node status, lymphovascular invasion, and perineural 
invasion were assessed using univariate cox-proportional hazard analysis, and none 
contributed significantly to survival, and therefore multivariate analysis was not 
performed.  The 4 miRNA signature was therefore an independent predictor of 
survival. 
 
Using miRDB and DAVID searches the 4 miRNAs were assessed for gene targets 
with biological significance to malignancy.  hsa-miR-765 was associated with 40 
genes with a prediction score greater than 80, and was enriched for genes involved in 
cell-adhesion, and TIMP3 was highlighted.  hsa-miR-1471 had two predicted gene 
targets, and IGF1 was highlighted for its role in the KEGG pathways p53 signaling, 
MTOR signaling, prostate cancer and melanoma. hsa-miR-663a was associated with 5 
gene targets, and there was gene enrichment for cell proliferation, highlighting 
FGFRL1. 
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Figure 86: Kaplan Meier Plot: Overall Survival Related to 4 miRNA signature 
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5.4 Discussion 
We have performed this study assessing miRNA alterations in cholangiocarcinoma.  
The first part of the study was to identify miRNA alterations associated with CC 
compared to normal tissue, and the second part of the study was to assess miRNA 
alterations to identify a prognostic signature. 
 
This is not the first study of miRNA expression in CC, however it is the most 
comprehensive study, assessing the most miRNAs, and is the first to identify a 
miRNA prognostic signature for survival.  Furthermore, it is the first UK study of 
miRNA alterations in CC, and as shown in the array-UK chapter, UK CC exhibits 
significantly different molecular alterations to Asian CC (the population on which 
previous miRNA studies have been performed). 
 
Three studies have been previously performed assessing global miRNA expression in 
CC: Meng et al. performed a study on 3 CC cell lines (Meng et al. 2006a); Selaru et 
al. performed a study on 5 CC samples (Selaru et al. 2009); and Chen et al. performed 
a study on 27 ICC samples (though used an array with only 156 miRNAs) (Chen et al. 
2009). 
 
Meng et al. used microRNA arrays to examine miRNA expression in biliary tract 
cancer cell lines, using 1 ICC, 1 ECC, and 1 GBCC cell line (KMCH-1, TFK, Mz-
ChA-1), compared to the H69 cell line (‘normal cholangiocyte’ cell line, immortalised 
by SV40 transfection) (Meng et al. 2006a).  They used the mirVana miRNA Array 
Probe Set (Ambion).  They identified the following miRNAs having significantly 
Chapter V: miRNA Array 
 
 
5-298 
upregulated expression in biliary tract cancer cell lines: miR-21, let-7a-1, let7c, let7f-
2, miR-320, and miR-16-1.  The following miRNAs revealed significantly down 
regulated expression in malignant cell lines: let-7b, miR-326, miR-351, miR-373, and 
miR-150.  When malignant cell lines were compared to the H69 ‘normal’ cell line, 
miR-200b, miR-21, miR-23a, miR-141, and miR-27a were found to be upregulated in 
the malignant cell lines relative to H69. However, none of the significantly altered 
miRNAs were consistent with the 37 significantly altered miRNA identified in our 
study.  This is likely due to cell lines exhibiting different alteration profiles to tumour 
tissue in general. 
 
Selaru et al. used miRNA arrays to assess miRNA expression in 5 CC and 5 normal 
bile ducts using a Human miR array chip (Agilent) containing 470 unique human 
miRNAs (Selaru et al. 2009).  Commonly upregulated miRNAs in CC compared to 
normal bile duct included: miR-1066, miR-21, miR-107, miR-106a, miR-93, miR-
27a, miR-19a, miR-103, miR-17-5p, and miR-25.  Commonly down regulated 
miRNAs in CC included: miR-560, miR-370, miR-198, miR-188, miR-662, miR-191, 
miR-512-3p, miR-520e, miR-513, and miR-494.  Cell lines Mz-ChA-1 and TFK also 
underwent miRNA array analysis, and revealed several differences compared to CC 
tissue samples, for example, miR-141 was upregulated in the cell lines, but not in the 
CC tissue samples. The most upregulated miRNA in CC tissue samples and cell lines 
was miR-21.   This was further confirmed by qRT-PCR for miR-21 in 18 CC tissue 
samples and 12 normal bile ducts, which showed up regulation in CC, and down 
regulation in normal tissue.  In silico analysis of potential miR-21 targets identified 
Programmed Cell Death 4 (PDCD4) and Tissue Inhibitor of Metalloproteinase 3 
(TIMP3) genes.  PDCD4 is an apoptosis-related protein that has been previously 
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proposed as a tumour suppressor gene, and TIMP3 is a pro-apoptotic protein.  In CC 
samples miR-21 was upregulated, and there were low levels of PDCD4 and TIMP3.  
When miR-21 was inhibited there was over expression of the apoptotic proteins 
PDCD4 and TIMP3, leading to the conclusion that PDCD4 and TIMP3 are tumour 
suppressor genes, and miR-21 is oncogenic in CC.  Furthermore, Meng et al studies 
(described previously) of CC cell lines also identified miR-21 to be upregulated.  Our 
study of CC did not find miR-21 to be upregulated, and none of the reported miRNA 
with significant alteration in Selaru’s study were the same as in our study.  However, 
TIMP3 was identified in our study as a potential gene target from our 4-miRNA 
prognostic signature, as a target for miR-765.   
 
Chen et al. performed miRNA arrays on 27 ICC, 10 normal cholangiocytes, and 8 
normal hepatocytes using the TaqMan® MicroRNA Assays Human Panel-Early 
Access Kit (Applied Biosystems) containing 156 miRNAs (Chen et al. 2009).  They 
identified 18 miRNAs that were upregulated, and 20 miRNAs down regulated in ICC 
compared to normal tissue (see Table 48). 
 
 
Using unsupervised hierarchical clustering, the ICC samples clustered into two 
groups, related to high or low (<100 KU/L) Ca 19.9 levels.  They also identified 
differential miRNA expression related to several pathological features, e.g. miR-141 
in multifocal tumours, miR-200c with vascular invasion, and miR200a with well 
differentiated tumours.  MicroRNAs miR-204 and miR-320 were selected for further 
analysis, as they were significantly down regulated in CC, and resided in or near 
regions previously reported to exhibit genomic loss in CC.  In silico analysis of miR-
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204 and miR-320 identified Mcl-1 and Bcl-2 as potential targets, (anti-apoptotic 
proteins).  Using CC cell lines QBC939 and RBE, and the embryonic kidney cell line 
KEK293, they were transfected to over-express miR204 or miR-320.  miR-204 over-
expression led to a decrease in Bcl-2 protein, and miR-320 over-expression led to a 
decrease in Mcl-1 protein.  Furthermore, cells over-expressing miR-320 sensitive to 
cytotoxic agents (5-FU), suggesting that down regulation of miR-320 in CC leads to 
apoptosis-resistance through increased Mcl- expression.  This is the only of the 
miRNA studies to identify miRNA alterations with similarity to our study.  We also 
found miR-145 and hsa-let-7a to be down regulated in our study.  We did not 
however find miRNA alterations specific to pathological phenotypes. 
 
Table 48: miRNAs differentially expressed between ICC and normal tissue 
(Chen et al) 
Upregulated miRNAs Down regulated miRNAs 
miR-21 miR-98 
miR-142-3p miR-204 
miR-25 miR-338 
miR-15a miR-198 
miR-193 miR-302d 
miR-17-5p miR-328 
miR-374 miR-337 
miR-106a miR-302b 
miR-224 miR-184 
miR-130b miR-320 
miR-19a miR-371 
miR-331 miR-185 
miR-324-5p miR-222 
miR-20 miR-214 
miR-17-3p miR-373 
miR-223 miR-145 
miR-15b miR-200c 
miR-103 Let-7a 
 Let-7b 
 miR-197 
 
In our study we identified 37 differentially altered miRNA differentiating malignant 
form non-malignant cholangiocytes. Thirteen proto-oncogenes were identified as gene 
targets for significantly down regulated miRNAs.  If a miRNA is down regulated, 
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there is less miRNA to cause degradation of the transcribed gene, and therefore there 
is increased gene function.  Using miRDB MYCL1 was identified with sequence 
homology with the seed region of miR-19b, with a prediction score of 80.  MYCL1 
was also identified using SP-PIR term searches as a ‘proto-oncogene’.  Wu et al. 
investigated over-expression and amplification of MYCL1 in ovarian carcinoma 
samples (Wu et al. 2003).  They used restriction landmark genomic scanning to detect 
regions of DNA amplification, and qRT-PCR for gene over-expression and found 
copy number gain in 10/47 samples, and mRNA over-expression in all 9 samples 
assessed with amplification.  Down regulation of miR-19b may lead to increased 
expression of the proto-oncogene MYCL1 in CC. 
 
The LIN-9 gene was identified as a tumour suppressor gene with sequence homology 
to significantly upregulated miR-671.  Its activity as a tumour suppressor gene was 
first identified in experiments with Caenorhabditis elegans (Gagrica et al. 2004).  Up 
regulation of miR-671 may lead to decreased LIN9 expression due to mRNA 
degradation, reducing its effect as a tumour suppressor gene and contributing to the 
malignant phenotype of CC. 
 
Meng et al. transfected malignant cell lines Mz-ChA-1 and KMCH-1 to over express 
IL-6, and implanted them into nude mice as xenografts (Meng et al. 2007b).  
Alterations in miRNA expression caused by IL-6 over expression were assessed using 
the mirVana miRNA Array Probe Set (Ambion).   MicroRNAs Let-7a, Let-7c, Let-
7d, Let-7f-1, Let-7f-2, miR-16- and miR-21 were found to be upregulated.  Further 
investigation of Let-7a using antisense inhibition demonstrated Let-7a’s role in anti-
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apoptotic survival, producing constitutive STAT3 phosphorylation, and increased 
expression of Survivin and Mcl-1.  The role of IL-6 in CC cell survival and 
proliferation has been previously identified (as described in Introduction Chapter I), 
activating the IL-6 receptor, and thus signaling via MAPK, PI3K/Akt, and STAT3 
pathways.  However this was a new finding identifying the role of let-7a in the 
pathway.  Our study also identified dysregulation of let-7a.   miR-199a was down 
regulated in our study, and predicted gene targets include MTOR, ERBB4 and 
MAP3K4 genes, key players in major malignancy-associated signaling pathways.  
Analysis of gene target for altered miRNA also highlighted gene enrichment for 
several signaling pathways, including p53 signaling pathway, TGF-beta signaling 
pathway, and Wnt signaling pathway.  Identifying alterations of key signaling 
pathways is important for the treatment of CC, as these pathways could potentially be 
targeted with molecular targeted agent. 
 
Key miRNAs identified in other malignancies were also dysregulated in this study.  
For example miR-16 has been identified to be down regulated in CLL, and miR-143 
down regulated in colorectal carcinoma, consistent with the findings in our study 
(Calin et al. 2002, Michael et al. 2003).  Also, let-7a down regulation was identified 
in lung and breast carcinoma associated with poor prognosis, and it was also found to 
be dysreguated in our study (Takamizawa et al. 2004). 
 
The most important finding of the study was the identification of a 4-miRNA 
signature that is protective for survival in CC.  The protective signature predicted an 
improved survival of 35.6 months, compared to 15.7 months without the signatures.  
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This signature now requires validation in a second set of CC cases in future studies to 
confirm its utility as a prognostic marker. 
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We have undertaken a comprehensive clinical and molecular analysis of CC in two 
contrasting populations.  A clinical database has been created to assess the incidence 
and survival of CC a two large HPB centres, and DNA and miRNA alterations have 
been identified with prognostic significance. 
 
The retrospective clinical analysis of two cohorts of CC cases identified our study to 
contain cases of comparable age and sex distribution to other studies.  However, we 
have identified a significant increase in ECC incidence that has not been previously 
reported.  This could represent differences in referral practices to these tertiary 
referral HPB centres, but could also represent a true change in incidence identified 
due to meticulous categorization of cases, which is not possible in large 
epidemiological studies where the investigators rely on coding performed by other 
sources.  Furthermore, there was a significant survival advantage identified for 
surgical management of CC, even with R2 resections (22 months for surgical 
management, compare to7 months median survival for medical management). 
 
Survival analysis of Thai cases revealed a significantly worse median survival than 
UK cases, though the reasons for this are not clear, due to a lack of further clinical 
data.  As hypothesized, Thai and UK cases exhibited different CNA profiles, which 
we believe are related to differing aetiological factors contributing to CC in these 
populations, with ‘multiple carcinogenic hits’ required in UK populations, 
contributing to the increased proportion of CNAs. 
 
It was expected that ICC and ECC would exhibit different molecular profiles, due to 
their different developments origins and differing clinical courses.  It was also 
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expected that PHCC would be more similar to ECC, as it is believed that they develop 
from the same hepatic bud.  Interestingly, there were significant differences between 
the CNA of ICC and ECC, however, we were surprised to find that PHCC clustered 
with ICC rather than ECC as predicted. 
 
Two copy number alterations were of particular note in this study, the CN gain of 
8q24.21-24.3 in the UK study, and CN gain of 7p11.2 in the Thai study.  Copy 
number gains of these regions were associated with worse survival, a key finding of 
this study.  Region 8q24.21-24.3 contained the genes c-myc and PTK2, oncogenes of 
particular interest for further study.  Furthermore, genes in this region were enriched 
for signaling pathways including ErbB, MAPK, JAK-STAT, and TGF-beta signaling.  
Region 7p11.2 was immediately downstream from EGFR, and was enriched for 
regulatory elements and motifs, which may influence gene dosing of EGFR, and 
needs further study. 
 
A 4-miRNA signature was identified related to improved prognosis, with a median 
survival of 15.7 months compared to 35.6 months without up regulation of the 4-
miRNAs.  One of the miRNAs in the signature contained sequence complimentarity 
with TIMP3 gene, a pro-apoptotic protein identified in another CC study of miRNA 
alterations, and may be key in the improvement in survival associated with the 
signature. 
 
Other miRNA alterations identified key molecular pathways, and alterations of 
miRNAs with oncogene (MYCL1) and tumours suppressor gene targets (LIN-9). 
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Robust prognostic information for CC is sadly lacking, and the identification of 
prognostic signatures for CC in this study will, once validated, significantly add to the 
information the doctor can give to the patient, and help formulated their decisions 
with regard to treatment options.  This is especially important with palliative disease, 
where medical therapy offers only a modest benefit in increased length survival.  
 
This study has identified DNA and miRNA alterations that potentially affect key 
signalling pathways in CC, that can be targeted with currently used molecular agents.  
Several small phase II trials have been performed in CC with targeted cancer 
therapies, however, to date the outcomes have been disappointing.  Lapatinib is an 
orally administered agent that targets EGFR and ErbB-2 tyrosine kinases.  It is 
licensed in the UK for the treatment of breast cancer in combination with capecitabine 
(Geyer et al. 2006).  A phase II trial involving 17 patients with biliary tree cancers 
demonstrated poor results with a median progression free survival of 1.8 months, an 
overall survival of 5.2 months, and no objective responses using lapatinib as a single 
agent (Ramanathan et al. 2009).   Measurement of EGFR expression was only 
performed in 2 cases (both positive) and ErbB-2 expression was not measured in the 
trial. 
 
Erlotinib is an EGFR TKI licensed for the treatment of pancreatic and non-small cell 
lung cancer in combination with conventional chemotherapy. The first phase II trial 
treating CC patients with erlotinib was published in 2006 (Philip et al. 2006). Forty-
two patients were treated daily with erlotinib monotherapy.  Median time to disease 
progression was 2.4 months and median overall survival was 7.5 months.  EGFR over 
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expression was assessed in 36 patients by immunohistochemistry of which 81% were 
positive (1+ to 3+).  EGFR status did not correlate significantly with clinical outcome.  
 
Bevacizumab is an intravenously administered mAb that inhibits vascular endothelial 
growth factor (VEFGA). In the UK it is licensed for the treatment of colorectal 
cancer, breast cancer, renal cell carcinoma and non-small cell lung cancer in 
combination with conventional chemotherapy. A recently completed single arm phase 
II trial treating 35 CC patients with gemcitabine, oxaliplatin, and bevacizumab has 
shown promising results (Zhu et al. 2010).  Median progression free survival was 7 
months, overall survival was 12.7 months and the objective response rate was 40%.  
There are currently 4 further phase II studies investigating the effect of bevacizumab 
on patients with CC. A more recent multi centre phase II trial recruited 53 patients for 
treatment with erlotinib and bevacizumab (Lubner et al. 2010).  Median overall 
survival was 9.9 months, and median time to disease progression was 4.4 months.  
They investigated EGFR mutation and serum VEGF; serum levels in 26 patients had 
no significant relation to outcome. 
 
Cediranib (Recentin, AZD2171) is an orally administered TKI targeting all three 
VEGFRs (VEGFR-1, -2 and -3), cKIT, PDGFRA and PDGFRB (Wedge et al. 2005).  
The ABC-03 trial (Valle et al. 2010b) is a randomised phase II/III trial designed to 
compare cediranib or placebo in combination with cisplatin/gemcitabine for patients 
with advanced biliary tract cancers. It is currently recruiting patients.  
 
Gruenberger et al. performed a phase II trial for histologically or cytologically proven 
unresectable biliary tract carcinoma in 30 patients (27 CC; 3 gallbladder carcinoma) 
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(Gruenberger et al. 2010).  All patients received gemcitabine and oxaliplatin plus 
cetuximab, chimeric (mouse/human) EGFR monoclonal antibody.  Three patients had 
a complete response, and 16 patients had a partial response, with 9 patients 
subsequently underwent curative surgery following response to the regime.  The 
treatment was well tolerated – the data was encouraging, however the trial would 
need to be extended to a phase III trial to determine impact on survival.  Cetuximab is 
used in K-ras wild-type metastatic colorectal carcinoma and squamous cell carcinoma 
of the head and neck in clinical practice (Bokemeyer et al. 2009). 
 
A recent prospective multicentre pilot study of sixty-six patients with malignant 
disease refractory to treatment (various malignancies included) underwent molecular 
stratification by IHC/FISH and limited gene-expression profiling (51 genes) for 
molecular targets with established targeted agents (Von Hoff et al. 2010).  Treatment 
was chosen based on the individual’s expression of molecular targets, and compared 
to progression-free survival on their previous regime.  Eighteen of sixty-six patients 
had improvements in progression free survival following molecular profiling-driven 
treatment choices, of 9.7 vs 5 months. These findings strengthen the argument for 
molecular profiling of patients with CC prior to treatment with biological agents. 
 
This study has identified the copy number gain of several key molecular targets, and 
alterations though dysregulation of miRNA and copy number alterations affecting key 
signaling pathways in CC, which could potentially be targeted in the treatment of CC.  
Cholangiocarcinoma is a tumour that is resistant to conventional chemotherapy 
regimes, which is possibly related to its high degree of tumour heterogeneity.  Using 
molecular stratification for targeted agents in combination with conventional 
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chemotherapy give broader therapeutic windows, with less toxic side effects.  Side-
effect profiles do not overlap with those of conventional chemotherapy, so can be 
used synergistically without, necessarily, the need for dose reduction. 
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